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General introduction
Medicines for children
Paediatric patients cannot simply use the same drug formulations and
dosages as adult patients. The appropriateness of a formulation is deter-
mined by the characteristics of the patient to be treated with the drug, the
specific drug and the dose to be used, and the environment in which it has
to be administered. Children are characterized by gaining in height and
weight until they grow up beyond adolescence, and by the size and function
of their organs changing over time [1]. The right dose has to be determined
for children taking into account the disease they suffer from, their age and
stage of development. This often results in the need for different amounts
of drugs relative to their weight, body surface area or maturation of organ
functions, and different formulations depending on their age and devel-
opment. Oral administration of drugs is generally considered the most
convenient method to administer drugs, also for children. For paediatric
oral drug therapy several aspects have to be considered [2]. Since the dose
might have to be changed while children grow and develop, drug formula-
tions with the possibility of flexible dosing are preferred. Different aspects
determine acceptability, such as food restrictions, size of tablets, amount of
drug to be taken and the palatability [2, 3]. Palatability is determined by
the taste, texture and smell of the formulation [4]. It can be expected that
the lower the acceptability of the drug formulation, the more important
also the dosing frequency is. Which type of formulation is appropriate for
a child changes during its growth and development [5]. Liquid formulations
are generally considered most appropriate for the youngest children, slowly
changing to the use of solid formulations, such as tablets and capsules, for
older children.
When no appropriate paediatric formulations are available, (hospital)
pharmacists can attempt to make medicines more child friendly, such
as preparing capsules or a liquid out of tablets with the ‘inappropriate’
strength, or by compounding using the pure active pharmaceutical ingre-
dient [6, 7]. Excipients have to be used to be able to develop such a new
formulation. For use in children, certain excipients used in adult drug
formulations should be avoided, if possible [4, 8]. For example excipi-
ents as alcohol and propylene glycol can have serious adverse effects in
children [4, 9, 10]. Not all drug formulations can be changed into a child
friendly formulation. For example, some active pharmaceutical ingredients
have to be protected from degradation in the gastrointestinal tract or can
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damage the mucosa of the oesophagus [11, 12]. Also, the rate and extent
of absorption of the active pharmaceutical ingredient can be changed when
manipulating the formulation. This may lead to higher or lower drug levels
in the blood, resulting in toxicity or loss of efficacy.
Efficacy of drug treatment is studied with a given formulation. It is
generally accepted that efficacy will be comparable when exposure to the
drug from different formulations is comparable [13, 14]. Exposure is deter-
mined by investigating the pharmacokinetics of the drug. Pharmacokinetics
describes the absorption, distribution, metabolism and elimination of the
drug in relation to time. When new formulations with the same drug are
developed, bioequivalence studies are performed to investigate whether the
use of these formulations results in comparable pharmacokinetics of the
drug.
Comparison of pharmacokinetic parameters of a drug is also used to
determine whether a different dosing regimen can be used, for example
whether the total daily dose can be administered once daily, instead of
divided in multiple doses over the day. This can be done by administering
the drug using the dosing regimens of interest to the target population,
or by extrapolation of data from different populations or different dosing
regimens to predict exposure in the target population.
Viral infections in children
Viruses are small organisms that can infect living cells and can cause disease
in the (human) host [15]. The infection can be acute (e.g., influenza) or
chronic [e.g., infection by hepatitis B virus or human immunodeficiency
virus (HIV)]. Viral infections can also become latent, which means the
virus remains quiescent until specific signals trigger the virus to become
active. Cold sores are an example of a reactivation of herpes simplex virus
latently present in the host [15]. Most viral infections are self-limiting and
do not need any antiviral treatment in immunocompetent children. Infec-
tions with herpes viruses, such as herpes simplex virus and varicella zoster
virus, require treatment only when they cause a severe disease as seen in
neonates and immunocompromised patients [16–18]. Immunocompromised
patients are also at risk of reactivation of herpes viruses latently present.
In those scenarios, antiviral drugs may be used either therapeutically or
prophylactically to prevent reactivation [19]. Antiviral drugs used in the
Netherlands for herpes simplex virus and varicella zoster virus infections
in children are aciclovir and valaciclovir. Bioavailability of aciclovir after
oral administration is low (approximately 20%), highly variable and dose
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dependent [20]. Therefore, oral administration of aciclovir involves frequent
and high dosing, and treatment of serious infections is given by intra-
venous administration [21]. Intravenous therapy carries several risks, such
as line related infections and it requires hospitalization or extensive use of
home health service. Valaciclovir is an oral prodrug of aciclovir with equal
efficacy, a similar safety profile and a higher, more reliable bioavailability,
with a resulting lower dosing frequency than aciclovir [22, 23]. However,
an appropriate paediatric formulation for oral administration is lacking for
valaciclovir.
Children infected with human immunodeficiency virus (HIV) require
antiviral treatment to prevent the development of acquired immune
deficiency syndrome (AIDS). It is estimated that worldwide about 2.6
million children under the age of 15 years were living with HIV in 2014, of
which 3,300 were living in Western & Central Europe and North America
[24]. With current knowledge and treatment options, HIV-infected children
can expect to have full adult life, but with the necessity to continue treat-
ment lifelong. To effectively treat an HIV-infection, a combination of at
least three drugs needs to be used: combination antiretroviral treatment, or
cART [25]. It is recommended to treat all HIV-infected children indepen-
dent of their immune states and the presence of overt disease [25–27].
Antiretroviral drugs can be divided into several classes based on their
mechanism of action. To prevent the virus becoming resistant to antiretro-
viral drugs, it is paramount to maintain long-term adherence with at
least two classes of antiretroviral drugs. The need of combination therapy
combined with the need of long-term adherence puts a challenge on the
patient and its caregivers (parents, carers and clinicians).
Aim and outline of this thesis
The aim of this thesis is to investigate how pharmacotherapy with antiviral
drugs can be optimized taken into account the above-mentioned issues, to
ensure safe and effective treatment for children suffering from acute and
chronic viral infections.
In the first part, the focus is on simplifying the dosing schedule of two
antiretroviral drugs as part of cART, lopinavir and darunavir. It is investi-
gated whether a once-daily dosing schedule can be used instead of a twice-
daily regimen. In chapter 1, a large international randomized clinical trial
investigating the efficacy, safety and pharmacokinetics of once- versus twice-
daily lopinavir/ritonavir is described. The effectiveness of the off-label
use of once-daily lopinavir/ritonavir in a real-life setting is analysed and
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described in chapter 2. In chapter 3 the exposure to once-daily darunavir
in children is investigated by collecting pharmacokinetic data in HIV-
infected children in the Netherlands. The calculated and approved once-
daily dosing regimen will thus be validated. Combining pharmacokinetic
data of children from different ages offers the possibility to characterise age-
related changes in pharmacokinetics. A population pharmacokinetic model
was built for lamivudine in which results from several pharmacokinetic
studies and therapeutic drug monitoring data were combined (chapter 4).
The second part of this thesis focuses on the drug formulation. A review
summarizing the published data about the influence of the formulation on
the pharmacokinetics of antiretroviral drugs is presented in chapter 5.
The pharmacokinetics of a new paediatric tablet of lopinavir combined
with ritonavir, developed by a pharmaceutical company, is studied in
chapter 6. The last two chapters focus on the development of a new
paediatric formulation of valaciclovir. First, the pharmaceutical develop-
ment and the bioequivalence assessment of the new paediatric valaciclovir
formulation are described (chapter 7). Secondly, the palatability is inves-
tigated, using in vitro (electronic tongue) and in vivo (paediatric and adult
taste panel) methods (chapter 8).
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Abstract
Objective
To evaluate whether once-daily (q.d.) lopinavir/ritonavir is noninferior to
twice-daily (b.i.d.) dosing in children.
Design
International, multicentre, phase II/III, randomized, open-label, noninferi-
ority trial (KONCERT/PENTA18/ANRS150).
Setting
Clinical centres participating in the PENTA, HIV-NAT and PHPT
networks.
Participants
Children/adolescents with HIV-1 RNA viral load less than 50 copies/ml for
at least 24 weeks on lopinavir/ritonavir-containing antiretroviral therapy.
Intervention
Children were randomized to continue lopinavir/ritonavir b.i.d. or change
to q.d.
Main outcome measure
Confirmed viral load ≥ 50 copies/ml by 48 weeks (12% noninferiority
margin).
Results
One hundred seventy-three children were randomized in the KONCERT
trial (86 q.d., 87 b.i.d.); 46% men, median (IQR) age 11 (9, 14) years,
CD4% 33 (27, 38)%. By week 48, 97 and 98% of time was spent on
q.d. and b.i.d., respectively (one q.d. child lost at week 4). Twelve q.d.
vs. seven b.i.d. children had confirmed viral load ≥ 50 copies/ml within
48 weeks; estimated difference in percentage with viral load rebound 6%
[90%CI (−2, 14)]. Numbers of children with grade 3/4 adverse events (11
vs. 7) or major resistance mutations (3 vs. 2) were similar, q.d. vs. b.i.d.
(both P > 0.3). Among 26 children in an intrasubject lopinavir/ritonavir
pharmacokinetic substudy, lower daily exposure (AUC0−24 161 h×mg/l vs.
224 h×mg/l) and lower Clast (1.03 mg/l vs. 5.69 mg/l) were observed with
q.d. vs. b.i.d. dosing.
Conclusion
Noninferiority for viral load suppression on q.d. vs. b.i.d. lopinavir/
ritonavir was not demonstrated. Although results, therefore, do not
support routine use of q.d. lopinavir/ritonavir, lack of safety concerns or
resistance suggest that q.d. dosing remains an option in selected, adherent
children, with close viral load monitoring.
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1.1 Introduction
Antiretroviral drugs have changed HIV-1 infection from a life-threatening
disease to a chronic infection. However, adherence to therapy remains a
key determinant of disease outcome. For perinatally HIV-infected children,
who face a lifetime on treatment, maintaining long-term adherence is
often a challenge. Simplification of treatment, including decreasing the
frequency of dosing, is likely to increase convenience and enhance adherence
to antiretroviral therapy (ART) [1]. Although several q.d. regimens have
been shown to have noninferior efficacy and safety in adults [2], resulting
in Food and Drug Administration (FDA) and European Medicines Agency
(EMA) approval and widespread use in clinical practice, fewer antiretroviral
drugs are licensed to be taken q.d. by children.
Protease inhibitors are potential candidates for q.d. dosing. They have
a high genetic barrier to development of resistance [3] and when coadmin-
istered with ritonavir, resulting in increased absorption and/or prolonged
terminal elimination half-life, have increasing potential for decreased dosing
frequency. The coformulation of ritonavir-boosted lopinavir (lopinavir/r) in
one tablet (also available as a smaller paediatric formulation) also enhances
convenience of dosing. Various studies have supported the licensing of q.d.
dosing of lopinavir/r for HIV-infected adults [2, 4–7]. However, based on
the currently available evidence in children, paediatric treatment guidelines
recommend lopinavir/r to be taken twice daily (b.i.d.) [8,9]. Small studies
using q.d. lopinavir/r oral solution or soft gel capsules in children showed
high interpatient variability in lopinavir pharmacokinetic parameters and
low trough levels [10, 11]. Reduced variability in lopinavir pharmaco-
kinetics in adults and children has been observed after administration of the
tablet formulation, suggesting that this formulation could be more appro-
priate for q.d. dosing [12, 13]. Here we report the results of KONCERT
(PENTA18/ANRS150), the first randomized controlled trial evaluating the
safety, efficacy and pharmacokinetics of lopinavir/r tablets dosed q.d. vs.
b.i.d. following FDA body-weight band dosing guidelines in virologically
suppressed ART-experienced children and adolescents.
1.2 Methods
1.2.1 Study design and participants
KONCERT was an open-label, multicentre, randomized trial (ISRCTN
02452400, EudraCT 2009-013648-35) in HIV-infected children aged below
18 years who had a stable CD4+ cell count on combination ART containing
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b.i.d. lopinavir/r and had been virologically suppressed (viral load < 50
copies/ml) for at least 24 weeks (single viral load < 400 copies/ml allowed).
In addition, eligibility required that children had viral load less than 50
copies/ml at screening, weighed ≥ 15 kg and were able to swallow tablets.
Kaletra tablets were used throughout. If required, lopinavir/r dose was
adjusted at screening in line with the US FDA dosing guidelines based on
bodyweight band [total daily dose: 400/100 mg lopinavir/r (15 to ≤ 25
kg), 600/150 mg (25 to ≤ 35 kg) or 800/200 mg (> 35 kg)] [14]. Children
were randomized 1 : 1 to continue taking lopinavir/r b.i.d. or to take their
total daily lopinavir/r in a single dose. Parents/guardians and adolescents
provided written consent, younger children gave assent according to their
age and knowledge of HIV status. The study received approval from ethics
committees and regulatory bodies in each participating country and clinical
site.
Randomization was stratified by weight band (as above) and participa-
tion in the pharmacokinetic substudy. The computer-generated sequen-
tially numbered randomization list (with variable block sizes) was prepre-
pared by the trial statistician and securely incorporated within the database
at the Trials Unit. Randomization was undertaken via a web service
accessed by the clinician or Trials Unit, who could access the next allocation
but not the whole list.
1.2.2 Outcome measures
The primary endpoint was a viral load at least 50 copies/ ml (confirmed
within 4 weeks) within the first 48 weeks of follow-up. Primary endpoints
for the pharmacokinetic substudies were pharmacokinetic parameters of
lopinavir/r [area under the curve (AUC), Cmax, Clast] [1], comparing b.i.d.
(week 0) to historical pharmacokinetic data, and [2] comparing q.d. (week
4) to b.i.d. (week 0) in the same children. Analysis of endpoint [1] has
previously been described [15]. Secondary outcomes included the following:
viral load at least 400 copies/ml (confirmed) within 48 weeks; number of
major HIV-1 RNA mutations in those with viral rebound; change in CD4
cell count/percentage from baseline to 48 weeks; adherence to, acceptability
of, and changes made to the ART regimen; ART-related grades 3 and 4
clinical or laboratory adverse events [16,17].
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1.2.3 Data collection and follow-up procedures
Follow-up visits were scheduled at weeks 4, 8 and 12, then 12 weekly until
the last child reached week 48 (Figure 1.1). Viral load was measured at each
study visit; children with viral load at least 50 copies/ml returned within
4 weeks for retest of viral load. Assessment of adherence to treatment
and a resistance test were requested when children had a confirmed viral
load at least 50 copies/ml. T-cell lymphocyte subsets were performed at
all visits; biochemistry and haematology were performed 12-weekly; blood
lipids were measured at weeks 0, 24 and 48; adherence questionnaires were
given to carers and children at weeks 0, 4, 12, 24 and 48; acceptability
questionnaires were completed at baseline and if children switched from
q.d. to b.i.d. dosing. At each study visit, a plasma sample was stored for
subsequent assessment of population lopinavir/r pharmacokinetics.
Figure 1.1: Trial profile.
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1.2.4 Pharmacokinetic substudy
Children who consented were enrolled in a pharmacokinetic substudy, until
a minimum of 16 children in each stratification weight band had evaluable
pharmacokinetic data. Children with nonevaluable pharmacokinetic results
were followed within the main study, but excluded from the pharmaco-
kinetic analysis. Lopinavir pharmacokinetics were determined at week
0 in both arms, and at week 4 if randomized to q.d. dosing. Prior
to the day of pharmacokinetic assessment, children took the paediatric
lopinavir/r tablet (100/25 mg) formulation for at least seven days, following
the FDA-recommended weight band-based dosing. On the pharmaco-
kinetic assessment day, 2 ml of blood was taken before observed intake
of lopinavir/r in the morning (T0) and at 2, 4, 6, 8 and 12 (week 0,
b.i.d.) or 24 h (week 4, q.d.) after the dose. Plasma concentrations were
determined using a validated ultrahigh performance liquid chromatography
assay with UV detection derived from a previously published assay [18].
Lopinavir pharmacokinetic parameters were determined using noncom-
partmental analysis (WinNonlin/ Phoenix version 6.3; Pharsight Corpora-
tion, Mountain View, California, USA): AUC0−24 [area under the plasma
concentration-time curve calculated (linear up-log down method) over a
dosing interval from time 0 to 24 h after dosing], Cmax (maximum observed
plasma concentration), Tmax (time of maximum observed plasma concen-
tration), Clast (last observed drug concentration) and clearance (CL/F).
The intensive pharmacokinetic analyses were performed at the Department
of Pharmacy, Radboud University Medical Center, Nijmegen, the Nether-
lands.
Lopinavir concentrations were also determined on available stored plasma
samples at the screening visit and at weeks 0, 4, 8, 12, 24, 36 and 48 on all
children. This was done to investigate the effect of having lopinavir plasma
concentration below the lower limit of quantification (LLOQ = 0.10 mg/l)
at any visit on virological rebound. Pharmacokinetic analyses for these
stored samples were performed at Radboud University Medical Center,
except for samples in Thailand which were performed at the PHPT-AMS
laboratory, Chiang Mai University, Thailand. Both laboratories participate
in an international interlaboratory quality control programme for thera-
peutic drug monitoring of antiretroviral drugs [19].
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1.2.5 Statistical analyses
A target enrolment of 160 children (80 in each arm) provided at least
80% power to exclude a noninferiority margin of 12% for the difference
between the two arms in the proportion of children reaching the primary
endpoint, assuming a 10% virological rebound rate and onesided α = 0.05.
An Independent Data Monitoring Committee reviewed interim data for
safety and efficacy three times during the study.
All comparisons between randomized arms (q.d. vs. b.i.d.) were
intention-to-treat, with follow-up censored at week 52 or last follow-up
date (if before the week 48 visit). The proportion of children experiencing
virological rebound by week 48 in each arm was estimated using the Kaplan-
Meier method, with 90% confidence intervals (CIs) for the difference in
proportions calculated using bootstrap standard errors [20]. Two prespeci-
fied sensitivity analyses of the primary outcome were completed: adjusting
for baseline stratification factors, and censoring follow-up at the time of
lopinavir/r treatment modification (change in dose, > 7-day interruption or
permanent discontinuation; a ‘per-protocol’ analysis). A post-hoc analysis
adjusting for chance imbalance between arms in viral load and CD4% at
baseline was also performed.
Change in CD4% and other continuous laboratory outcomes from
baseline to 48 weeks were analyzed using normal regression, adjusting
for the baseline measurement and stratification factors. Major resistance
mutations known to confer resistance to antiretroviral drugs not seen in
any pretrial resistance tests were summarized by drug class. Categorical
variables were compared using Fisher’s exact tests; rates were estimated
using Poisson regression. All P values were two sided and all statis-
tical calculations were performed using STATA (Stata Statistical Software,
Release 13; StataCorp LP, College Station, Texas, USA).
All paired evaluable pharmacokinetic assessments [on b.i.d. (week 0)
and q.d. (week 4)] in children randomized to q.d. were included. Within
subject ratios of AUC0−24, clearance (CL/F/kg), Cmax and Clast for q.d.
vs. b.i.d. dosing were calculated. AUC0−24 for b.i.d. dosing was calcu-
lated as 2×AUC0−12. An overall geometric mean ratio (GMR) for each
pharmacokinetic parameter was calculated after log-transformation of the
within-subject ratios; 90%CIs were calculated (using the t-distribution)
using the bioequivalence crossover design tool approach within the Phoenix
WinNonlin software package (with fixed effects in the model specification).
A GMR with a 90%CI including 1.0 and falling entirely within 0.80–1.25
was considered as bioequivalence for AUC0−24 and Cmax. Relative risk
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ratios were calculated comparing the likelihood of virological rebound for
children with at least one sample with lopinavir concentration levels below
LLOQ to those children with all samples ≥ LLOQ.
1.3 Results
1.3.1 Baseline characteristics
Between August 2010 and August 2012, 173 children were randomized (86
allocated to q.d., 87 to b.i.d.) (Figure 1.1); 80 children from Europe, 59
from Thailand and 34 from South America; participants were from 49
clinical centres in 12 countries. Fifty-three took part in the pharmaco-
kinetic substudy, 27 randomized to the q.d. arm; 46, 50 and 77 children
were in the 15 to 25 kg, > 25 to 35 kg, > 35 kg weight bands, respectively.
Baseline demographics were similar in the two arms (Table 1.1); median
(IQR) age was 11.0 (8.7, 14.3) years and 94 (54%) were female. More
children in the q.d. arm had advanced HIV disease, lower CD4% and a viral
load at least 50 copies/ml at baseline (Table 1.1). Pretrial ART exposure
was comparable between arms; 35 (20%) children were on their first-line
regimen at baseline, and half had been exposed to three different antiretro-
viral drug classes. The children were on a variety of NRTI backbones at
baseline (44% zidovudine + lamivudine or emtricitabine, 20% abacavir +
lamivudine or emtricitabine, 16% tenofovir + any other NRTI, 20% other);
29% of backbone NRTIs were taken as q.d. dosing (28% q.d. arm, 30%
b.i.d. arm); this proportion increased over the time of the trial.
1.3.2 Follow-up and antiretroviral therapy received
One q.d. child withdrew consent at week 4; all other children completed 48
weeks follow-up and are included in all analyses. In total, 98 and 97% of
follow-up time was spent on q.d. and b.i.d. dosing of lopinavir/r in the q.d.
and b.i.d. arms, respectively. Twenty-nine (17%) children made changes to
their ART regimen in the first 48 weeks of follow-up [20 (23%) q.d., 9 (10%)
b.i.d.]. In the q.d. arm, two children switched back to b.i.d. lopinavir/r
dosing (at week 1 and 39), 17 children changed their NRTI backbone (66%
to q.d. regimens), and one child did both at week 8. In the b.i.d. arm,
one child switched to q.d. lopinavir/r dosing at week 38 and eight children
changed their NRTI backbone.
24 Making things easier
1.3 Results
Table 1.1: Baseline characteristics
Once-daily Twice-daily Total
Children randomized: n 86 87 173
Men: n (%) 41 (48) 38 (44) 79 (46)
Age (years): median (IQR) 10.8 (8.7, 14.2) 11.2 (9.0, 14.5) 11.0 (8.7, 14.3)
[range] [4.3, 17.6] [3.8, 17.7] [3.8, 17.7]
Ethnic origin: n (%)
White 27 (31) 17 (20) 44 (25)
Black: African or other 17 (20) 29 (33) 46 (27)
Mixed black/white 5 (6) 6 (7) 11 (6)
Asian/Thai 31 (36) 30 (34) 61 (35)
Other 6 (7) 5 (6) 11 (6)
Vertically infected: n (%) 86 (100) 84 (97) 170 (98)
CDC stage: n (%)
N or A 28 (33) 39 (45) 67 (38)
B or C 58 (68) 48 (55) 106 (61)
Viral load (HIV-1 RNA) ≥ 50 copies/ml at randomization∗:
n (%) 12 (14) 4 (5) 16 (9)
Median [range] 120 [51, 91 201] 135 [57, 270] 120 [51, 91 201]
CD4%: mean (sd) 32.0 (6.5) 33.9 (8.6) 32.9 (7.7)
Weight (kg): median 33.3 32.2 33.1
(IQR) (24.6, 42.0) (23.9, 43.8) (24.6, 42.6)
[range] [15.0, 72.5] [15.6, 68.9] [15.0, 72.5]
Baseline ART
first regime: n (%) 18 (21) 17 (20) 35 (20)
Exposed to three classes
of ART: n (%) 41 (48) 46 (53) 87 (50)
∗ All < 50 copies/ml at screening.
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1.3.3 Primary outcome
Nineteen children (12 q.d., seven b.i.d.) experienced confirmed viral
rebound at least 50 copies/ml during 48 weeks of follow-up; all but one
rebound (q.d.) was considered by the treating clinician to be adherence
related. The estimated percentage of children with viral rebound by 48
weeks was 14% [95%CI (8, 24%)] in the q.d. arm vs. 8% [(95%CI (4, 16%)]
in the b.i.d. arm, an estimated difference between arms of 6% [(90%CI
(−2, 14%), bootstrap P = 0.19] (Figure 1.2). The upper 90% confidence
limit of 14% was greater than the predefined noninferiority margin of 12%.
Figure 1.2: Time to virological failure.
Results were similar after adjustment for stratification factors – estimated
difference between arms of 6% [90%CI (−2, 14%), bootstrap P = 0.20]
– and for per-protocol analyses wherein follow-up for eight children was
censored as a result of treatment modification – estimated difference
between arms of 5% [90%CI (−3, 13%), bootstrap P = 0.27]. A post-hoc
analysis adjusting for the chance imbalance between arms in viral rebound
at baseline, reduced the estimated difference in proportion rebounding to
4% [90%CI (−4, 11%), bootstrap P = 0.39], bringing the upper 90% confi-
dence limit just within the noninferiority margin.
Fifteen children [nine (75%) q.d., six (86%) b.i.d.] remained on the same
dosing regimen of lopinavir/r after rebound, the majority of whom went
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on to resuppress [seven (78%) q.d., four (67%) b.i.d.]. Two children (q.d.)
returned to b.i.d. dosing (one of whom resuppressed during follow-up) and
two (one q.d., one b.i.d.) discontinued lopinavir/r after rebound (both
resuppressed).
1.3.4 Secondary outcomes
Viral rebound defined as at least 400 copies/ml was observed in 11 children
(eight q.d., three b.i.d.); the estimated difference between arms in the
probability of rebounding by 48 weeks was 6% [90%CI (0, 12%), P = 0.10].
Genotypic resistance tests were available in 18 (12 q.d., 6 b.i.d.) children
with rebound within 48 weeks; major new resistance-associated mutations
were detected in five (three q.d., two b.i.d.; one b.i.d. did not resupress
< 50 copies/ml during follow-up). Major protease inhibitor mutations
were detected in none of the children on q.d. vs. two children on b.i.d.
lopinavir/r (L90M, M46I + V82A). The M184V mutation was detected in
one child from each arm; three children (two q.d., one b.i.d.) had at least
one thymidine-associated mutation.
Mean changes in CD4% from baseline to week 48 were similar in both
arms: 0.4% for the q.d. arm and 0.1% for the b.i.d. arm [difference 0.3%,
95%CI (−1.0, 1.7%), P = 0.61]. Changes in biochemistry, haematology and
lipid measurements were also minimal and comparable (data not shown).
There were no new CDC stage C events or deaths reported during the
trial. Three new stage B events were reported (two q.d.: pneumonia and
herpes zoster; one b.i.d.: cholecystitis).
There were no significant differences between the trial arms for any of
the clinical safety endpoints (Table 1.2).
Fifteen serious adverse events in 14 children occurred during the first 48
weeks of the trial [episodes (children): nine (8) q.d., six (6) b.i.d., Fisher’s
exact test: P = 0.6], none of which were fatal or life threatening. All
reported serious adverse events were as a result of hospitalization; only
one event, diarrhoea reported during the first week of the trial in a child
taking q.d. lopinavir/r, was considered possibly related to lopinavir/r by
the treating clinician. The incident risk ratio for q.d. relative to b.i.d. was
1.72 [95%CI (0.63, 4.66), GEE Poisson regression P = 0.29].
Twenty-two grade 3 or 4 clinical or laboratory adverse events in 18
children were reported: [episodes (children): 13 (11) q.d., 9 (7) b.i.d.,
Fisher’s exact test: P = 0.3]. Three children experienced adverse events
that led to treatment modification: two children on q.d. with nausea and
vomiting changed back to b.i.d. dosing at weeks 1 and 8; one child on b.i.d.
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Table 1.2: Summary of adverse events to week 48 assessment
Once-daily Twice-daily Total
episodes episodes episodes
(children) (children) (children) P value*
Total adverse events 271 (73) 232 (76) 503 (149) 0.7
Grades 1 and 2 adverse events 256 (70) 222 (76) 478 (146) 0.3
Grades 3 and 4 adverse events 13 (11) 9 (7) 22 (18) 0.3
Gastrointestinal disorders 2 (2) 2 (1) 4 (3) 1.0
Infections and infestations 4 (4) 3 (3) 7 (7) 0.7
Laboratory investigations† 5 (4) 3 (2) 8 (6) 0.4
Blood and lymphatic
system disorders 0 (0) 1 (1) 1 (1) 1.0
Hepatobiliary disorders 1 (1) 0 (0) 1 (1) 0.5
Nervous system disorders 1 (1) 0 (0) 1 (1) 0.5
Adverse events leading to
treatment modification 4 (2) 1 (1) 5 (3) 0.6
Serious adverse events 9 (8) 6 (6) 15 (14) 0.6
Gastrointestinal disorders 2 (2) 1 (1) 3 (3) 0.6
Infections and infestations 5 (5) 4 (4) 9 (9) 0.75
Respiratory, thoracic and
mediastinal disorders 0 (0) 1 (1) 1 (1) 1.0
Hepatobiliary disorders 1 (1) 0 (0) 1 (1) 0.5
Surgical and medical
procedures 1 (1) 0 (0) 1 (1) 0.5
SAE rate per 100 9.5 6.7 8.0
person-years (95%CI) (4.7, 19.0) (3.0, 14.9) (4.8, 13.6) 0.6**
SAE, serious adverse event.
* Fisher’s exact test.
** Poisson regression.
† Abnormal laboratory values without reported associated clinical symptoms.
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had neutropenia at week 4 and substituted abacavir for zidovudine.
Both children and carers reported a preference for q.d. dosage of
lopinavir/r; 120 of 140 (86%) children and 128 of 144 (89%) carers
completing the acceptability questionnaire at trial enrolment thought q.d.
dosing would be easier than b.i.d. dosing. This preference persisted at the
end of trial, when 50 of 68 (74%) of children and 45 of 64 (70%) of carers
reported a preference. Combining responses to adherence questionnaires
completed by children or carers at each trial visit during the first 48 weeks
(89% completion rate), missing a dose within 3 days of the clinic visit was
only reported on 20 occasions [14 (3.5%) q.d. vs. 6 (1.5%) b.i.d., GEE
logistic regression: P = 0.2].
1.3.5 Pharmacokinetic analysis
Intraindividual, paired comparison of lopinavir twice-daily and once-daily
dosing
Twenty-six out of 27 children randomized to the q.d. arm in the pharmaco-
kinetic substudy had evaluable full pharmacokinetics at weeks 0 and 4.
Tables 1.3 (a) and (b) show child demographic data and pharmacokinetic
parameters for lopinavir, respectively. Fifteen (58%) children on q.d.
dosing at week 4 compared with all children on b.i.d. dosing at baseline
had a Clast above 1.0 mg/l, a measurement associated with optimal
virological response in b.i.d. regimens [9]. The GMR (90%CI), q.d. vs.
b.i.d., of lopinavir AUC0−24 and lopinavir Cmax were calculated as 0.72
(0.62, 0.83) and 1.13 (1.00, 1.26), respectively. Neither falling within the
80–125% limits required for bioequivalence.
Routine measurement of lopinavir plasma concentrations
Most children (76 q.d., 74 b.i.d.) had eight samples available during the
initial 48 weeks of follow-up for determination of lopinavir plasma concen-
tration (19 children had seven samples, 1 had six, 2 had five, 1 had three).
Overall, 28 (16.2%) children had at least one lopinavir concentration that
was below the LLOQ of 0.10 mg/l: 21 (24.4%) q.d. vs. 7 (8.0%) b.i.d.,
Fisher’s exact test P = 0.004. A higher proportion of children reaching
the primary endpoint of viral rebound had at least one lopinavir plasma
concentration < LLOQ [11 (57.9%) at least 1 sample < LLOQ vs. 8 (42.1%)
no samples < LLOQ: 9 q.d. 2 b.i.d., Fisher’s exact test P = 0.03].
The overall relative risk (95%CI) of viral rebound, stratified by random-
ized arm, given at least one lopinavir concentration < LLOQ was 7.61
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(2.95, 19.69). A trend was observed of an increasing proportion experi-
encing virological rebound when the number of samples with concentra-
tions < LLOQ increased: 5.5% with no samples < LLOQ, 21.4% with one
sample < LLOQ and 57.1% with two or more samples < LLOQ.
Table 1.3 (a): Within-children pharmacokinetic substudy in 26 children
randomized to once-daily arm – Baseline characteristics
Weight band
15–25 kg 25–35 kg > 35 kg Total
Children: n 7 8 11 26
Men: n (%) 4 (57) 5 (63) 3 (27) 12 (46)
Age (years):
median 7.1 10.6 14.3 12.8
(IQR) (6.7, 8.7) (9.5, 15.0) (13.5, 15.4) (8.7, 14.7)
[range] [4.4, 8.9] [6.3, 16.0] [12.7, 16.8] [4.4, 16.8]
Weight (kg):
median 19.4 30.7 42.0 32.1
(IQR) (19.0, 23.1) (29.8, 32.1) (38.5, 49.5) (24.1, 41.0)
[range] [15.0, 24.1] [26.4, 33.8] [36.0, 72.5] [15.0, 72.5]
BMI (kg/m2):
median 15.1 15.7 17.7 16.5
(IQR) (14.4, 15.7) (14.8, 18.0) (17.4, 20.6) (15.1, 18.6)
[range] [11.5, 15.8] [14.5, 19.4] [16.0, 27.6] [11.5, 27.6]
Vertically infected:
n (%) 7 (100) 8 (100) 11 (100) 26 (100)
Ethnic origin: n (%)
White 0 (0) 1 (13) 1 (9) 2 (8)
Black: African or other 2 (29) 3 (38) 2 (18) 7 (27)
Mixed black/white 1 (14) 1 (13) 0 (0) 2 (8)
Asian/Thai 4 (57) 3 (38) 7 (64) 14 (54)
Other 0 (0) 0 (0) 1 (9) 1 (4)
1.4 Discussion
KONCERT is the first randomized controlled trial in children and adoles-
cents to investigate the safety and efficacy of q.d. vs. b.i.d. dosing of
lopinavir/r. Children from a wide age-range were included, and all main
ethnic groups were represented. The rate of virological rebound, defined
as confirmed viral load at least 50 copies/ml at any time within 48 weeks,
was low in both arms. However, noninferiority of lopinavir/r q.d. vs.
lopinavir/r b.i.d. dosing, when taken as part of combination ART, was not
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Table 1.3 (b): Within-children pharmacokinetic substudy in 26 children
randomized to once-daily arm – Pharmacokinetic parameters
for lopinavir on once-daily (week 4) and twice-daily (week 0)
dosing
n Once-daily Twice-daily Once-/twice-daily
geometric mean geometric mean geometric mean
(95%CI)c (95%CI)c ratio (90%CI)
AUC0−24 (h×mg/l)a
Total: 26 160.9 (138.4, 187.0) 223.9 (194.8, 257.4) 0.72 (0.62, 0.83)
Weight:
15–25 kg 7 172.6 (121.3, 245.7) 232.1 (153.3, 351.4)
25–35 kg 8 159.3 (120.6, 210.5) 256.8 (209.3, 315.2)
> 35 kg 11 155.0 (116.8, 205.6) 198.1 (159.8, 245.5)
Cmax (mg/l)
Total: 26 14.0 (12.7, 15.6) 12.5 (11.1, 14.0) 1.13 (1.00, 1.26)
Weight:
15–25 kg 7 15.5 (12.4, 19.4) 13.5 (9.8, 18.7)
25–35 kg 8 15.0 (12.2, 18.5) 14.1 (11.4, 17.3)
> 35 kg 11 12.5 (10.7, 14.7) 10.9 (9.3, 12.6)
Clast (mg/l)
Total: 26 1.03 (0.61, 1.75) 5.69 (4.58, 7.07) 0.18 (0.12, 0.27)
Weight:
15–25 kg 7 0.91 (0.27, 3.07) 4.92 (2.65, 9.16)
25–35 kg 8 0.93 (0.38, 2.26) 6.65 (5.22, 8.47)
> 35 kg 11 1.20 (0.42, 3.44) 5.57 (3.73, 8.32)
Clearance (l/(h×kg))b
Total: 26 0.115 (0.099, 0.134) 0.084 (0.074, 0.095) 1.37 (1.19, 1.57)
Weight:
15–25 kg 7 0.112 (0.076, 0.165) 0.085 (0.062, 0.117)
25–35 kg 8 0.120 (0.091, 0.158) 0.076 (0.062, 0.094)
> 35 kg 11 0.114 (0.086, 0.150) 0.089 (0.071, 0.113)
Tmax(h)
c
Total: 26 4.0 (2.0, 8.0) 3.5 (0.0, 12.0)
Weight:
15–25 kg 7 4.0 (2.0, 8.0) 3.8 (0.0, 4.1)
25–35 kg 8 4.0 (2.0, 6.0) 2.8 (1.7, 4.0)
> 35 kg 11 4.0 (2.0, 8.0) 3.4 (1.7, 12.0)
a AUC0−24 for b.i.d. dosing = AUC0−12×2.
b Clearance calculated as
CL/F/kg = dose (mg)/[AUC0−24(h×mg/l)×body weight (kg)].
c For Tmax median values (minimum, maximum) are reported.
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demonstrated; 6% more children in the q.d. arm experienced viral load
rebound within the first 48 weeks, and the upper bound of the CI of 14%
was outside the predetermined noninferiority bound of 12%. This differ-
ence was partially explained by the chance imbalance between arms in viral
rebound which occurred between screening and baseline. However, even
after adjustment the upper bound of the CI was 11%, only just within the
predefined 12% margin of noninferiority. No significant safety issues were
demonstrated and there were no differences between arms in development
of resistance mutations.
The within patient pharmacokinetic substudy showed that administra-
tion of lopinavir/r paediatric tablets q.d. resulted in lower daily exposure
to lopinavir and a lower Clast compared with b.i.d. dosing in the same
child. In adults, higher exposure (AUC0−24 206.5 h×µg/ml), but compa-
rable Cmax (14.8 µg/ml) has been observed after q.d. dosing of 800/200 mg
lopinavir [21]. Elimination half-life (t1/2) was comparable with values found
in adults: mean t1/2 (sd) in our study was 6.0 h (3.0 h) for q.d. and 7.7 h
(3.0 h) for b.i.d., compared with 6.1 h (2.5 h) and 8.6 h (4.2 h) in adults,
respectively [5]. Previous smaller paediatric studies have reported that the
AUC0−24 of lopinavir after q.d. dosing of lopinavir/r using various formu-
lations (solution, soft-gel capsules and tablets) lies between 150 and 215
h×mg/l, and Clast between 1.6 and 5.8 mg/l [10–12, 22–25]. In our larger
study, the AUC was at the lower end of this range and Clast below it. This
cannot be explained by lower dose, as the median lopinavir dose received by
children in the pharmacokinetic study was 19.0 mg/kg or 537 mg/m2 q.d.,
which is comparable or higher than the doses received by children in the
other studies. In addition, exposure to lopinavir from tablets in adults was
shown to be significantly higher than from softgel capsules, although the
90%CI of the GMR was reported to be within the bioequivalence range [13].
Additional findings from this trial reflect ‘real life’ dosing, as not only
were formal ‘within-child’ pharmacokinetic studies undertaken, but also
sparse random sampling in all children attending clinic throughout the
48 weeks. We demonstrated that more children in the q.d. treatment
group had at least one undetectable (< LLOQ) lopinavir plasma concen-
tration: 24.4% q.d. vs. 8.0% b.i.d. Further we observed a pharmaco-
kinetic/pharmacodynamic relationship, with the overall risk of viral load
rebound being over seven-fold greater among children with at least one
lopinavir concentration < LLOQ, and twice as high in q.d. vs. b.i.d.
children (9.3 vs. 4.6). These findings together with the results of the
within-child pharmacokinetics show that lopinavir is less forgiving when
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children are dosed q.d., and thus if children are nonadherent, there is a
higher chance of virological rebound. Despite this during the trial, nine
out of 12 children on q.d. who rebounded later resuppressed, and seven
of the nine remained on q.d. lopinavir/r. Although drug concentration
measurements demonstrated that missed q.d. doses had a greater risk of
viral rebound, reassuringly due to the relatively high resistance barrier of
ritonavir-boosted lopinavir, development of new mutations remained low,
and similar to b.i.d. dosing.
Both children and carers reported a preference for taking lopinavir/r q.d.,
but data from the adherence questionnaires suggests that a small number
of children may miss more doses on q.d.
In resource-rich countries, other q.d. boosted protease inhibitor treat-
ments are now widely available for children, but in resource poor situations,
which carry the burden of the epidemic, lopinavir/r remains the mainstay
of paediatric protease inhibitor based therapy (Habiyambere V, WHO ARV
use survey, 2014, personal communication) [26], and the findings of the trial
are particularly relevant to these settings.
In conclusion, based on the combination of viral load rebound and
pharmacokinetic results in the KONCERT trial, q.d. lopinavir/r cannot
be routinely recommended as a simplification option for children with
suppressed viral load on b.i.d. lopinavir/r. However, among selected
adherent children for whom regular viral load monitoring is available, q.d.
dosing remains an option, as we have demonstrated that it is both safe and
not associated with any increased risk of developing resistance mutations.
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Abstract
Background
The use of lopinavir/ritonavir once daily (LPV/r q.d.) has not been
approved for children. Good short-term clinical, virological and immuno-
logical outcomes have been observed in children on LPV/r q.d.
Methods
We evaluated the long-term effectiveness of a LPV/r q.d. containing
regimen in HIV-1 infected children in clinical practice. Selected children
(aged 0–18 years) with an undetectable HIV-1 RNA viral load (< 50
copies/ml) for at least 6 months on a twice-daily (b.i.d.) LPV/r-containing
regimen switched to LPV/r q.d. The main outcome measures were the
percentage of patients with an undetectable HIV-1 viral load each subse-
quent year after switch to LPV/r q.d. (on treatment and last observation
carried forward (LOCF)), and virological failure during follow-up (> 400
copies/ml twice within 6 months). Also the exposure to LPV on the initial
once-daily dosing regimen was determined.
Results
Forty children (median age 6.5 years; range: 1.0, 17) were included. Median
follow-up was 6.3 years (range 1.0, 10.3). During yearly follow-up, the
percentage of children with an undetectable viral load varied between 82–
100% (on treatment) and 83–93% (LOCF). Five children (12.5%) met the
criteria for failure. CD4+ and CD8+ counts remained stable at normal
values. Geometric mean LPV AUC0−24 was 169.3 h×mg/l and Clast 1.35
mg/l. Adverse events were encountered in eight patients, were mainly
gastro-intestinal and in these cases no reason to stop treatment.
Conclusion
A once-daily LPV/r containing regimen in HIV-1 infected children with
intensive clinical and therapeutic drug monitoring is well tolerated and has
good long-term clinical, virological, and immunological outcome.
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2.1 Introduction
Lopinavir boosted with ritonavir (LPV/r) is the only protease inhibitor
(PI) available as tablet and liquid combination formulation for children
under the age of 3 years [1,2]. LPV/r is an effective protease inhibitor and
has a high barrier of resistance. Furthermore it is generally well tolerated
[2, 3]. Therefore, LPV/r is currently recommended as first-line protease
inhibitor in combination with other antiretroviral drugs in the treatment of
HIV-1-infected children aged < 6 years [1]. LPV/r is approved by the U.S.
Food and Drug Administration (FDA) and the European Medicines Agency
(EMA) to be used twice daily (LPV/r b.i.d.) in children. For adult patients
a once-daily regimen (LPV/r q.d.) has also been approved with virological
and immunological responses comparable to a twice-daily regimen [2,4–10].
For children < 18 years LPV/r q.d. has not been approved.
Seven studies on the pharmacokinetics and clinical efficacy of LPV/r q.d.
in HIV-infected children have been published in the past decade [11–17].
These studies show that LPV/r q.d. can result in an adequate exposure
to LPV, but that there is a high interindividual variability in pharmaco-
kinetics, especially in young children. Despite frequently reported subthera-
peutic trough levels (Clast < 1.0 mg/l), most of the children in these studies
showed good short-term clinical, virological and immunological outcomes
(follow up between 6 and 12 months). To answer the question whether once-
daily LPV/r is non inferior to twice-daily LPV/r, a prospective randomized
controlled trial on LPV/r q.d. versus b.i.d. was initiated within the PENTA
network, and results have recently been published [16]. This study was
inconclusive concerning the noninferiority of q.d. LPV/r compared with
b.i.d. LPV/r. Although recommended to be dosed twice daily, the PENTA
group suggests that LPV/r may be used once daily in specific cases where
adherence is monitored and routine clinical follow-up is available [1, 16].
Two of the pharmacokinetic studies on LPV/r q.d. were initiated in our
center in 2002 [15,17]. After completion of these studies, patients who were
on LPV/r q.d. were allowed to continue LPV/r q.d. as long as their viral
loads were undetectable. Subsequently, we gave selected children that had
not participated in the study the chance to switch to LPV/r q.d. on off-
label use basis. To ensure that children had adequate exposure to LPV,
therapeutic drug monitoring (TDM) was used. This study reports the
results of a long-term follow-up of clinical, virological and immunological
response to a TDM controlled regimen of q.d. LPV/r in 40 HIV-1-infected
children.
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2.2 Methods
2.2.1 Study design and population
All children included in the previously published pharmacokinetic studies
on LPV/r q.d. were included in the current long-term follow up study
[15, 17]. After completion and publication of the pharmacokinetic study
on LPV/r q.d., also children not included in the pharmacokinetic study
in our center were offered to switch to (off-label) LPV/r q.d. Inclusion
criteria were an expected good compliance and an undetectable viral load
during the previous 6 months. Children with a follow-up shorter than 12
months were excluded from this study. Data were retrospectively collected
and derived from data obtained in long-term follow-up studies in which
all patients participated. The long-term follow-up study protocols were
approved by the medical ethics committee of the ErasmusMC University
Medical Center Rotterdam, the Netherlands. Written informed consent
was obtained from patients and their parents.
2.2.2 Treatment and clinical follow-up
Treatment-experienced children were initially switched to a regimen
containing LPV/r 460 mg/m2 q.d. based on the results of the previous
pharmacokinetic study or to a higher or lower dose if the LPV dose in
their b.i.d. regimen had been adjusted to a higher or lower dose because of
pharmacokinetic evaluation [15]. The daily dose of LPV q.d. was equiva-
lent to the daily dose the child received b.i.d. Children visited the clinic for
follow-up and counseling with one of the nurse practitioners and/or pedia-
tricians every 3 months. During the clinical visit HIV-1 viral load, CD4+
and CD8+ T-cell count, liver and kidney function, whole blood cell count
and LPV plasma levels were determined, and urinalysis was performed.
Lipid profile was analyzed once a year.
Follow-up for this study stopped when children discontinued LPV/r q.d.
or when they were lost to follow-up, eg because of transfer to adult care.
2.2.3 Therapeutic drug monitoring
Within 2–4 weeks after switch to the once-daily regimen, intensive thera-
peutic drug monitoring (TDM) was performed as standard of care.
Children came to the clinic without having taken their LPV/r that day.
Samples were taken before observed intake and at 2, 4, 6, 8, 12, 18
and 24 hours after intake. Pharmacokinetic parameters of LPV for the
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total group were determined using noncompartmental analysis (Phoenix,
WinNonlin version 6.3. Pharsight Corporation, Mountain View, CA, USA):
AUC0−24 (area under the plasma concentration-time curve (linear up-log
down method) over a dosing interval from time 0 to 24 hours after dosing),
Cmax (maximum observed plasma concentration), Clast (last observed drug
concentration) and clearance (CL/F). LPV concentration was considered
subtherapeutic if Clast was measured or predicted to be < 1.0 mg/l [18].
If needed, the dose was adjusted using the individuals curve and popula-
tion data. TDM was then repeated on a single sample, preferably a trough
sample until plasma concentration of LPV was deemed therapeutic [15].
Furthermore, during follow-up, single plasma levels were monitored every
three months.
LPV plasma concentrations were determined using a validated ultrahigh
performance liquid chromatography assay with ultraviolet detection derived
from a previously published assay [19]. The analysis was performed at the
Department of Pharmacy, Radboud University Medical Center Nijmegen,
the Netherlands.
2.2.4 Statistical analysis
Primary outcome of the study was the percentage of children with an
undetectable HIV-1 viral load (< 50 copies/ml) each subsequent year after
starting LPV/r q.d. Secondary outcomes were 1) sustained viral suppres-
sion (< 50 copies/ml) rates during three-monthly follow-up visits, 2) time to
virological failure during follow-up, 3) immunological and clinical response
including adverse events, and 4) exposure (AUC0−24) to LPV on the initial
once-daily dosing regimen.
The percentage of children with an undetectable HIV-1 viral load was
calculated with an on-treatment and last observation carried forward
(LOCF) analysis. A Kaplan-Meier curve was constructed to evaluate time
to failure. For this analysis, failure was defined as confirmed viral rebound
with an HIV-1 viral load > 400 copies/ml at least twice within 6 months.
Additionally, a single confirmed HIV-1 viral load > 400 copies/ml resulting
in termination of the LPV/r q.d. regimen was also considered as failure [20].
Next to absolute counts, CD4+ and CD8+ T cell counts were calculated
as percentages of age-specific reference values, because absolute CD4+ and
CD8+ T cell reference values are age related [21].
For statistical analysis SPSS version 21.0 (IBMr SPSSr Statistics) and
Excel 2010 (Microsoft) was used.
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2.3 Results
2.3.1 Population
Between March 2002 and January 2014, 43 treatment-experienced HIV-1-
infected children switched to LPV/r q.d. of whom 40 could be included in
our study. Reasons for exclusion were: follow-up period shorter than 12
months (n = 1), detectable viral load during the half year before switch
(n = 1) and age > 18 years at start of LPV/r q.d. (n = 1). Baseline
characteristics are summarized in Table 2.1. Figure 2.1 shows the number
of children on treatment with LPV/r q.d. per year from 2002 through 2013.
Figure 2.1: Number of children on LPV/r q.d. per year.
The median duration of follow-up was 6.3 years (range 1.0, 10.3). First
yearly follow-up was at exact 12 months after starting LPV/r q.d. The
interval of each subsequent yearly follow-up was aimed at 12 months but
varied from 9–15 months depending on scheduled appointments.
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Table 2.1: Baseline characteristics of HIV-1-infected children in this study
of clinical response to lopinavir/ritonavir once daily (n = 40)
Characteristic Value
Sex (male/female) 23/17
Age in years (range)† 6.3 (1.0, 17)
Route of HIV transmission
Vertical 33
Blood contact 2
Sexual abuse 1
Unknown 4
CDC HIV disease classification‡
N1, N2, N3 7, 3, 3
A1, A2, A3 2, 4, 1
B1, B2, B3 2, 5, 1
C1, C2, C3 1, 1, 10
Plasma HIV-1 RNA level† (copies/ml) 50 (< 50, 145)
HIV RNA < 50 copies/ml 37
HIV RNA > 50 copies/ml 3
CD4+ T cell value†
Absolute cell count (×106 cells/ml) 920 (340, 2760)
Percentage of normal for age 93 (34, 267)
CD8+ T-cell value†
Absolute cell count (×106 cells/ml) 920 (240, 2280)
Percentage of normal for age 137 (30, 413)
Total T-cell value†
T-cell count (×106 cells/ml) 2055 (670, 5450)
Percentage CD4+ of total T-cell count 48 (26, 70)
cART regimen prior to LPV/r q.d.
3TC/AZT/LPV/r b.i.d. 19
3TC/AZT/IDV/r b.i.d. 6
LPV/r/EFV b.i.d. 5
3TC/AZT/ABC 2
3TC/ABC/LPV/r b.i.d. 2
Other combinations 6
Combinations with LPV/r q.d. Initial After switch
3TC/ABC 18 33
3TC/AZT 15 2
EFV 5 3
TDF/FTC 2 2
† at start LPV/r q.d. regimen
‡ at start antiretroviral therapy
Data are presented as number of patients or median (range) values. CDC, centers of
disease control and prevention; b.i.d., twice-daily; q.d., once-daily; 3TC, lamivudine;
AZT, zidovudine; LPV/r, lopinavir/ritonavir; IDV/r, indinavir/ritonavir; EFV,
efavirenz; ABC, abacavir; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine
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2.3.2 Treatment
All children received combination antiretroviral therapy (cART) prior to
starting LPV/r q.d. (Table 2.1 with a mean duration of 3.4 years (range
0.7, 9.6 years). Nineteen (48%) of them used a combination of lamivudine,
zidovudine and LPV/r twice daily. If children switched from cART not
containing LPV/r, they started their regimen with LPV/r b.i.d. before
switching to LPV/r q.d.
At start of the once-daily regimen, 15 children (38%) started with the
liquid formulation, 15 (38%) with soft-cell capsules and 10 (25%) with
tablets. Median dose at start of the regimen was 465 mg/m2 (range 275,
637 mg/m2). During follow-up, in 31 children dose was adjusted 120 times.
Median number of dose changes per child was 2 (range 0, 10). Reasons
for changing dose were growth (increase in body surface area) (50.8%),
low plasma concentrations of LPV (25%) or change of LPV/r formulation
(20.8%). In 2 children LPV/r dose was lowered once because of too high
concentrations of LPV with risk of toxicity. Most doses were adjusted in
children who started the once-daily regimen on LPV/r liquid and were
based on growth. Backbone therapy was changed 13 times in 13 children
(33% of all children) during follow-up. Simplification was the reason for
changing the nucleoside reverse transcriptase inhibitor backbone medica-
tion in all cases.
Eight children (20%) discontinued the once-daily regimen. Five of them
switched to a one pill-once a day regimen with efavirenz/emtricitabine/
tenofovir DF for simplification reasons. One child switched cART because
of toxicity of the regimen (see below). Two children stopped cART (1
because of religious beliefs and 1 because of adherence problems due to
severe depression).
2.3.3 Virological and immunologic response to therapy
Figure 2.2 shows the percentage of children with an undetectable viral load
(< 50 copies/ml) for each subsequent year after starting LPV/r q.d. At
start of the LPV/r q.d. regimen 37 (93%) children had an undetectable viral
load. Three children had a single detectable viral load < 400 copies/ml at
start, after being undetectable for 6 months or more. These 3 children had
an undetectable viral load again during follow-up after this initial detectable
viral load. During follow-up the percentage of children with an undetectable
viral load varied between 82–100% (on treatment) and 83–93% (LOCF).
In 13 children (33%) HIV-RNA was detectable (> 50 copies/ml) at least
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Figure 2.2: Percentage of children with a viral load < 50 copies/ml during
follow-up; t0 = start LPV/r q.d.; n = number of children on
LPV/r q.d. at yearly time-point; LOCF, Last Observation
Carried Forward.
once during three-monthly follow-up. In 6 of these children viral load did
not exceed 400 copies/ml. In 7 children viral load was higher than 400
copies/ml at least once during follow-up. Figure 2.3 shows the Kaplan-
Meier curve for time to virological failure. During the entire follow-up
period a total of 5 (12.5%) children met the criteria for failure (viral
load > 400 copies at least twice within 6 months during follow-up). All
children returned to an undetectable viral load within one year after being
detectable. All children who had a detectable viral load during follow-up,
admitted to have adherence problems to therapy at that time.
At baseline median absolute CD4+ and CD8+ counts were 920 × 106
cells/ml (range 340, 2760) and 920×106 cells/ml (range 240, 2280), respec-
tively. These absolute counts corresponded with a median percentage of
age-specific reference values of 93% (CD4+) and 136% (CD8+). During
follow-up median CD4+ counts remained stable at normal levels. Addition-
ally, median CD8+ counts also remained at normal levels during follow-up.
Median percentage CD4+ of total T-cell count was 48% (range 26, 70) and
was 48% (range 23, 70) during follow-up.
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Figure 2.3: Kaplan-Meier curve for time to virological failure; virological
failure defined as a viral load > 400 copies/ml two or more
times within 6 months, or viral load > 400 copies/ml resulting
in discontinuation of LPV/r q.d.
2.3.4 Therapeutic drug monitoring
Full pharmacokinetic curves after switch to LPV/r q.d. were available
for 39 out of 40 children. Geometric mean (95%CI) area under the curve
(AUC0−24) for LPV was 169.3 (144.9, 197.8) h×mg/l, Cmax 12.5 (11.0,
14.3) mg/l and Clast 1.35 (0.86, 2.12) mg/l, see also Table 2.2. A total of 15
children (38%) had a Clast < 1.0 mg/l. Ten of these 15 children (67%) had
their dose changed after baseline pharmacokinetic analysis. Two children
had their curves repeated after which no dose change was needed and 3
children remained on the same dose because virological and immunological
response to the initial dose was good.
Out of the 15 children who had Clast < 1.0 mg/l at baseline, 2 children
had a detectable viral load after switching to LPV/r q.d. One child (Clast =
0.41 mg/l) had a viral load of 52 copies/ml that returned to an undetectable
load at the next measurement without the need of changing the dose. One
child (Clast = 0.58 mg/l) had a viral load of 453 copies/ml, which returned
to an undetectable viral load 4 months after dose was increased based on
the results of pharmacokinetic analysis. Out of the 24 children who had
Clast > 1.0 mg/l at baseline, 1 child had a detectable viral load after switch
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Table 2.2: Geometric mean (95%CI)∗ pharmacokinetic parameters of
lopinavir (n = 39)
AUC0−24 (h×mg/l) 169.3 (144.9, 197.8)
Cmax (mg/l) 12.5 (11.0, 14.3)
Clast (mg/l) 1.35 (0.86, 2.12)
Clearance (l/(h×kg))§ 0.104 (0.088, 0.123)
Tmax (h)
∗ 6.2 (0.0, 18.6)
§ Clearance calculated as
CL/F/kg = dose (mg)/[AUC0−24(h×mg/l)×body weight (kg)]
∗ For Tmax the median value (minimum, maximum) is reported.
to LPV/r q.d. This child (Clast = 6.27 mg/l) experienced a viral load of 110
copies/ml but returned to an undetectable load within 3 months without
the need of changing the dose.
2.3.5 Adverse events and laboratory findings
Adverse events were encountered in 8 children (20%). Seven experienced
gastrointestinal side effects such as nausea and/or diarrhea. For these
children, symptoms were mild and there was no need to stop treatment.
One child stopped treatment because of persistent elevated lipid-levels, with
highest measured cholesterol of 9.4 mmol/l and triglycerides of 7.8 mmol/l.
In other children lipid profiles varied, but were mainly within range of the
reference values. A total of 31 lipid profiles (32 triglycerides profiles) were
available at baseline. 191 lipid profiles were analyzed during follow-up (24
profiles missing in 19 patients during follow-up). Mean cholesterol at start
(n = 31) of the once-daily regimen was 4.7 mmol/l (range 2.9, 7.2) and
during follow-up (n = 40) 4.9 mmol/l (range 2.8, 9.4). Values for triglyc-
erides were a mean of 1.38 mmol/l (range 0.58, 5.34) at start (n = 32) of
the regimen and 1.54 mmol/l (range 0.42, 7.83) during follow-up (n = 40).
2.4 Discussion
In this long-term follow-up observational cohort study in 40 patients we
show that a once-daily LPV/r containing regimen can result in a high
virological suppression rate (83–93% undetectable viral load with median
follow-up of 6.3 years, range 1.0, 10.3). During the years of follow-up
27 (68%) HIV-1-infected children had continuously suppressed viral loads
< 50 copies/ml, when treated with LPV/r q.d. Out of the children with
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virological rebound, 6 children experienced a viral load < 400 copies/ml.
Out of the children with virological rebound > 400 copies/ml, five children
met the criteria for failure (viral load > 400 copies/ml within 6 months at
least twice). All children with a detectable viral load, regardless of absolute
count, returned to an undetectable viral load within a year after the viral
rebound. CD4+ and CD8+ counts in children remained stable at normal
values during follow-up.
The suppression rate in our study, is either comparable to or higher
than the results of real-life cohort studies on the long term follow-up
of HIV-1 infected children treated with a twice-daily LPV/r containing
regimen [22,23]. Our results are also comparable to the virological response
rates on different, and variable cART regimens found in two nationwide
cohort studies from European countries comparable to our setting [20,21].
A long-term follow-up study performed in 997 HIV-1 infected children in
the United Kingdom and Ireland reported an optimal virological response
rate in 92% of the children after 12 months of follow-up, but with estimated
higher failure rates as follow-up progressed. The other study was performed
in the Dutch cohort where 89% of 210 children treated with cART had
undetectable viral loads during a median follow-up period of 8.7 years. The
40 children included in the current study are part of these 210 children.
To our knowledge there are no other studies that report on the long-term
(> 1 year) real-life virological and immunological response to LPV/r q.d.
in children. Some studies report on the short-term results of LPV/r q.d.,
with response rates between 57 and 100% [11, 12, 14]. Based on results
from a recent large randomized trial comparing LPV/r q.d. with twice-
daily dosing of LPV/r in treatment-experienced children performed by the
PENTA network (KONCERT), the 2015 PENTA guidelines on the treat-
ment of HIV-1 infected children advise that LPV/r should be dosed twice
daily, but that once-daily dosing may be used in selected children by whom
adherence is monitored and routine clinical follow-up is available [1, 16].
The KONCERT study reports that 86% of the children maintained viral
suppression after 48 weeks on a once-daily regimen vs 92% on twice-daily
dosing, (an estimated difference between arms of 6% [90%CI −2%, 14%],
bootstrap P = 0.19). A baseline imbalance between groups in viral rebound
and CD4-percentage complicated the interpretation of these results. Our
results support PENTAs statement that in a monitored clinical setting and
in children with expected good adherence to therapy, LPV/r q.d. can be a
good alternative in treating children.
All children in our study who failed on therapy admitted to have adher-
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ence problems at that time. We recognize the risk of virological failure in a
once-daily regimen when children are non-adherent to therapy. We there-
fore stress the importance of adherence when a once-daily dosing regimen
is considered. The possible higher chance of virological failure when being
non-adherent has been suggested previously [12,16]. Counseling by trained
nurses, addressing adherence issues, and a strict failure protocol will also
have supported our children to achieve virological suppression.
Performing intensive TDM might have been a key to detect under or over
dosing and possible non-adherence and thus increase virological response
rates in our cohort. We performed intensive pharmacokinetic evaluation
in all children about 2 weeks after start of LPV/r q.d. and TDM every
3 months. Exposure to LPV was comparable to what was found in other
pediatric studies [11,13–15,17]. LPV trough concentrations > 1.0 mg/l are
associated with better virological outcome in subjects treated with LPV/r
b.i.d. [18]. We showed that both children with Clast below this limit as well
as children that were above this limit experienced viral rebounds. These
findings are comparable to results from other studies [11,12].
Once-daily LPV/r was well tolerated, also in the younger age group
that had to take the liquid formulation with poor palatability. This
might be explained by the LPV/r experienced population. Intolerability is
mostly reported in treatment-na¨ıve children [6]. In our study lipid profiles
remained stable and within the normal range in most children. This is
similar to findings in other studies [11,16].
A limitation of this study is the population that was selected based
on expected good adherence and pre-existing viral suppression, which
makes the results not generalizable to unselected populations. Additionally,
because of the retrospective nature of the study, no control group could be
included.
LPV/r is approved to be used twice daily only in children, and once-daily
use is therefore considered off-label [2, 7]. When drugs are used off-label,
safety and efficacy have not been reviewed by regulatory authorities, and
need to be evaluated for each patient [24,25]. When a drug is used off-label
in real-life setting in such a relatively large population as ours we feel it is
important to evaluate outcome in a structured manner and to report the
results found.
In conclusion, we suggest that, based on our results, especially for
younger children in whom LPV/r is the only boosted PI option, LPV/r
q.d. can be a good alternative for b.i.d. dosing in selected cases with pre-
existing undetectable viral load, expected good adherence, and intensive
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Abstract
Background
The approved dosing recommendations for children 6–12 years old are based
on a modelling and simulation procedure by the company. The aim of this
study was to validate the proposed dosing recommendation for once-daily
darunavir/ritonavir in HIV-infected children 6–12 years of age.
Methods
This pharmacokinetic study is a multicenter phase-1 trial in HIV-infected
children and has been performed by paediatric HIV-centres in the Nether-
lands. Children took darunavir tablets following the approved dose. A
24h pharmacokinetic curve was collected after observed intake. Pharmaco-
kinetic parameters (area under the plasma concentration-time curve
(AUC), maximum plasma concentration (Cmax), last observed plasma
concentration in dosing interval (Clast)) were determined using noncom-
partmental analysis and were compared to historical data.
Results
Twelve children were included. The geometric mean (%CV) AUC0−24 was
63.1 (33%) h×mg/l, Cmax 5.6 (34%) mg/l and Clast was 1.5 (44%) mg/l.
The lower limit of the one sided 90%CI of the AUC0−24 was 55.7 h×mg/l,
which is 62% of the adult value (89.7 h×mg/l). Ten out of the 12 children
had an AUC0−24 below the adult target value, of which eight had an AUC
below 0.8 of the adult target value. Clast of all of the children was found
to be adequate.
Conclusion
The AUC of darunavir in children 6–12 years was substantially lower than
predicted by the population pharmacokinetic model, which was used for
approval of the once-daily dosing regimen of darunavir/ritonavir in children.
Since trough levels were above the target value, the treatment was consid-
ered adequate.
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3.1 Introduction
3.1 Introduction
Antiretroviral treatment that can be administered once daily instead
of twice daily is generally preferred for the treatment of HIV-infected
children [1,2]. Protease inhibitors that are approved to be used once daily
in children are atazanavir, with or without ritonavir, and recently also
darunavir boosted with ritonavir (darunavir/r). Dosing recommendations
for darunavir/r once daily in children have been derived from results from
several pharmacokinetic studies in children [3–5]. These included once-daily
pharmacokinetic data from the DIONE trial in adolescents (12–18 years)
demonstrating a slightly lower darunavir plasma exposure, but comparable
virologic response and safety profile compared to treatment-naive adults,
and results from children in the ARIEL trial (3–6 years) who received the
darunavir suspension [3,4]. A population pharmacokinetic model was built
from data of these paediatric studies combined with adult data [6]. This
model was used to predict exposure to darunavir using different potential
dosing regimens. The dosing regimen that was predicted to approach the
adult exposure best, was chosen to be included as dose recommendation in
the label [6].
The predicted exposure after administration of the recommended once-
daily dose has not yet been studied in the target population. Because of the
lack of clinical and supporting pharmacokinetic data, once-daily darunavir
is not yet recommended for children under the age of twelve years in current
paediatric guidelines [1]. To fill this gap in information the aim of this
study was to describe the pharmacokinetics for the recommended once-
daily darunavir/r dose in children 6–12 years old and to determine whether
exposure is comparable to the target in adults.
3.2 Methods
This pharmacokinetic study was an open label, multi-center phase I
trial in HIV-infected children (6–12 years of age) who were treated with
darunavir/r once daily as part of their current combination antiretro-
viral treatment. The trial has been performed by paediatric HIV-
centres in the Netherlands and was approved by the medical ethical
committee of the Radboud university medical center (CMO Arnhem-
Nijmegen, NCT02285478).
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3.2.1 Population and treatment
Children could be included when they were using darunavir/r once-daily
in the approved dose: 600/100 mg if 15–30 kg; 675/100 mg if 30–40 kg;
800/100 mg if > 40 kg). Furthermore, they must have had an undetectable
viral load (< 50 copies/ml) for at least 6 months, had a body weight of
15 kg or more and were able to swallow intact tablets. Children who
previously failed on a protease inhibitor-containing regimen could not be
included. The use of concomitant drugs was not allowed unless permission
was granted by the trial team. Other exclusion criteria were: inability to
understand the nature and extent of the trial and the procedures required;
a documented history of sensitivity to darunavir or ritonavir medicinal
products or its excipients and a relevant history that might interfere with
drug absorption, distribution, metabolism or excretion.
3.2.2 Sample size
Darunavir plasma exposure should be similar compared to adults when
using the approved dosing regimen. The target geometric mean area under
the plasma concentration time curve over a dosing interval (AUC0−24) in
adults is 89.7 mg×h/l. A variation coefficient of 29% in AUC0−24 has been
observed in adolescents [3]. Based on these values it was aimed to include
12 children to be able to determine with a power of 80.3% that the lower
limit of the 90% one sided confidence interval of the geometric mean of the
AUC is higher than 0.8 of the value found in adults. This was based on a
simulation study in SASr performed to establish the power of the study
for varying sample sizes. For each choice of sample size 10 000 simulations
were performed.
3.2.3 Pharmacokinetic assessment
Prior to the day of pharmacokinetic assessment children took darunavir
tablets in the morning for at least 3 days. Children came to the clinic fasting
and without having taken the morning dose of darunavir/r. Darunavir
was administered with a breakfast. A 24h pharmacokinetic curve (7 or 8
samples) was collected after observed intake. Samples (2 ml of blood) were
taken just before dosing and at 2, 3, 4, 6, 8, 12 and 24h post ingestion.
For logistic reasons (eg travelling distance to hospital), the 12h sample was
allowed to be left out.
Plasma concentrations of darunavir and ritonavir were determined using
a validated ultra-high performance liquid chromatography assay with UV
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detection derived from the previously published assay [7]. The analysis was
performed at the Department of Pharmacy, Radboud university medical
center, Nijmegen, the Netherlands. The analytical range of the assay for
darunavir was 0.10–30 mg/l and for ritonavir 0.045–30 mg/l. The intraday
and interday precision for both assays ranged from 0.6 to 4.3% (coefficient
of variation) and 0.3 to 2.4%, respectively. The percentage accuracy of the
assay ranged from 98.2 to 105.6%.
3.2.4 Acceptability questionnaire
Acceptability of a drug regimen is important for adherence. Aspects such as
dosing frequency, ease of administration and palatability are important for
acceptability. Therefore, during the day of the pharmacokinetic assessment
children and their parents were asked about the preference for the current
or previous antiretroviral regimen. They were also asked what the main
reason for the preference was.
3.2.5 Pharmacokinetic and statistical analysis
Darunavir and ritonavir pharmacokinetic parameters were determined
using noncompartmental analysis (Phoenixr WinNonlinr version 6.4,
Pharsight Corporation, Mountain View, CA, USA). The actual sampling
times were used for pharmacokinetic analysis. Pharmacokinetic parameters
of interest were AUC0−24 (area under the plasma concentration-time curve
calculated over a dosing interval from time 0 to 24 hours after dosing (linear
up-log down trapezoidal method)), maximum observed plasma concentra-
tion (Cmax), time of Cmax (Tmax), drug concentration 24 hours post-dose
(C24), clearance (CL/F/kg) and elimination half life (t1/2).
3.3 Results
3.3.1 Population
Twelve children were enrolled between July 2015 and August 2016, of which
seven were girls. Median (range) age of the included children was 8.9 (6.3,
11.7) years and weight was 26.6 (22.4, 45.0) kg. Further demographic
data of the children are presented in Table 3.1. Seven children used
darunavir/r 600/100 mg, two 675/100 mg and three 800/100 mg. The
median (range) darunavir dose administered to the children was 22.6 (17.8,
26.8) mg/kg. All children used abacavir and lamivudine once daily as
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antiretroviral background regimen. The use of other concomitant medica-
tion was reported for two children (one child: levetiracetam, valproic acid,
clobazam; one child: triptorelin). None of these drugs are known to
influence the metabolism of darunavir or ritonavir. Three children used
vitamin D. One child suffered from anxiety starting 4 weeks after switch to
darunavir/r and 2 weeks after the pharmacokinetic assessment, resulting
in hallucinations at 6 weeks after start. Darunavir/r was stopped and the
child fully recovered within 4 days after discontinuation. This child used
600 mg (24 mg/kg) darunavir.
Table 3.1: Demographic data of the children at the day of the pharmaco-
kinetic assessment (n = 12)
median (range)
Sex (female/male) 7/5
Age (years) 8.9 (6.3, 11.7)
Weight (kg) 26.6 (22.4, 45.0)
Darunavir dose (mg/kg) 22.6 (17.8, 26.8)
Ritonavir dose (mg/kg) 3.8 (2.2, 4.5)
Dosing regimen darunavir/r (n)
600/100 mg (15–30 kg) 7
675/100 mg (30–40 kg) 2
800/100 mg (≥ 40 kg) 3
3.3.2 Darunavir pharmacokinetics
The calculated pharmacokinetic parameters of all of the children (n = 12)
were used for the final pharmacokinetic model. The geometric mean (%CV)
AUC0−24 was 63.1 (33%) h×mg/l, Cmax 5.6 (34%) mg/l and Clast was
1.5 (44%) mg/l, see also Table 3.2. The mean plasma concentration time
profile is shown in Figure 3.1. It was predefined that exposure would be
adequate, when the lower limit of the 90% one sided confidence interval of
the geometric mean of the AUC0−24 was higher than 0.8 of the value of
adults (0.8×89.7 = 71.8 h×mg/l). The lower limit of the one sided 90%CI
was 55.7 h×mg/l, which is 62% of the adult value. Therefore, this target
was not reached. The geometric mean AUC0−24 was 70% of the AUC0−24
found in adults. Ten out of the 12 children (83%) had an AUC0−24 below
the adult target value, of which eight (67%) had an AUC below 80% of the
adult target value, see also Figure 3.2.
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Clast of all of the children was measured between 23.1 and 25.1 hours
after the observed intake and all were above 0.55 mg/l (range: 0.69, 2.38
mg/l), which is the target for protease inhibitor experienced patients.
Table 3.2: Darunavir pharmacokinetic parameters after once-daily dosing
in HIV-infected children (n = 12)
geometric mean (CV%)
AUC0−24 (h×mg/l) 63.1 (33%)
Cmax (mg/l) 5.6 (34%)
Clast (mg/l) 1.5 (44%)
Clearance (l/h×kg) 0.36 (40%)
AUC0−24: Area under the plasma concentration time curve over 24 hours;
Cmax: maximum plasma concentration;
Clast: last observed plasma concentration within the dosing interval;
Clearance: (CL/F/kg) = dose/(AUC0−24×body weight).
Figure 3.1: Mean (± SD) plasma concentration time curve.
3.3.3 Acceptability
All children completed the questionnaire together with their parents. For
all children the antiretroviral regimen used before darunavir once daily
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Figure 3.2: Area under plasma concentration time curve versus dose in
comparison to the adult target value of 89.7 h×mg/l.
was lopinavir/r administered as tablets once daily (n = 3) or twice daily
(n = 9). Ten of the children and ten of the parents thought it was easier
or much easier to take darunavir/r once daily, compared to the previous
dosing regimen. One child and two of the parents did not think it was a
difference. One child had more difficulties with it, because the child had
to get used to the taste. A once-daily regimen compared to a twice-daily
regimen was preferred by most of the subjects (n = 11), one did not think
it made a difference. The main reason for preference for once-daily use was
the lower impact on daily activities (‘Child doesn’t have to be woken up
for medication’, ‘Child doesn’t have to take medicines to social activities’).
The preferred moment to take the medication was the evening for eight of
the children and in the morning for four of the children.
3.4 Discussion
A lower than predicted exposure (AUC) to darunavir was observed in
HIV-infected children, aged 6–12 years, using the recommended once-daily
dosing regimen. The by the EMA and FDA approved dosing regimen was
based on a population pharmacokinetic model, that predicted a mean AUC
in children between 80 and 130% of the adult value of 89.7 h×mg/l [6]. The
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geometric mean exposure in our paediatric population was 63.1 h×mg/l,
which is 70% of the adult value. For only four of the twelve children, an
exposure between the predicted limits was found. However, since Clast of
all of the children was above 0.55 mg/l, it is our opinion that exposure is
adequate and that the once-daily dose recommendations can be maintained.
This is the first study to report on the pharmacokinetics of the approved
once-daily dosing regimen of darunavir/r in children aged 6–12 years.
Two studies investigated the exposure to darunavir in adolescents, one
in children under the age of 6 years [3, 6, 8]. The observed exposure in
adolescents treated with once-daily darunavir/r 800/100 mg in the DIONE
trial was slightly lower than observed in adults [3]. The geometric mean
AUC0−24 was 80.7 mg×h/l, which is 90% of the adult target. A paedi-
atric study in Thailand (n = 8) found also a lower exposure to darunavir,
in children aged 11–19 years [8]. The dose used in this study was lower
than the approved dosing regimen. A higher exposure was observed
in 10 treatment-experienced children in the ARIEL study who switched
from twice- to once-daily dosing of darunavir after 24 weeks of therapy.
Children used the liquid formulation for which bioequivalence compared
to the commercial tablets has been shown under fed conditions in adults
[9]. Pharmacokinetic parameters were determined after two weeks and
darunavir mean AUC0−24 was 128% of the adult AUC0−24 [9]. Children in
this study were administered a higher bodyweight based dose (40/7 mg/kg
darunavir/r, or 600/100 mg from 15 kg), which could partly explain the
higher exposure.
It can be debated whether AUC is the best parameter to determine the
efficacy of darunavir, since for most protease inhibitors efficacy is found to
be correlated with the trough level [2]. However, for darunavir no corre-
lation has been found between the observed trough levels (nor AUC) and
efficacy, but in clinical studies trough levels remained widely above the
median effective concentration for wild-type HIV-1 [10].
The bioavailability of darunavir increases from about 37% to 82% when
a single dose darunavir 600 mg is combined with 100 mg ritonavir in HIV-
negative volunteers [10]. This indicates an important effect from ritonavir
on darunavir absorption and/or first pass metabolism. In the popula-
tion pharmacokinetic model the ritonavir concentration was not included
as covariate. However, most of the subjects included in the population
pharmacokinetic model used darunavir/r twice daily instead of once daily.
Next to this, children have a lower gastro-intestinal volume than adults,
which might influence the amount of darunavir that is dissolved and avail-
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able for absorption. Especially for a low-solubility class drug such as
darunavir, this might also partly explain the observed lower exposure [11].
In conclusion we found that the AUC of darunavir in children 6–12 years
was substantially lower than predicted by the population pharmacokinetic
model, which was used for approval of the once-daily dosing regimen of
darunavir/r in children. Since trough levels were above the target value,
the treatment was considered adequat.e
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Abstract
Aim
The objectives of this study were to characterise age-related changes in
lamivudine pharmacokinetics in children and evaluate lamivudine exposure,
followed by dose recommendations for subgroups in which target AUC0−24
is not reached.
Methods
Population pharmacokinetic modelling was performed in NONMEM using
data from two model building datasets and two external datasets (n = 180
(aged 0.4–18 years, bodyweight 3.4–60.5 kg); 2 061 samples (median 12
per child)) in which a daily oral dose ranging from 60–300 mg (3.9–17.6
mg/kg) was given. The model was validated both internally and externally.
AUC0−24 was calculated per individual.
Results
A two-compartment model with sequential zero-order and first-order
absorption best described the data. Apparent clearance and central volume
of distribution was 13.2 l/h and 38.9 l for a median individual of 16.6 kg,
respectively. Bodyweight was identified as covariate on apparent clearance
and volume of distribution using nonlinear functions. The external evalu-
ation supported the predictive ability of the final model. In 94.5% and
35.8% of the children with a bodyweight > and < 14 kg, respectively, the
target AUC0−24 was reached.
Conclusion
Bodyweight best predicted the developmental changes in apparent lamivu-
dine clearance and volume of distribution. For children with a bodyweight
< 14 kg, the dose should be increased to 10 mg/kg/day if the adult
target for AUC0−24 is aimed for. In order to identify whether bodyweight
influences bioavailability, clearance and/or volume of distribution, future
analysis including data on intravenously administered lamivudine is needed.
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4.1 Introduction
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) which
is widely used as part of the treatment of human immunodeficiency virus
(HIV)-infected children. It is currently recommended as part of first-line
NRTI backbone together with either a protease inhibitor or non-nucleoside
reverse transcriptase inhibitor [1]. Lamivudine is available in solid and
liquid dosage forms, as well as in single entity and fixed dose combination
products. Several issues have been raised concerning the treatment with
lamivudine, such as bioavailability issues [2–6] and possible underdosing in
the youngest age group [7–9].
Several studies on the pharmacokinetics of lamivudine in children have
been performed. Most studies applied noncompartmental analysis [4, 5,
8–15] and some developed a population pharmacokinetic model [7, 16–20].
Most of these studies were based on a small number of children, narrow
age ranges or the relationship between parameters and covariate was fixed
a priori. None of the models has been validated externally, in other words
the models have not been evaluated in how well they generalize to new
data, which have not been included in the model-building dataset.
As highlighted before, dosing in children should be based on the under-
standing of the developmental changes in the pharmacokinetic and/or
pharmacodynamic relation of drugs instead of applying the adult mg/kg
dose to children [21–23]. For lamivudine, the area under the daily plasma
concentration-time curve (AUC0−24) is mainly used as a surrogate for the
intracellular exposure to lamivudine triphosphate. In adults, an average
AUC0−24 of 8.9 mg×h/l is reached after administration of a daily dose of
300 mg [2]. Also in children, this value is used as a target for lamivudine
exposure [7, 15,16,24].
The objectives of this study were to characterise age-related changes in
lamivudine pharmacokinetics in infants, children and adolescents, and to
test how well this model can be generalized to new patients not included in
the model-building dataset. Based on the developed population pharmaco-
kinetic model, lamivudine exposure upon currently used dosing recommen-
dations was evaluated and, when necessary, a new dose will be calculated
for subgroups in which target AUC0−24 was not reached.
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4.2 Methods
4.2.1 Patients and treatment
Model building was based on data from two datasets of in total 85
children using lamivudine twice daily. The first dataset consisted of 64
children, aged 0.5–14.9 years, who participated in the CHAPAS1 trial [25].
CHAPAS1 was an open, randomized controlled phase I/II trial designed
to assess the appropriate dosing of and adherence to Triomuner. Lamivu-
dine was administered in a fixed-dose combination tablet of lamivudine,
nevirapine and stavudine. Daily dosing was based on acquiring an appro-
priate nevirapine dose. Daily lamivudine dose varied between 60 and 240
mg (6.3–17.6 mg/kg). In the second dataset, 21 children, aged 1.7–18.0
years, were included in whom therapeutic drug monitoring on lopinavir
was performed as part of routine clinical care. In the available samples,
lamivudine concentrations were also determined. Lamivudine was dosed
orally according to the PENTA guideline valid at that time [26]. Daily
lamivudine dose varied between 80 and 300 mg (5.1–10.5 mg/kg) for the
children included in this cohort. An overview of the patient characteristics
is given in Table 4.1.
External evaluation of the model was performed with two external
datasets [8, 14, 15, 27]. The first external dataset consisted of 24 children,
aged 1.6–17.3 years, in whom therapeutic drug monitoring on lopinavir was
performed. Lamivudine concentrations were determined on samples from
different occasions (range: 1, 10 occasions). Sixteen of these 24 children
participated in the RONDO trial [27]. Lamivudine was dosed both once and
twice daily according to the PENTA guideline valid at that time and daily
dose varied between 90 and 300 mg (3.9–10.2 mg/kg) [26]. The second
external dataset consisted of 77 children, aged 0.4–12.8 years, who were
included in three studies: PENTA13 [8], PENTA15 [15] and ARROW [14].
All three studies were cross-over studies to compare the pharmacokinetics of
once-daily lamivudine dosing versus twice-daily dosing. Daily dose varied
between 60 and 300 mg (4.9–15.0 mg/kg). An overview of the patient
characteristics is given in Table 4.1. Data on different dosing occasions of
six children were included in both the model building dataset as well as in
the dataset for external validation.
4.3 Blood sampling and assay
For all children included in the model building datasets and the second
external dataset, at least one complete concentration-time profile after
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dosing was available (≥ 6 samples). This also applied for 15 children (63%)
included in the first external dataset. Sampling was performed until the
end of the dosing interval.
For the data from the CHAPAS1 trial, PENTA trials and therapeutic
drug monitoring study, lamivudine concentrations were measured using
a high-performance liquid chromatography assay with ultraviolet detec-
tion [28]. The lower limit of quantification was 0.05 mg/l. Data below
the limit of quantification were excluded (M1 method [29]). For the data
from the ARROW trial, lamivudine was measured using a high-performance
liquid chromatography assay with tandem mass spectrometry detection.
The lower limit of quantification was 0.0025 mg/l.
4.3.1 Pharmacokinetic analysis and model evaluation
Model building was performed in four different steps: 1) testing of both
a one- and two-compartment model and different absorption models in
order to select a structural model; 2) selection of a statistical model; 3)
covariate analysis; and 4) model evaluation. For oral absorption, a zero-
order and first-order model, a lag time model, transit compartment model,
and combined absorption models were evaluated [30].
Discrimination between structural models was achieved by comparison
of the objective function value (OFV) and the total number of parameters.
A decrease in the OFV of more than 3.8 points was considered statistically
significant for the structural model (P < 0.05 based on χ2 distribution).
The goodness-of-fit plots (observed versus both individual- and population-
predicted concentrations and both time and population predictions versus
conditional weighted residuals) were evaluated. Improvement of individual
plots, confidence intervals of the parameter estimates and the correlation
matrix were also assessed.
4.3.2 Covariate analysis
Covariates were plotted against individual post hoc parameter estimates
and the weighted residuals to visualise potential relationships. The covari-
ates bodyweight, age, height and formulation were evaluated. Potential
covariates were separately implemented in the model, using a linear or
power equation
Pi = Pp ×
(
covi
covmedian
)k
,
where Pi represents the individual parameter estimate of the i
th subject,
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Table 4.1: Patient characteristics of the children in the two model building
datasets and the two datasets used for external validation.
Values are expressed as median [range]
Model building
Dataset 1 Dataset 2 Total
Number of children 64 21 85
Age (years) 7.0 [0.5, 14.9] 8.0 [1.7, 18.0] 7.2 [0.5, 18.0]
Bodyweight (kg) 16.3 [3.4, 29.0] 27.8 [10.5, 59.2] 16.6 [3.4, 59.2]
Number of dose 64 (1) 21 (1) 85 (1)
(mean per child)
Number of observations 433 (6.8) 205 (9.8) 638 (7.5)
(mean per child)
Daily dose (mg) 120 [60, 240] 200 [80, 300] 120 [60, 300]
Daily dose (mg/kg) 8.9 [6.3, 17.6] 7.8 [5.1, 10.5] 8.5 [5.1, 17.6]
Formulation FDC: 64 NA: 21 FDC: 64
NA: 21
∗ 16 of the 24 children in this dataset were part of the RONDO trial; 6 of the 24
children were also included in model building dataset 2 on a different occasion;
FDC: fixed dose combination tablet; NA: not available
Pp is the population parameter estimate, cov is the covariate and k is the
exponent. k was fixed at 1 for a linear function or estimated for a power
function. The framework proposed by Krekels et al. to systematically
evaluate the descriptive and predictive performance of a paediatric model
was used as a guide to discriminate between different covariate models
[31]. A decrease in OFV of at least 7.8 was applied to evaluate covariates
in forward inclusion. In backward deletion, a more stringent P -value of
< 0.001 was used (a decrease in OFV of at least 10.83 points). When
two or more covariates were found to significantly improve the model, the
covariate causing the largest decrease in OFV was kept in the model. In
order to be retained in the model, additional covariates had to reduce this
OFV further. The clinical relevance of a covariate relationship was also
considered [31]. In order to confirm the final covariate model, individual and
population parameter estimates were plotted against the most predictive
covariate to evaluate whether the individual predicted parameters were
equally distributed around the population predicted parameters.
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Table 4.1: Patient characteristics of the children in the two model building
datasets and the two datasets used for external validation.
Values are expressed as median [range] (continued)
External validation Total
Dataset 1∗ Dataset 2 Total
24 77 101 180
8.4 [1.6, 17.3] 5.8 [0.4, 12.8] 6.0 [0.4, 17.3] 6.6 [0.4, 18.0]
30.2 [11.0, 54.1] 17.4 [7.4, 60.5] 18.2 [7.4, 60.5] 17.0 [3.4, 60.5]
88 (3.7) 153 (2.0) 241 (2.4) 326 (1.8)
232 (9.7) 1 191 (15.5) 1 423 (14.1) 2 061 (11.5)
200 [90, 300] 150 [60, 300] 160 [60, 300] 150 [60, 300]
7.3 [3.9, 10.2] 8.6 [4.9, 15.0] 8.2 [3.9, 15.0] 8.2 [3.9, 17.6]
Solution: 17 Solution: 63 Solution: 80 FDC: 64
Tablet: 9 Tablet: 90 Tablet: 99 Solution: 80
NA: 62 NA: 62 Tablet: 99
NA: 83
4.3.3 Internal evaluation procedure
The final model was evaluated using two methods: the bootstrap method
and the normalised prediction distribution error (NPDE) method [31–34].
The bootstrap analysis was used to evaluate the stability and precision of
the model. The model building dataset was resampled to produce 2000 new
datasets of the same size, containing a different combination of individuals.
The final model was sequentially fitted to all of these newly generated
datasets. The parameter estimates were summarised in terms of median
values and 90% confidence intervals, and were compared with the estimates
obtained from the model building datasets.
The accuracy of the model was evaluated with the NPDE method [33,
34]. Each observation was simulated 1000 times, after which the observed
and simulated concentrations were compared. The software assembled the
quantiles of each observation in its predicted distribution, on the basis of
the simulated values. The observations and predictions were decorrelated.
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The NPDEs were then obtained after the inverse function of the normal
cumulative density function was applied.
4.3.4 External evaluation procedure
External evaluation of the model was performed with two external datasets,
as described above [8, 14, 15, 27]. These datasets were not included when
the model was fitted to the data.
The final pharmacokinetic model was used to simulate concentrations
for each data point in the two external datasets. Additionally, the final
pharmacokinetic model was used to compute the NPDE for each of the
external datasets [33, 34]. Finally, the parameters of the final model were
re-estimated on the basis of the two model building datasets combined with
both external datasets.
4.3.5 Evaluation of currently used dosing guidelines
For the first available dosing occasion per individual, AUC0−24 was noncom-
partmentally derived from the estimated individual parameter estimates.
Target AUC0−24 was 8.9 mg×h/l, the AUC0−24 that is obtained in adults
after once-daily administration of 300 mg [2]. Based on the results, a dose
adaptation was proposed for subgroups of children not reaching the target
AUC0−24.
4.3.6 Software
The pharmacokinetic analysis and evaluation procedures were performed
using the nonlinear mixed-effects modelling software NONMEM version
7.3 (Icon Development Solutions, Hanover, MD). Tools like PsN version
4.2.0 [35] (University of Uppsala, Sweden), Pirana version 2.9.0 (Pirana
Software & Consulting BV, Amsterdam, the Netherlands) and R version
3.1.1 (R Foundation for Statistical Computing, Vienna, Austria) were used
to visualise and evaluate the models. For the NPDE analysis, the NPDE
software package in R was used [34].
4.4 Results
4.4.1 Population pharmacokinetic model building
Model building was based on 638 observations from 85 children while
external evaluation was based on 1 423 observations from 101 children
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(Table 4.1). A two-compartment model with sequential zero-order and first-
order absorption best described the data. A two-compartment model was
preferred over a one-compartment model, since the model building data,
and especially the highest concentrations, were more accurately described
with a two-compartment model. The final model was parameterised in
terms of a zero-order absorption phase (D1), which was followed by a
first-order absorption process (Ka) (i.e. sequential zero-order and first-
order absorption model), apparent clearance (CL/F), inter-compartmental
clearance (Q/F) and the apparent volumes of distribution of the central
compartment (V2/F) and peripheral compartment (V3/F). Because there
were difficulties estimating reliable values for V3/F, the model was simpli-
fied by equalising V3/F to V2/F. The residual variability was best described
using a combined additive and proportional error model.
4.4.2 Systematic covariate analysis
The covariate analysis identified bodyweight as the most important
covariate for both CL/F and V2/F. The exponent for the effect of
bodyweight on CL/F was 0.506 (20.2%) and for the effect on V2/F 0.489
(32.3%). The parameter estimates for the simple and final model are shown
in Table 4.2. In Figure 4.1, the individual estimates of variability (ETA)
of CL/F and V2/F are plotted against bodyweight for the simple and final
models. A significant part of the inter-individual variability is explained
after inclusion of bodyweight as a covariate, with a decrease of 19% in
the inter-individual variability of CL/F and 15% in the inter-individual
variability of V2/F (Table 4.2). After inclusion of bodyweight, no other
covariates (i.e. age, height or formulation) could be identified (P > 0.05).
4.4.3 Internal evaluation of the final pharmacokinetic model
Table 4.2 gives an overview of the parameter estimates of the simple and
final model, together with the values obtained from the bootstrap analysis.
The median estimated values based on the bootstrap were within 10% of
the values obtained in the final model. In Figures 4.2a and 4.2b, observed
versus individual and population-predicted concentrations are given for the
final model, while in Figure 4.2c a histogram of the NPDE is shown. No
trend was seen in the NPDE versus time or versus predicted concentrations
(results not shown). Figure 4.5 shows that the data in different weight
groups are well described.
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Table 4.2: Population parameter estimates of the i) simple and ii) final
pharmacokinetic model based on two model building datasets,
iii) the values obtained after bootstrap of the final pharmaco-
kinetic model and iv) the parameter estimates after combining
the model building data with the two external datasets
Parameter Simple Final Bootstrap final Model
pharmaco- pharmaco- pharmacokinetic building
kinetic kinetic model data and
external
data
Fixed effects
CL/F
16.6 kg (l/h) 13.2 [4.8] 13.2 [4.2] 13.2 13.1 [2.8]
[12.1–14.3; 4.3]
θ in CL/F
16.6 kg 0.506 [20.2] 0.524 0.372 [18.6]
×(BW/16.6)θ [0.298–0.716; 21.9]
V2/F16.6 kg = 37.0 [7.6] 38.9 [7.0] 37.8 36.6 [6.8]
V3/F16.6 kg (l) [30.3–43.9; 8.4]
θ in V2/F16.6 kg 0.489 [32.3] 0.531 0.581 [19.8]
×(BW/16.6)θ [0.127–0.836; 34.9]
Q/F (l/h) 2.09 [17.7] 2.02 [13.4] 2.14 2.65 [11.3]
[1.53–3.76; 24.1]
D1 (h) 0.697 [15.1] 0.847 [10.3] 0.823 0.655 [9.7]
[0.493–1.05; 16.1]
Ka (h
−1) 2.47 [11.5] 3.41 [17.3] 3.16 1.73 [12.1]
[1.56–6.78; 37.3]
Inter-individual variability
ω2 (CL/F) 0.468 [7.5] 0.379 [7.9] 0.374 0.336 [6.4]
[0.319–0.436; 16.3]
ω2 (V2/F) 0.645 [6.9] 0.550 [9.0] 0.559 0.435 [7.2]
[0.467–0.686; 19.7]
Omega block 0.848 0.820 0.812 0.718
(CL/F – V2/F) [0.797–0.813]
ω2 (D1) 0.815 [10.7] 0.704 [10.5] 0.721 0.796 [9.0]
[0.560–0.986; 29.6]
Residual variability
σ2 (proportional) 0.133 [9.2] 0.147 [9.3] 0.144 0.301 [5.2]
[0.118–0.174; 19.5]
σ2 (additive) 0.0477 [10.9] 0.0450 [11.4] 0.0443 0.088 [27.9]
[0.0340–0.0542; 22.2]
Data presented as value [%RSE]; bootstrap results presented as median [95%CI;
%RSE (sd/mean)]; θ: parameter of interest; ω2, σ2: variance, BW: bodyweight;
CI: confidence interval; CL/F: apparent clearance for a typical individual with BW of
16.6 kg; D1: duration of zero-order absorption; Ka: rate constant of first-order absorption;
Q/F: inter-compartmental clearance; V2/F16.6: volume of distribution of the central
compartment for a typical individual with BW of 16.6 kg; V3/F16.6: volume of distribution
of the peripheral compartment for a typical individual with BW of 16.6 kg
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Figure 4.1: Inter-individual variability (dots) for the simple (left) and final
model (right) for apparent clearance (ETA on CL/F) and
apparent volume of distribution (ETA on V2/F) versus weight
(two model building datasets) with trendline (blue line) and
95% confidence interval (grey area).
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4.4.4 External evaluation of the final pharmacokinetic model
The predictive performance of the final model was evaluated using two
external datasets (Table 4.1) [8, 14, 15, 27]. In Figure 4.2, observed versus
individual predicted concentrations (Figures 4.2d and 4.2g) and observed
versus population-predicted concentrations (Figures 4.2e and 4.2h) are
given for both external datasets. Additionally, the histograms of the NPDE
are shown in Figures 4.2f and 4.2i. While the final model is able to
predict the data in external dataset 2 without bias, a slight bias is seen
for external dataset 1, in which the sampling was more sparse, compared
to the model building datasets. This bias is observed in Figure 4.2e, which
shows observed versus population predicted concentrations, as well as in
Figure 4.2f.
Combined analysis of the two model building datasets and both external
datasets revealed that fairly similar parameter values were obtained
(Table 4.2). The concentrations in all four datasets could be well described
by this model without bias and with adequate precision (Figure 4.6).
4.4.5 Evaluation of currently used dosing guidelines
94.5% of the children with a bodyweight above 14 kg reached the adult
target AUC0−24 of 8.9 mg×h/l with the currently administered daily dose.
However, this did not hold for all children with a bodyweight below 14
kg (Figure 4.3). If the daily dosage for these children is increased to at
least 10 mg/kg/day, it is expected that most children will have adequate
exposure to lamivudine (64.2% before dose adaptation, 92.5% thereafter;
Figure 4.4).
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Figure 4.2: Observed versus individual predicted concentrations and
observed versus population predicted concentrations of (a–b)
the two model building datasets, (d–e) external dataset 1 and
(g–h) external dataset 2. The histograms show the distribu-
tion of the normalized prediction distribution error (NPDE) of
the (c) model building datasets, (f) external dataset 1 and (i)
external dataset 2.
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Figure 4.3: Simulated AUC0−24 versus daily dose administered (mg) split
by bodyweight: ≤ 14, 14–21 kg, 21–30 kg and > 30 kg. The
dotted line indicates an AUC0−24 of 8.9 mg×h/l (adult target
for once-daily dosing). Vertically occurring sequences of dots
occur because of fixed dose tablets.
Figure 4.4: Simulated AUC0−24 versus daily dose administered (mg/kg
bodyweight) for children with a bodyweight ≤ 14 kg after
administered dose (a) and adapted dose where a minimum of
10 mg/kg is administered (b). The dotted line indicates an
AUC0−24 of 8.9 mg×h/l (adult target for once-daily dosing).
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A model-based approach has been applied in order to describe the
pharmacokinetics of lamivudine in children. The model was based on a
large and relatively rich dataset, since for most of the children at least six
samples within one dosing interval were available. Also, the full paediatric
age range is covered, with a large proportion of children below the age of
3 years (n = 16 (18.8%) in the dataset used for model building; n = 41
(22.8%) in total). The two-compartment model used to describe the data
is in agreement with previously developed models [7, 16, 20, 36]. In order
to obtain reliable estimates of the peripheral volume, the model had to be
simplified by stating that the central and peripheral volume of distribution
were equal to each other (Table 4.2), however this did not lead to reduced
descriptive or predictive value (Figures 4.2 and 4.5).
Bodyweight best predicted the developmental changes in both apparent
lamivudine clearance and apparent central volume of distribution. This is
consistent with previous studies [7, 16–20]. Although the typical param-
eter estimates for an individual of 16.6 kg are comparable, the estima-
tions of both scaling exponents were lower in our analysis [7,16,18–20,37].
Remarkable is the difference in the relationship between apparent volume
of distribution and bodyweight. The majority of the performed studies
fixed this relationship a priori to 1 [7, 16, 18–20]. Piana et al. found an
exponent of 0.635, which seems close to the exponent of 0.489 we identified
(Table 4.2) [17].
The stability of the final model was indicated by the NPDE and the
bootstrap as well as the ability to predict external dataset 2 accurately.
For external dataset 1, the predictive performance was slightly biased. This
may be explained by the sparse nature of the data available in that dataset.
When the data from all datasets were combined and analysed together, the
data in external dataset 1 were described without any bias (Figure 4.6).
The target AUC0−24 of 8.9 mg×h/l that has been identified in adults
was reached in 85.6% of the children. However, 35.8% of the children
with a bodyweight below 14 kg did not reach this target. It was shown
previously that lamivudine exposure was lower in the youngest group of
children compared to older and heavier children [7–9, 37]. For children
with a bodyweight below 14 kg we calculated that the target AUC0−24 can
be reached with a dose of at least 10 mg/kg/day, based on the expected
apparent clearance. The same dose was also proposed by Bouazza et al. for
children with a bodyweight < 17 kg [7]. We chose our cut-off bodyweight in
line with the approved dosing regimens of the antiretroviral drugs frequently
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used in children and with the data found in our model [1].
In the model, the absorption phase was relatively difficult to describe,
which can partly be explained by the limited data available for that
part of the concentration-time profile. In most paediatric population
pharmacokinetic models for lamivudine, a first-order absorption model is
used [7,16,18,19,36]. However, also a delay in absorption with either a lag-
time or transit compartments has been described [20, 37]. During model
building, all these absorption models, as well as a zero-order absorption,
were tested. A sequential zero- and first-order absorption model was finally
found to best describe the data.
A limitation of the current study is that we could not fully study the
influence of the formulation on the pharmacokinetics. As shown before,
the type of drug formulation can affect the lamivudine exposure signifi-
cantly in children [4, 5, 19, 24]. However, similar to previous population
pharmacokinetic studies, the formulation used by the children could not be
identified as a possible covariate in our study as information on the formu-
lation used was not complete for all of the children [16,37,38]. Next to this,
we could not study the influence of renal function in this analysis. Lamivu-
dine is a renally excreted drug and it has been shown in adults that renal
function can affect the pharmacokinetics of lamivudine [2, 3, 39–41]. Even
though in several paediatric studies, serum creatinine could not be identi-
fied as possible covariate for clearance, we could not study this covariate as
information on renal function was incomplete [16,18,19].
In conclusion, lamivudine pharmacokinetics was best described by a two-
compartment model with sequential zero-order and first-order absorption.
Bodyweight was found as covariate on apparent clearance and apparent
central volume of distribution, both in a nonlinear function. The model
generalizes well to patients not included in the model-building dataset. In
order to identify whether these (nonlinear) changes result from changes
in bioavailability, clearance and/or volume of distribution, future analysis,
which includes intravenously administered lamivudine, is warranted. The
results of this study suggest that the currently recommended dose for
children with a bodyweight below 14 kg should be increased to at least
10 mg/kg/day in order to reach an AUC0−24 of 8.9 mg×h/l.
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Figure 4.5: Diagnostic plots (observed versus predicted concentrations in
the model building data) of the final model split by bodyweight:
a: < 10 kg, b: 10–15 kg, c: 15–20 kg, d: 20–25 kg, e: 25–30
kg, f: > 30 kg. Dots indicate the observed concentration versus
population predicted concentration, grey dotted lines show x =
y, red striped lines show trend line.
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Figure 4.6: Diagnostic plots of the model based on both the two model
building and the two external datasets: observed versus popula-
tion predicted concentrations split by dataset: a: dataset 1, b:
dataset 2, c: dataset 3, d: datset 4. Dataset 1 and 2 have been
used for model building, datset 3 and 4 for external validation.
Dots indicate the observed versus population predicted concen-
tration, grey lines show x = y, red lines show trend line.
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Abstract
Introduction
A multitude of antiretroviral drug formulations are now available for HIV-
infected adults and children. These formulations include individual and
co-formulated drugs, many of which are also supplied in generic versions.
Many antiretroviral drugs have a low aqueous solubility and poor bioavail-
ability. Drug formulation can significantly affect bioavailability, and given
the increasing number of new formulations and drug combinations, it is
important to be aware that formulation can influence the pharmacokinetics
of antiretroviral drugs.
Areas covered
This review provides an overview of studies assessing the pharmaco-
kinetics of different antiretroviral drug formulations in adults and children,
including fixed-dose combinations. For some antiretroviral drugs, differ-
ences in pharmacokinetics have been described, with largest differences in
exposure when a liquid formulation is compared to a tablet or capsule
formulation. Biopharmaceutical properties of antiretroviral drugs relevant
to bioavailability are discussed.
Expert opinion
Antiretroviral drug formulations and their excipients can significantly
impact drug exposure. However, this is not yet fully recognized. It is
important to realize that children use different formulations than adults.
Effort should be made to ensure that adequate drug exposures are achieved
to treat HIV-infected children. In addition, manipulation of drug formula-
tions may lead to differences in pharmacokinetics.
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5.1 Introduction
Globally, 35 million people were estimated to be HIV infected in 2012,
of which 3.3 million were children under 15 years of age [1, 2]. The
successful roll out of national and international antiretroviral treatment
programs has dramatically reduced AIDS-related morbidity and mortality
in many countries. Within these programs, a marketing application can
be submitted for antiretroviral drugs even if they are still under patent or
market protection. Despite the rapid scale up of antiretroviral treatment
worldwide, only 34% of the children eligible for antiretroviral treatment
were receiving it in 2012, compared to 64% for HIV-infected adults. The
2013 WHO treatment guidelines now recommend treating all HIV-infected
children below the age of 5 years, independent of disease stage [3].
A combination of three different drugs from at least two different
classes, often referred to as combination antiretroviral therapy, is generally
used to treat HIV/ AIDS. Antiretroviral drugs are divided into different
classes based on their mechanism of action. Current drug classes are:
i) nucleoside reverse transcriptase inhibitors (NRTIs); ii) non-nucleoside
reverse transcriptase inhibitors (NNRTIs); iii) protease inhibitors (PIs);
iv) integrase inhibitors; and v) entry and fusion inhibitors. An overview
of current (tentative) FDA-approved drug formulations for HIV treat-
ment is shown in Table 5.1. In children, the pharmacological goal is
to achieve similar drug exposure to adults [4]. The pharmacokinetics of
some antiretroviral drugs in children is different to adults, primarily due to
differences in the maturation of metabolic and renal pathways [5]. Patient
characteristics, such as age, weight, renal function and host genetics, can
explain a large portion of the interpatient variability observed, but drug
formulation can also be a key component.
The low aqueous solubility and poor bioavailability of many antiretro-
viral drugs have been challenging for the development of antiretroviral
drug products, particularly for pediatric formulations. Drug formulations
are normally investigated in healthy adults, and it is generally assumed
that any formulation effect would be the same in children. However, it is
possible that a formulation can potentially behave differently in adults than
in children, for example because of age-related differences in solubility and
dissolution rate of a drug from a formulation [6]. Also, children are often not
using the same formulation as adults and different exposures may be due
to differences in bioavailability of the child-friendly formulation available
compared to the adult formulation. In addition, excipients used to develop
a (pediatric) formulation can influence the pharmacokinetics of drugs [7–9].
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Sometimes, in order to administer drugs to children, adult formulations are
manipulated, that is, crushed or split and this can affect the rate and extent
of drug absorption.
This review aims to provide an overview of studies assessing the
pharmacokinetics of different antiretroviral formulations that are currently
marketed, including generic drugs. A literature search was performed
using the PubMed, EMBASE and Cochrane databases (until March 2014).
Combinations of the following words and variations on these words were
used in the search strategy (title, abstract, mesh): ‘pharmacokinetics’ and
‘antiretroviral therapy’ and ‘bioequivalence’ or ‘child.’ Studies in both
HIV-infected and -uninfected participants, published in English, were
included. Conference abstracts and posters were not included. Latest drug
label information was accessed through the US FDA website.
5.2 Bioavailability of drug formulations
It is important to determine whether a different type of formulation that
is, tablet versus liquid, or a new generic drug formulation provides similar
exposure compared to the innovator product. Drug formulations containing
the same active pharmaceutical ingredient are considered ‘bioequivalent’ if
the ratio of the bioavailability (rate and extent of absorption) after admin-
istration of the two formulations in the same molar dose falls within preset
limits [10, 11]. Pharmacokinetic parameters analyzed to assess bioequiva-
lence are the area under the concentration time curve (AUC), as a measure
of the extent of exposure, and the maximum plasma concentration (Cmax),
which is influenced by the rate of absorption. For both pharmacokinetic
parameters, the 90%CI for the ratio of the test and reference products
should be within the acceptance interval of 80–125%.
The rate and extent of absorption from the gastrointestinal tract can be
influenced by the dissolution rate, solubility and permeability of the drug.
Many physiological factors are also important for absorption, such as pH
and gastrointestinal transit time. A drug must be dissolved before it can be
absorbed. Physicochemical characteristics, such as pKa and lipid solubility,
determine the solubility and permeability of a drug [12]. The biophar-
maceutics classification system (BCS) is used by regulators to determine
whether in vivo bioequivalence studies are necessary for the approval of new
generic drug products of solid immediate release dosage forms [10,11,13,14].
According to this system, the active pharmaceutical ingredient of a formu-
lation can be classified into one of four categories depending on its aqueous
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solubility and intestinal permeability, where solubility is based on the
highest dose strength of the innovator product (to be) approved. The BCS
class of antiretroviral drugs is shown in Table 5.2 [14–19]. Theoretically, it
is expected that the influence of the formulation on pharmacokinetics will
be largest for drugs with low solubility.
Excipients can affect the pharmacokinetics of drugs [7–9]. For example,
bioavailability can be influenced by an altered gastrointestinal transit time,
for example, by polyethylene glycol, sugars and sweeteners such as sorbitol,
possibly related to their osmotic and/or viscosity-enhancing effect [7,9,20].
Excipients can also change transporter-mediated uptake and eﬄux of drugs
[8]. Antiretroviral drugs, even within the same antiretroviral drug class,
can be substrates for different drug transporters [21]. The impact of drug
transporters on antiretroviral drug disposition is reflected in the Biophar-
maceutics Drug Disposition Classification System (BDDCS), as suggested
by Wu and Benet (Table 5.2) [22,23].
5.3 Antiretroviral drug formulations
5.3.1 NRTI formulations
NRTIs are categorized in BCS class 1 (high solubility, high permeability)
or class 3 (high solubility, low permeability). Most of the NRTIs have both
solid and liquid formulations licensed. Despite the good solubility in water,
abacavir, emtricitabine and lamivudine liquid formulations use propylene
glycol as an organic co-solvent. Propylene glycol is an unfavorable excipient
for children because of its potential toxic effects, especially for infants [24].
A maximum allowed daily intake of 25 mg/kg is recommended by the FDA,
which is exceeded when abacavir is dosed according to the label.
5.3.2 NNRTI formulations
All NNRTIs have a very low solubility in water and are categorized as either
BCS class 2 (low solubility, high permeability) or class 4 (low solubility, low
permeability). The low solubility of NNRTIs is also reflected in the compo-
sition of the liquid formulations of efavirenz and nevirapine: efavirenz liquid
formulation contains medium chain triglycerides as a solvent and nevirapine
is formulated as a suspension.
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5.3.3 Protease inhibitor formulations
All PIs are either BCS class 2 or 4 drugs. The low aqueous solubility
is reflected in the available liquid formulations being either a suspen-
sion (darunavir), powder for suspension (nelfinavir) or solution containing
organic co-solvents, such as propylene glycol (fosamprenavir, tipranavir),
or propylene glycol combined with ethanol (lopinavir/ritonavir, ritonavir).
Most PIs are licensed in combination with low doses of ritonavir due to the
more favorable pharmacokinetic profile. Administration of the ritonavir
liquid formulation is challenging, particularly in children, because of its
poor palatability. The licensed doses of fosamprenavir and tipranavir do
not exceed the maximum recommended daily intake of propylene glycol,
but combined with ritonavir these limits are exceeded. Lopinavir is co-
formulated with ritonavir. The innovator lopinavir/ritonavir oral solution
contains 15.3% propylene glycol and 42.2% alcohol. Using the dosing
recommendations in the label, the amount of propylene glycol exceeds
the recommended maximum daily intake. The risk of toxicity may also
be increased because of the inhibition of propylene glycol metabolism by
the ethanol present in the solution. Significant clinical toxicity has been
observed in neonates after use of lopinavir/ritonavir liquid and has been
related to the high concentrations of these excipients [25].
5.3.4 Integrase inhibitor formulations
All integrase inhibitors are classified as BCS class 2 or 4. Next to tablets,
only for raltegravir a granule formulation for oral suspension is currently
available.
5.3.5 Entry and fusion inhibitor formulations
Together with the integrase inhibitors, the entry and fusion inhibitors are
the newest classes of antiretroviral drugs. The only entry inhibitor approved
is maraviroc, which is categorized as a BCS class 3 drug. Only tablet
formulations of maraviroc are available. The fusion inhibitor enfuvirtide is
administered subcutaneously, and no BCS class has been determined.
5.3.6 Fixed-dose combination formulations
Antiretroviral therapy is currently a lifelong treatment. Combining differ-
ent antiretroviral drugs into a single formulation, termed fixed-dose combi-
nations (FDC), has been one of the strategies to reduce pill burden and
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improve long-term adherence. To stimulate the development and avail-
ability of antiretroviral drug products, a guidance on FDC was released
by the FDA in 2006 [26]. To date, both dual and triple innovator and/or
generic FDC have been approved (Table 5.1). Adult and pediatric FDC
formulations have been developed. Many of these formulations have been
developed by generic pharmaceutical companies specifically for resource-
limited settings.
5.4 Comparing the bioavailability of antiretroviral drug
formulations
5.4.1 Studies comparing liquid and solid antiretroviral drug
formulations
Intestinal transit time of liquid and solid formulations can differ, and it
takes time for solid dosage forms to disintegrate into smaller particles, from
which the drug can dissolve easier. For this reason, it is generally expected
that the absorption rate of a liquid will be higher compared to a solid formu-
lation. However, it is easier to manipulate solid dosage forms to aid in vivo
solubility, for example by reducing particle size, changing the salt or crystal
form of the drug and use of excipients. Thus, in some instances bioavail-
ability can be higher for solid compared to liquid formulations, particularly
for BCS class 2 and 4 drugs.
Liquids are commonly used for pediatric formulations but have several
disadvantages over solid formulations [27]. For example, it can be
challenging to develop liquid formulations that are palatable and have
adequate stability. Subsequently, more excipients have to be used, for
example, for preservation, to mask bad taste and sometimes increase
solubility. As described in Section 5.2, excipients can influence the
pharmacokinetics of drugs.
Several studies have evaluated the pharmacokinetics of solid versus
liquid formulations, and most of the studies published were performed in
HIV-infected children. An overview of these studies is shown in Table 5.2.
Studies on efavirenz, emtricitabine, lamivudine and raltegravir show
differences in bioavailability between solid and liquid formulations and will
be further discussed below.
5.4.1.1 Efavirenz
The oral efavirenz solution is less bioavailable than the hard capsule on
an mg per mg basis (the liquid formulation is approved by the EMA but
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not the US FDA) [28]. In healthy adults, the efavirenz AUC and Cmax
following a 240 mg dose of the liquid were 97 and 78%, respectively, of the
values following a 200 mg dose with the hard capsules. Therefore, 20–35%
higher doses are recommended when efavirenz is administered with the
liquid formulation. A population pharmacokinetic study in HIV-infected
children reported that the bioavailability of the liquid formulation was
more than 50% lower than the capsule formulation [29]. A pharmacometric
model also suggested a lower relative bioavailability of two liquid formu-
lations compared to the capsule [30]. In addition, this model estimated
a different relative bioavailability for children of different ages. For
children 1 year of age, the relative bioavailability was estimated 42%, for
3 years of age 61% and reaching 90% of the mature value at the age 8 years.
5.4.1.2 Emtricitabine
The pharmacokinetics of a liquid and capsule formulation of emtric-
itabine has been assessed in HIV-infected adults and children 6–17 years
old [31, 32]. In children, the AUC and Cmax were higher after administra-
tion of the capsule compared to the solution. The relative bioavailability
of the capsule was 120% compared to the liquid formulation. A shorter
gastrointestinal transit time of the solution compared to the capsule,
resulting in a reduced mucosal contact time, was proposed as possible
explanation for the observed difference. Excipients used in the liquid
formulation might also be able to influence absorption of emtricitabine.
The authors noted no meaningful statistical comparison was possible
between the formulations due to the small sample size and lack of random-
ization. A higher maximum dose for emtricitabine solution (240 vs. 200
mg with the tablet) is approved [4, 32].
5.4.1.3 Lamivudine
Numerous studies have assessed the pharmacokinetics of the lamivudine
oral solution and/or tablet formulations in adults and children [33–40].
Comparable bioavailability of the oral formulations has been reported in
adults [40]. In contrast, several recent studies in HIV-infected children
have not found the same result. One study evaluated the bioequivalence
of the innovator liquid solutions of zidovudine, lamivudine and abacavir
to the innovator tablets in HIV-infected children (ARROW trial) [35].
Exposure to lamivudine was significantly higher with the co-formulated
lamivudine/zidovudine tablet compared to the liquid formulation. The
dose-normalized lamivudine AUC, Cmax and minimum plasma concentra-
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tion (Cmin) were 58, 55 and 29% higher, respectively. Of note, lamivu-
dine was administered alone in the adult study while in the ARROW
trial the liquid formulation of lamivudine was administered together with
zidovudine and abacavir liquid formulations. Therefore, it is possible
that excipients from the different liquid formulations interact and influ-
ence drug absorption. For example, all three liquids contain sugars, sweet-
eners and/or sugar alcohols, which could possibly impact gastrointestinal
transit time. No significant differences in bioavailability of zidovudine or
abacavir were observed. Using the BDDCS classification, lamivudine is
classified as class 3 and both abacavir and zidovudine are classified as class 1
(Table 5.2) [22]. Theoretically, the influence of transporters on absorption
processes is important for lamivudine, but only minimal for abacavir and
zidovudine [23]. Thus, another possible explanation could be an influence
of excipients on transporter-mediated absorption of lamivudine.
Lower lamivudine exposure was also found with the innovator liquid
formulation compared to generic pediatric FDC tablets containing lamivu-
dine in children [33, 34]. These pediatric generic FDC tablets containing
lamivudine were found to be an independent predictor of lamivudine
bioavailability in a pooled population pharmacokinetic model, including
both innovator solid and liquid formulations [39].
In contrast to these findings, a study showed bioequivalence of a pediatric
generic FDC tablet (lamivudine, stavudine, nevirapine) compared to the
individual innovator and generic liquid formulations in HIV-infected
children [41]. Three studies also showed bioequivalence of different
pediatric FDC granules/tablet for oral suspension containing lamivudine,
compared to the individual liquid formulations in healthy adults [42–44].
For one study, the excipients of the granules were described, which
included xylitol and sucralose [42]. Population pediatric pharmacokinetic
models developed using data from HIV-infected children receiving the
liquid or solid formulation of lamivudine also did not find formulation to
be a predictor of lamivudine concentrations [36, 37, 45]. No information
on co-medication was provided, and it was not known how many children
used either the tablet or liquid formulation.
5.4.1.4 Raltegravir
The pharmacokinetics of raltegravir after administration of the different
pediatric formulations has been studied in healthy adults [46]. Compared
to the film-coated tablet, the granules for suspension had a 2.6-fold higher
AUC0−∞ and a 4.6-fold higher Cmax.
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5.4.2 Studies comparing solid antiretroviral drug formulations
Several of the available antiretroviral drugs have different solid formula-
tions available, for example, both a capsule and a tablet. The number of
generic antiretroviral drugs available has rapidly increased over the last
five years: over 160 generic formulations were (tentatively) approved by
the US FDA at the beginning of 2014. Studies in which bioequivalence or
comparable pharmacokinetics has been shown of solid antiretroviral drug
formulations are summarized in Table 5.3. Studies showing differences in
bioavailability between solid formulations are discussed below.
5.4.2.1 Didanosine
Didanosine is unstable in acidic solutions. During the drug development
phase, the pharmacokinetics of buffered tablets, enteric-coated tablets,
sachets and an intravenous solution were assessed [47]. Large differences
in bioavailability between formulations were observed. The first approved
didanosine formulations contained a buffer that increases the risk of
drug-drug interactions. Encapsulated enteric-coated beads were developed
to try and overcome this problem, but were not bioequivalent to the
buffered tablet formulation in healthy adults and HIV-infected subjects
(Cmax of the enteric-coated bead formulation was 42% lower in healthy
subjects and 36% lower in HIV-infected individuals) [48,49].
5.4.2.2 Lopinavir and ritonavir
Lopinavir co-formulated with ritonavir (lopinavir/r) is available as tablets,
soft gel capsules and oral solution. A qualitative and quantitative
analysis was performed on a generic tablet, which was not prequalified by
WHO [50]. The tablets contained comparable amounts of both lopinavir
and ritonavir as the innovator tablet. However, a small study in four
healthy adults showed that the median lopinavir trough level of the generic
tablets was substantially lower compared to the innovator tablets: 158
ng/ml compared to 3884 ng/ml.
5.4.2.3 Nelfinavir-mesylate
A 625 mg tablet of nelfinavir mesylate was developed to reduce the
pill-burden of the 250 mg tablet. Bioequivalence of these two tablets
in healthy adults was shown under fed conditions but not under fasting
conditions, with the 625 mg tablet having a 27% lower AUC [51]. It
is unclear whether a different tablet formulation has eventually been
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marketed, since the data presented in the label information report a 34
and 24% higher AUC for the 625 mg tablet compared to the 250 mg tablet
under fasting and fed conditions, respectively, in healthy adults.
5.4.2.4 Raltegravir
The film-coated and chewable tablet formulation of raltegravir are not
bioequivalent [46, 52]. Compared to the film-coated tablet, the chewable
tablet had a 1.8-fold higher AUC0−∞ and a 3.2-fold higher Cmax in healthy
adults [46].
5.5 Manipulation of antiretroviral drug formulations
If no pediatric formulations are available, adult formulations are sometimes
manipulated and administered to children, that is, tablets are cut or split to
achieve a lower dose, and sometimes also crushed to ease administration.
Deviations from the optimal dose can occur when splitting or crushing
tablets, which can significantly impact drug efficacy and/or toxicity. Only
five studies were found in which the effect on the pharmacokinetics of
antiretroviral drugs of manipulation of the formulation was investigated.
These studies are summarized in Table 5.4, and studies in which bioequiv-
alence was not shown are further discussed below [53–57].
5.5.1 Efavirenz, emtricitabine and tenofovir DF
In an attempt to facilitate the oral administration of the single FDC tablet
of efavirenz, emtricitabine, tenofovir DF a liquid compounded out of the
crushed innovator tablet formulation was tested [54]. In healthy adults,
only emtricitabine was found to be bioequivalent. Exposure parameters for
tenofovir were higher after administration of this liquid formulation: AUC
20% higher and Cmax ∼ 40% higher. Exposure to efavirenz was highly
variable, and the 90%CI criteria were not met for this drug. These findings
are in line with the need to develop a bilayer film-coated FDC tablet to
achieve bioequivalence to the separate innovator formulations [58].
5.5.2 Lopinavir and ritonavir
Although not recommended, the co-formulated lopinavir/ritonavir tablets
are sometimes broken or crushed. Lopinavir exposure was decreased in
HIV-infected children after crushing 200/50 mg tablets: AUC decreased
by 45% and Cmin by 33% [56]. To attempt to reduce the pill count and
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overcome the need of refrigeration of the soft gel capsules, melt-extrusion
technology has been used to obtain a solid dispersion of lopinavir and
ritonavir in a polymer, which is further processed into tablets [12,59]. This
solid dispersion is a system in which a solubilizing polymer gives rise to an
optimal transfer of the drug from the formulation into the aqueous environ-
ment of the gastrointestinal tract. Crushing the tablets results in disruption
of this system and bioavailability can thus be decreased.
5.6 Expert opinion
The composition of a drug formulation can be indicative for some of the
biopharmaceutical properties of the active pharmaceutical ingredient. The
influence of formulation due to drug-excipient interactions is not yet fully
understood nor recognized and described for only a small number of excip-
ients [7–9]. The possible influence of excipients is even more complicated
when different formulations are used together. The exact impact the formu-
lation can have on the pharmacokinetics of an individual antiretroviral drug
is sometimes difficult to predict, even for drugs within the same antiretro-
viral drug class.
Bioequivalence studies for regulatory purposes are generally performed
in healthy adults and not in HIV-infected subjects, or children. Develop-
mental changes affecting the drug absorption process could result in differ-
ences in the rate and extent of drug absorption. More research is needed to
fully understand the ontogeny of drug absorption [6,60]. Whether bioequiv-
alence criteria are met for different formulations can also depend on the
meal conditions under which it is studied. The influence of food on the
absorption of drugs is of extra importance for children for several reasons:
food can be used to ease the administration of drugs, for example to mask
bad taste of the drug and intake with food can reduce side effects.
Variability in exposure has been found after administration of liquid
and solid formulations of drugs in several BCS classes. The majority
of published studies comparing solid and liquid formulations have been
performed in children. The BCS classification is based on adult dosing
and physiological data, and extrapolation to children needs to be done
with caution. In this light, the role of the dose/solubility ratio is of extra
importance, since children receive different doses than adults. Drugs that
show a certain dose/solubility ratio in adults cannot be assumed to show
the same ratio in pediatric patients [61]. It is debated how the BCS
should be adjusted to be applied to children [6]. A ‘BCS-shift’ to a lower
solubility class, because of higher dose/solubility ratio in children, might
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partly explain observed differences in exposure between adults and children.
A dose-dependent BCS has been proposed, which could be applied to drugs
used in children [62,63].
The observed lower exposure to lamivudine after administration of the
liquid is concerning, and more research is warranted in children. These
results have not yet been included in (pediatric) guidelines [3, 4, 64].
Almost all published results of studies in healthy adults where a generic
single-drug formulation was compared to the innovator product showed
that formulations were bioequivalent. More problems, although mostly
minor, are seen with generic FDC formulations. Unfortunately, only a
small proportion of data from in vivo bioequivalence trials are published
and could thus be found.
Only a few studies were found in which the effect of manipulating solid
formulations was investigated. It is important to know whether exposure
is still adequate, which might be a problem when for example lopinavir/r
tablets are crushed, or exposure is too high, which could lead to more
adverse events. This is relevant for children, but also for HIV-infected
patients who (temporarily) are not able to swallow solid drug formulations
and crushed formulations need to be administered via a feeding tube.
Several bioequivalence studies included only a small number of subjects,
herewith limiting the power of the results found. For some of the studies,
this was also reflected in the large variability of the calculated pharmaco-
kinetic parameters. Studies in which population pharmacokinetic models
are developed not always include formulation as possible covariate. When
formulation has been investigated and included as covariate in a popula-
tion pharmacokinetic model, this needs to be confirmed in a bioequivalence
study.
The role of formulation is also important on the adherence to antiretro-
viral treatment. Long-term compliance is essential to reduce the risk of
selecting drug-resistant viruses. Important issues to improve adherence are
related to the formulation, such as palatability, pill size, liquid volume,
conspicuousness and use of FDC formulations [3, 65]. Effort must be
made to facilitate the administration of antiretroviral treatment, to enhance
treatment compliance and thus treatment outcome.
It is recognized that there still is a need for more and better antiretroviral
formulations, especially for children, as reflected in the most recent WHO
guideline and pediatric HIV as one of the focuses of the Drugs for Neglected
Disease initiative. Developments in the use of nanotechnology, which can
help to improve the dissolution and bioavailability of drugs, are promising
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to develop better formulations of antiretroviral drugs.
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Table 5.1: Antiretroviral drug formulations (tentatively) approved by the
US FDA
Formulation Strength
Single-drug formulations
Nucleoside reverse transcriptase inhibitors
Abacavir Tablets 300 mg (scored)
60, 300 mg
Solution 20 mg/ml
Tablets for oral suspension 60 mg
Didanosine Capsules, delayed release 125, 200, 250, 400 mg
Powder for oral solution 2 and 4 g,
to obtain 10 mg/ml
suspension
Tablets for oral suspension 100, 150, 200 mg
Emtricitabine Capsules 200 mg
Solution 10 mg/ml
Lamivudine Tablets 150 (scored), 300 mg
Solution 10 mg/ml
Stavudine Capsules 15, 20, 30, 40 mg
Powder for oral solution 1 mg/ml
Tenofovir Tablets 150, 200, 250, 300 mg
(disoproxil fumarate) 300 mg
Oral powder 40 mg/g
Zidovudine Tablets 300 mg
60, 100, 300 mg
Capsules 100 mg
Syrup 10 mg/ml
Non-nucleoside reverse transcriptase inhibitors
Efavirenz Tablets 600 mg
50, 100, 200 (scored),
600 mg
Capsules 50, 200 mg
50, 100, 200 mg
Liquid (only EMA approval) 30 mg/ml
Etravirine Tablets 25 (scored), 100, 200 mg
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Table 5.1: Antiretroviral drug formulations (tentatively) approved by the
US FDA (continued)
Name Age approved from (FDA)
Single-drug formulations
Nucleoside reverse transcriptase inhibitors
Abacavir Ziagen 3 months
Generic
Ziagen 3 months
Generic
Generic
Didanosine Videx 6 years
Generic
Videx 2 weeks
Generic
Generic
Generic
Emtricitabine Emtriva 3 months
Generic
Emtriva 0 month
Lamivudine Epivir 3 months
Generic
Epivir 3 months
Generic
Stavudine Zerit Birth
Generic
Zerit Birth
Generic
Tenofovir Viread 2 years
(disoproxil fumarate) Generic
Viread 2 years
Zidovudine Retrovir 4 weeks (birth, prophylactic)
Generic
Retrovir 4 weeks (birth, prophylactic)
Generic
Retrovir 4 weeks (birth, prophylactic)
Generic
Non-nucleoside reverse transcriptase inhibitors
Efavirenz Sustiva 3 months
Generic
Sustiva 3 months
Generic
Stocrin/Sustiva 3 years
Etravirine Intelence 6 years
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Table 5.1: Antiretroviral drug formulations (tentatively) approved by the
US FDA (continued)
Formulation Strength
Nevirapine Tablets 200 mg
Tablet extended release 100, 400 mg
400 mg
Suspension 10 mg/ml
Tablets for oral suspension 50, 100 mg
Rilpivirine Tablets 25 mg
Protease inhibitors
Atazanavir Capsules 150, 200, 300 mg
100, 150, 200, 300 mg
Atazanavir/ritonavir Tablets 300/100 mg
Darunavir Tablets 75, 150, 600, 800 mg
75, 150, 300,
400, 600 mg
Oral suspension 100 mg/ml
Fosamprenavir Tablets 700 mg
Oral suspension 50 mg/ml
Indinavir Capsules 200, 400 mg
Lopinavir/ritonavir Tablets 100/25, 200/50 mg
Capsules 133.3/33.3 mg
Solution 80/20 mg/ml
Nelfinavir Tablets 250, 625 mg
Ritonavir Tablets 100 mg
Capsules 100 mg
Solution 80 mg/ml
Saquinavir Capsules 200 mg
Tablets 500 mg
Tipranavir Capsules 250 mg
Solution 100 mg/ml
Entry inhibitor
Enfuvirtide Powder for subcutaneous 108 mg, to
injection obtain 90 mg/ml
CCR5 co-receptor antagonist
Maraviroc Tablets 150, 300 mg
1 PNA: Postnatal age
2 PMA: Post-menstrual age
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Table 5.1: Antiretroviral drug formulations (tentatively) approved by the
US FDA (continued)
Name Age approved from (FDA)
Nevirapine Viramune 15 days
Generic
Viramune XR 6 years
Generic
Viramune 15 days
Generic
Generic
Rilpivirine Edurant 18 years
Protease inhibitors
Atazanavir Reyataz 6 years
Generic
Atazanavir/ritonavir Generic
Darunavir Prezista 3 years
Generic
Prezista 3 years
Fosamprenavir Lexiva 4 weeks
Lexiva 4 weeks
Indinavir Crixivan 18 years
Lopinavir/ritonavir Kaletra 14 days
Generic
Kaletra 14 days
Kaletra 14 days (PNA1) and 42 weeks (PMA2)
Generic
Nelfinavir Viracept 2 years
Ritonavir Norvir 1 month
Generic
Norvir 1 month
Norvir 1 month (PMA2 44 weeks)
Saquinavir Invirase 16 years
Invirase 16 years
Tipranavir Aptivus 2 years
Aptivus 2 years
Entry inhibitor
Enfuvirtide Fuzeon 6 years
CCR5 co-receptor antagonist
Maraviroc Selzentry 18 years
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Table 5.1: Antiretroviral drug formulations (tentatively) approved by the
US FDA (continued)
Formulation Strength
Integrase inhibitors
Dolutegravir Tablet 50 mg
Raltegravir Tablets 400 mg
Chewable tablet 25, 100 mg (scored)
Powder for suspension 100 mg/packet
Fixed-dose combination formulations
Abacavir/lamivudine Tablets 600/300 mg
Tablets 60/30 mg
Tablets for oral suspension 60/30 mg
Abacavir/lamivudine/ Tablets 300/150/300 mg
zidovudine
Efavirenz/emtricitabine/ Tablets 600/200/300 mg
tenofovir DF
Efavirenz/lamivudine/ Tablets 600/300/300 mg
tenofovir DF
Elvitegravir/cobicistat/ Tablets 150/150/200/300 mg
emtricitabine/
tenofovir DF
Emtricitabine/ Tablets 200/300 mg
tenofovir DF
Emtricitabine/rilpivirine/ Tablets 200/25/300 mg
tenofovir DF
Lamivudine/stavudine Tablets 150/30, 150/40,
60/12, 30/6 mg
Lamivudine/zidovudine Tablets 150/300 mg (scored)
Tablets (for oral suspension) 30/60 mg
Lamivudine/tenofovir DF Tablets 300/300 mg
Lamivudine/stavudine/ Tablets 150/30/200,
nevirapine 150/40/200 mg
Tablets, dispersible 30/6/50, 60/12/100 mg
Lamivudine/zidovudine/ Tablets 150/300/200 mg
nevirapine Tablets for oral suspension 30/60/50 mg
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Table 5.1: Antiretroviral drug formulations (tentatively) approved by the
US FDA (continued)
Name Age approved from (FDA)
Integrase inhibitors
Dolutegravir Tivicay 12 years
Raltegravir Isentress 4 weeks
Isentress 4 weeks
Isentress 4 weeks
Fixed-dose combination formulations
Abacavir/lamivudine Epzicom 18 years
Generic
Generic
Generic
Abacavir/lamivudine/ Trizivir Adolescents
zidovudine Generic
Efavirenz/emtricitabine/ Atripla 12 years
tenofovir DF Generic
Efavirenz/lamivudine/ Generic
tenofovir DF
Elvitegravir/cobicistat/ Stribild 18 years
emtricitabine/
tenofovir DF
Emtricitabine/ Truvada 12 years
tenofovir DF
Generic
Emtricitabine/rilpivirine/ Complera 18 years
tenofovir DF
Lamivudine/stavudine Generic
Lamivudine/zidovudine Combivir bodyweight of 30 kg
Generic
Generic
Lamivudine/tenofovirDF Generic
Lamivudine/stavudine/ Generic
nevirapine
Generic
Lamivudine/zidovudine/ Generic
nevirapine Generic
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Table 5.2: Studies comparing solid and liquid formulations of antiretroviral
drugs. Studies were performed in HIV-infected subjects, unless
specified otherwise.
BCS BDDCS Compared formulations
[14–19] [22]
Nucleoside reverse transcriptase inhibitors
Abacavir (ABC) 3 1 Tablet and solution
Innovator scored tablet and solution
Tablet and solution
Innovator (scored) tablet and solution
Didanosine 3 3 See section 5.4.2.1
Emtricitabine 1 3 Tablet and solution
Lamivudine (3TC) 1/3 3 Tablet and solution
Innovator scored FDC tablet
(3TC/ZDV) and liquids
Generic pediatric FDC granules for
suspension (3TC/ZDV/NVP) and
innovator liquids
Generic pediatric FDC tablets
(3TC/ZDV/NVP) and innovator liquids
Generic pediatric FDC tablet
(3TC/ZDV/NVP) and innovator liquids
Generic pediatric FDC tablet for
suspension (3TC/d4T/NVP) and liquids
Generic pediatric FDC tablet
(3TC/d4T/NVP) and innovator liquids
Generic FDC tablet (3TC/d4T/NVP)
and innovator liquids
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Table 5.2: Studies comparing solid and liquid formulations of antiretroviral
drugs. Studies were performed in HIV-infected subjects, unless
specified otherwise (continued)
Subjects Outcome Ref.
(years, range)
Adult GMR (90%CI): AUC0−∞: [66]
1.01 (0.93, 1.10)
Cmax: 0.89 (0.77, 1.02)
Child (1.8 – 4) GMR (90%CI): AUC0−12: [35]
0.96 (0.83, 1.12)
Cmax: 1.02 (0.89, 1.17)
Child (0 – 16) Formulation not retained as [67]
covariate in final population
pharmacokinetic model
Child (0.4 – 13) Formulation not retained as [68]
covariate in final population
pharmacokinetic model
[47–49]
Child (6 – 17) Relative bioavailability of capsule [31]
formulation was 120% compared
to the solution
Adult GMR (90%CI): AUC0−∞: [40]
0.98 (0.98, 1.00)
Cmax: 0.98 (0.98, 1.01)
Child (1.8 – 4) GMR (90%CI): AUC0−12: [35]
1.58 (1.37, 1.81)
Cmax: 1.55 (1.33, 1.81)
Healthy adults GMR (90%CI): AUC0−τ : [42]
1.06 (0.96, 1.18)
Cmax: 0.94 (0.86, 1.03)
Healthy adults Comparable pharmacokinetic [69]
profile
Child (0.5 – 12) GMR (90%CI): AUC: 1.79 (1.68, [34]
1.90)
Healthy adults GMR (90%CI): AUC0−τ : [44]
1.08 (1.01, 1.15)
Cmax: 1.15 (1.07, 1.24)
Child (0.5 – 11) GMR (90%CI): AUC: 1.41 (1.30, [33]
1.53)
Cmax: 1.59 (1.39, 1.82)
Child (1.3 – 14) GMR (90%CI): AUC0−6: [41]
0.80 (0.64, 1.01)
Cmax: 0.76 (0.58, 0.99)
How to improve antiviral drug treatment for children 115
5 The role of formulation on the pharmacokinetics of antiretroviral drugs
Table 5.2: Studies comparing solid and liquid formulations of antiretroviral
drugs. Studies were performed in HIV-infected subjects, unless
specified otherwise (continued)
BCS BDDCS Compared formulations
[14–19] [22]
Tablet and solution
Generic FDC tablet (3TC/ZDV/NVP or
3TC/d4T/NVP) and innovator liquid
Stavudine 1/3 3 Tablet and solution
(d4T)
Generic pediatric FDC tablets
(3TC/ZDV/NVP) and innovator liquids
Generic pediatric FDC tablet for
suspension (3TC/d4T/NVP) and liquids
Generic pediatric FDC tablet
(3TC/d4T/NVP) and innovator liquids
Generic FDC tablet (3TC/d4T/NVP) and
innovator liquids
Tenofovir DF 3 3 No liquid formulation approved
Zidovudine 1/3 1 Innovator capsule and solution (syrup)
(ZDV)
Innovator scored FDC tablet
(3TC/ZDV) and liquids
Generic pediatric FDC tablet
(3TC/ZDV/NVP) and innovator liquids
Generic pediatric FDC granules for
suspension (3TC/ZDV/NVP) and
innovator liquids
Tablets and liquid
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Table 5.2: Studies comparing solid and liquid formulations of antiretroviral
drugs. Studies were performed in HIV-infected subjects, unless
specified otherwise (continued)
Subjects Outcome Ref.
(years, range)
Child Formulation not retained as [36, 37, 45]
(several age groups) covariate in final population
pharmacokinetic model
Child (0.1 – 14) Formulation was found to be an [39]
independent predictor for
bioavailability and was retained in
the final population
pharmacokinetic model
Child (0 – 16) Formulation not retained as [70]
covariate in final population
pharmacokinetic model
Healthy adults Comparable pharmacokinetic [69]
profile
Healthy adults GMR (90%CI): AUC0−τ : [44]
0.92 (0.89, 0.95)
Cmax: 0.89 (0.83, 0.94)
Child (0.5 – 11) GMR (90%CI): AUC: 0.97 (0.92, [33]
1.02)
Cmax: 1.08 (0.97, 1.20)
Child (1.3 – 14) GMR (90%CI): AUC0−6: [41]
0.96 (0.69, 1.34)
Cmax: 0.88 (0.60, 1.28)
Adult GMR (syrup:capsule) (90%CI): [71]
AUC: 0.95 (0.83, 1.00)
Child (1.8 – 4) GMR (90%CI): AUC0−12: [35]
1.01 (0.87, 1.18)
Cmax: 1.07 (0.92, 1.25)
Child (0.5 – 12) GMR (90%CI): AUC: 0.99 (0.92, [34]
1.06)
Healthy adults GMR (90%CI): AUC0−τ : [42]
1.12 (1.00, 1.25)
Cmax: 0.95 (0.83, 1.09)
Child (0.2 – 18) Formulation not retained as [72]
covariate in final population
pharmacokinetic model
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Table 5.2: Studies comparing solid and liquid formulations of antiretroviral
drugs. Studies were performed in HIV-infected subjects, unless
specified otherwise (continued)
BCS BDDCS Compared formulations
[14–19] [22]
Non-nucleoside reverse transcriptase inhibitors
Efavirenz 2/4 2 Tablet, capsule and liquid
Capsule and liquids
Etravirine 4 2 No liquid formulation available
Nevirapine 2 2 Generic pediatric FDC tablet for
(NVP) suspension (3TC/d4T/NVP) and liquids
Generic pediatric FDC tablets
(3TC/ZDV/NVP) and innovator liquids
Generic pediatric FDC tablet
(3TC/d4T/NVP) and innovator liquids
Generic FDC tablet (3TC/d4T/NVP)
and innovator liquids
Generic pediatric FDC granules for
suspension (3TC/ZDV/NVP) and
innovator liquids
Generic pediatric FDC tablet
(3TC/ZDV/NVP) and innovator liquids
Rilpivirine 2 – No liquid formulation approved
Protease inhibitors
Atazanavir 2 2 No liquid formulation approved
Darunavir 2 2 No comparison data published
Fosamprenavir 2 2 No comparison data published
Indinavir 2/4 2 No liquid formulation approved
Capsule and extemporaneous
suspension
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Table 5.2: Studies comparing solid and liquid formulations of antiretroviral
drugs. Studies were performed in HIV-infected subjects, unless
specified otherwise (continued)
Subjects Outcome Ref.
(years, range)
Child (0.9 – 19) The population pharmacokinetic [29]
model estimated a relative
bioavailability of the liquid
compared with the capsule and
tablet formulations of 46.6%
Child (0.2 – 17) The pharmacometric model [30]
estimated a lower and age-dependent
relative bioavailability of
the liquid formulations compared
to the capsule formulation
Healthy adults GMR (90%CI): AUC0−τ : [44]
1.00 (0.96, 1.04)
Cmax: 1.05 (0.99, 1.12)
Healthy adults Comparable pharmacokinetic [69]
profile
Child (0.5 – 11) GMR (90%CI): AUC: 1.08 (1.04, [33]
1.13)
Cmax: 1.14 (1.08, 1.19)
Child (1.3 – 14) GMR (90%CI): AUC0−6: [41]
0.99 (0.84, 1.15)
Cmax: 0.97 (0.82, 1.15)
Healthy adults GMR (90%CI): AUC0−τ : [42]
0.97 (0.89, 1.06)
Cmax: 0.98 (0.88, 1.09)
Child (0.5 – 12) GMR (90%CI): AUC: 0.85 (0.81, [34]
0.88)
Healthy adults GMR (liquid:capsule) (90%CI): [73]
AUC0−8: 0.95 (0.92, 0.99)
Cmax: 1.00 (0.95, 1.06)
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Table 5.2: Studies comparing solid and liquid formulations of antiretroviral
drugs. Studies were performed in HIV-infected subjects, unless
specified otherwise (continued)
BCS BDDCS Compared formulations
[14–19] [22]
Lopinavir 2/4 2 Solid and liquid formulation
Soft gel capsule and liquid
Nelfinavir 2/4 2 No liquid formulation approved
Tablets and extemporaneous
suspension
Ritonavir 2/4 2 Not included, since no longer used
as protease inhibitor
Saquinavir mesylate 4 2 No liquid formulation approved
Tipranavir 2 2 No comparison data published
Entry, fusion and integrase inhibitors
Enfuvirtide – – No oral formulation approved
Maraviroc 3 1 No liquid formulation approved
Dolutegravir 2 – No liquid formulation approved
Elvitegravir 2 – No liquid formulation approved
Raltegravir 2/4 2 Film-coated tablet and granules for
suspension
AUC: Area under the concentration time curve
BCS class: Biopharmaceutics classification system:
class 1 (high solubility, high permeability)
class 2 (low solubility, high permeability)
class 3 (high solubility, low permeability)
class 4 (low solubility, low permeability)
BDDCS class: Biopharmaceutics drug disposition classification system:
class 1 (high solubility, extensive metabolism)
class 2 (low solubility, extensive metabolism)
class 3 (high solubility, poor metabolism)
class 4 (low solubility, poor metabolism)
FDC: Fixed-dose combination formulations
GMR (90%CI): Geometric mean ratio with 90%CI (tablet:liquid, unless specified
otherwise)
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Table 5.2: Studies comparing solid and liquid formulations of antiretroviral
drugs. Studies were performed in HIV-infected subjects, unless
specified otherwise (continued)
Subjects Outcome Ref.
(years, range)
Child (0 – 18) Formulation not retained as [74]
covariate in final population
pharmacokinetic model
Child (5 – 18) Formulation was significantly [75]
associated with absorption lag
time: median lag time was twofold
shorter for liquid compared to
capsules
Healthy adults GMR (suspension: tablets) (90% [76]
CI): AUC0−∞: 0.9 (0.90, 1.24)
Cmax: 1.0 (0.92, 1.08)
Healthy adults GMR (granules:tablet) (90%CI): [46]
AUC0−∞: 2.62 (2.17, 3.17)
Cmax: 4.64 (3.41, 6.30)
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Table 5.3: Studies showing bioequivalence or comparable pharmacokinetics
of solid antiretroviral drug formulations
Antiretroviral Compared formulations
Nucleoside reverse transcriptase inhibitors
Abacavir Generic and innovator tablet‡
Didanosine Generic and innovator chewable
tablet‡
Generic and innovator powder for
oral solution‡
Lamivudine Generic and innovator tablet‡
Stavudine Generic and innovator capsule‡
Tenofovir Generic and innovator tablet‡
Zidovudine Generic and innovator capsule‡
Generic and innovator tablet‡
Non-nucleoside reverse transcriptase inhibitors
Efavirenz Generic and innovator capsule‡
Etravirine Innovator tablets§
Innovator tablets‡
Nevirapine Generic and innovator tablet‡
Generic and innovator tablet‡
Protease inhibitors
Atazanavir Generic and innovator capsule‡
Darunavir Generic and innovator tablet‡
Indinavir Generic and innovator capsule‡
Generic and innovator capsule§
Lopinavir/ritonavir Generic and innovator capsule‡
Generic and innovator tablet‡
Generic and innovator tablet‡
Innovator capsule and innovator
tablet§
Innovator capsule and innovator
tablet§
Innovator capsule and generic
tablet§
Innovator capsule and (cut) generic
tablet§
Innovator capsule and generic
tablet§
Generic tablets§
Nelfinavir Generic and innovator tablet‡
Saquinavir mesylate Innovator capsule and tablet‡
Innovator capsule and innovator
tablet§
Generic and innovator tablet‡
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Table 5.3: Studies showing bioequivalence or comparable pharmacokinetics
of solid antiretroviral drug formulations (continued)
Strength Subjects Meal condition Ref.
300 mg Healthy adults Fasting and fed [77]
100 mg Healthy adults Fasting [78]
4 g Healthy adults Fasting [79]
150 mg Healthy adults Fasting [80–83]
40 mg Healthy adults Fasting [84–86]
300 mg Healthy adults Fasting and fed [87, 88]
100 mg Healthy adults Fasting [89, 90]
300 mg Healthy adults Fed [91]
200 mg Healthy adults Fasting [92]
100 and 25 mg Healthy adults Fed [55]
100 and 200 mg Healthy adults Fed [55]
200 mg Healthy adults Fasting [93–95]
200 mg HIV-infected adults Fasting [96]
300 mg Healthy adults Fasting [97]
600 mg Healthy adults Fasting and fed [98]
400 mg Healthy adults Fasting [99]
400 mg∗ HIV-infected adults Fasting [100]
133/33 mg Healthy adults Fed [101]
200/50 mg Healthy adults Fasting [102, 103]
200/50 mg compared to two HIV-infected adults Not described [104]
100/25 innovator tablets
133/33 and 200/50 mg Healthy adults Various meal [59]
conditions
133/33 and 200/50 mg HIV-infected adults Not described [105]
133/33 and 200/50 mg HIV-infected adults Variable [106]
133/33 and 200/50 mg HIV-infected children Not described [107]
133/33 and 200/50 mg HIV-infected adults Not described [108]
200/50 mg HIV-infected adults Not described [108]
250 mg Healthy adults Not described [109]
200 and 500 mg Healthy adults Fed [110]
200 and 500 mg HIV-infected adults Not described [111]
500 mg Healthy adults Fed [112]
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Table 5.3: Studies showing bioequivalence or comparable pharmacokinetics
of solid antiretroviral drug formulations (continued)
Antiretroviral Compared formulations
Fixed-dose combination formulations
Abacavir/lamivudine/zidovudine Innovator tablet and separate
innovator tablets‡
Innovator tablet and innovator
abacavir + FDC lamivudine/
zidovudine tablets‡
Efavirenz/emtricitabine/tenofovir DF Innovator tablet and separate
innovator tablets‡
Emtricitabine/rilpivirine/tenofovir DF Innovator tablet and separate
innovator capsule and tablets‡
Lamivudine/nevirapine/stavudine Generic tablet and separate
innovator tablets‡
Generic tablet and separate
innovator tablets§
Generic tablet and separate
innovator tablets and capsule‡
Generic tablet and nevirapine
tablet§
Lamivudine/nevirapine/zidovudine Generic tablet and separate
innovator tablets‡
Generic tablet and innovator
nevirapine + FDC lamivudine/
zidovudine tablet§
Lamivudine/stavudine Generic tablet and separate
standard tablet and capsule‡
Generic tablet and separate
innovator tablet and capsule§
Lamivudine/tenofovir DF Generic tablet and separate
innovator tablets‡
Lamivudine/zidovudine Innovator tablet and separate
innovator tablets‡
Generic tablets and innovator FDC‡
Eight subunit pediatric tablet and
generic FDC tablet‡
∗ The formulation was not specifically described, but as these were adult patients on
antiretroviral treatment with indinavir, it is expected that the 400 mg capsule
formulation was used.
‡ Bioequivalence criteria were met.
§ Bioequivalence criteria not determined or not met, but comparable
pharmacokinetic parameters.
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Table 5.3: Studies showing bioequivalence or comparable pharmacokinetics
of solid antiretroviral drug formulations (continued)
Strength Subjects Meal condition Ref.
300/150/300 mg Healthy adults Fasting and fed¶ [113]
300/150/300 mg HIV-infected adults Fasting [114]
600/200/300 mg Healthy adults Fasting [58]
200/25/300 mg Healthy adults Fed [19]
150/200/40 mg Healthy adults Fasting [115]
150/200/40 mg HIV-infected adults Fasting and fed [116–118]
150/200/30 mg Healthy adults Fasting [119]
30/6/50 and 60/12/100 mg Healthy adults Fasting [69]
150/200/300 mg Healthy adults Fasting [120]
150/200/300 mg Healthy adult women Fasting [121]
150/40 mg Healthy adults Fasting [122]
150/30 mg Healthy adults Unknown [123]
300/300 mg Healthy adults Fasting [124]
150/300 mg Healthy adults Fasting and fed [125]
150/300 mg Healthy adults Fasting [126]
160/300 mg Healthy adults Fasting [127]
¶ The GMR (90%CI) of the FDC tablet under fed compared to fasting conditions
was 0.68 (0.62, 0.76).
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Table 5.4: Studies comparing the influence of manipulation of antiretroviral
drug formulations on pharmacokinetics
Antiretroviral Compared formulations Subjects
Efavirenz Intact innovator capsules Healthy adults
and opened capsules mixed with food
Efavirenz, emtricitabine, Intact innovator tablet Healthy adults
tenofovir DF and extemporaneously compounded
liquid out of tablets
Etravirine Innovator 100 mg tablet as a whole Healthy adults
and dispersed in 100 ml water
Lopinavir/ritonavir Innovator 200/50 mg tablet as a whole Children
and crushed (10-16 years)
Stavudine Whole compared to opened generic Healthy adults
capsules
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Table 5.4: Studies comparing the influence of manipulation of antiretroviral
drug formulations on pharmacokinetics (continued)
Outcome Ref. Antiretroviral
Bioequivalence criteria met [53] Efavirenz
GMR (liquid:tablet) (90%CI): [54] Efavirenz, emtricitabine,
Efavirenz: AUC0−∞ 0.97 (0.82, 1.26) tenofovir DF
and Cmax 0.86 (0.75, 1.04)
Emtricitabine: AUC0−∞ 0.99 (0.91, 1.05)
and Cmax 1.15 (0.97, 1.25)
Tenofovir: AUC0−∞: 1.21 (1.07, 1.40)
and Cmax 1.38 (1.12, 1.70)
Bioequivalence criteria met [55] Etravirine
GMR (crushed:whole) (90%CI): [56] Lopinavir/ritonavir
Lopinavir: AUC: 0.55 (0.45, 0.69)
and Cmax 0.75 (0.61, 0.92)
Ritonavir: AUC: 0.53 (0.4, 0.71)
and Cmax 0.7 (0.51, 0.97)
Bioequivalence criteria met [57] Stavudine
How to improve antiviral drug treatment for children 127
References
References
[1] UNAIDS. Global Report. UNAIDS Report on the global AIDS epidemic 2013.
[2] UNAIDS. Global Report 2013. HIV estimates with uncertainty bounds.
[3] World Health Organization. Consolidated guidelines on the use of antiretroviral
drugs for treating and preventing HIV infection. Recommendations for a public
health approach., 2013.
[4] Panel on Antiretroviral Therapy and Medical Management of HIV-
Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric
HIV Infection.
[5] M.N. Neely and N.Y. Rakhmanina. Pharmacokinetic optimization of antiretroviral
therapy in children and adolescents. Clin Pharmacokinet, 50(3):143–189, 2011.
[6] S.M. Abdel-Rahman, G.L. Amidon, A. Kaul, et al. Summary of the National
Institute of Child Health and Human Development-best pharmaceuticals for
Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharma-
ceutics Classification System Working Group. Clin Ther, 34(11):S11–24, 2012.
[7] T.R. Buggins, P.A. Dickinson, and G. Taylor. The effects of pharmaceutical excip-
ients on drug disposition. Adv Drug Deliv Rev, 59(15):1482–1503, 2007.
[8] J. Goole, D.J. Lindley, W. Roth, et al. The effects of excipients on transporter
mediated absorption. Int J Pharm, 393(1-2):17–31, 2010.
[9] R. Panakanti and A.S. Narang. Impact of excipient interactions on drug bioavail-
ability from solid dosage forms. Pharm Res, 29(10):2639–2659, 2012.
[10] European Medicines Agency: Committee for Medicinal Products for Human use
(CHMP). Guideline on the investigation of bioequivalence., 20 January 2010 2010.
[11] U.S. Food, Drug Administration: Center for Drug Evaluation, and Research.
Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence
Studies for Immediate-Release Solid Oral Dosage Forms on a Biophamaceutics
Classification System, 2000.
[12] M.E. Aulton and K.M.G. Taylor. Aulton’s Pharmaceutics, The Design and
Manufacture of Medicines. Churchill Livingstone, 4th edition edition, 2013.
[13] G.L. Amidon, H. Lennernas, V.P. Shah, et al. A theoretical basis for a biophar-
maceutic drug classification: the correlation of in vitro drug product dissolution
and in vivo bioavailability. Pharm Res, 12(3):413–420, 1995.
[14] M. Lindenberg, S. Kopp, and J.B. Dressman. Classification of orally adminis-
tered drugs on the World Health Organization Model list of Essential Medicines
according to the biopharmaceutics classification system. Eur J Pharm Biopharm,
58(2):265–278, 2004.
[15] Oral Formulations Platform. Inter-Agency Agreement between the Eunice
Kennedy Shriver National Institute of Child Health and Human Development
(NICHD) and the U.S. Food and Drug Administration (FDA).
[16] FDA. US Food and Drug Administration.
[17] European Medicines Agency.
[18] J.C. Ruela Correa, D.M. D’Arcy, C.H. dos Reis Serra, et al. Darunavir: a critical
review of its properties, use and drug interactions. Pharmacology, 90(1-2):102–109,
2012.
[19] A. Mathias, M. Menning, L. Wiser, et al. Bioequivalence of the emtric-
itabine/rilpivirine/tenofovir disoproxil fumarate single tablet regimen. Journal
of Bioequivalence and Bioavailability, 4(7):100–105, 2012.
128 Making things easier
References
[20] M.L. Chen, A.B. Straughn, N. Sadrieh, et al. A modern view of excipient effects
on bioequivalence: case study of sorbitol. Pharm Res, 24(1):73–80, 2007.
[21] A. Olagunju, A. Owen, and T.R. Cressey. Potential effect of pharmacogenetics
on maternal, fetal and infant antiretroviral drug exposure during pregnancy and
breastfeeding. Pharmacogenomics, 13(13):1501–1522, 2012.
[22] L.Z. Benet, F. Broccatelli, and T.I. Oprea. BDDCS applied to over 900 drugs.
AAPS J, 13(4):519–547, 2011.
[23] C.Y. Wu and L.Z. Benet. Predicting drug disposition via application of BCS:
transport/absorption/ elimination interplay and development of a biopharmaceu-
tics drug disposition classification system. Pharm Res, 22(1):11–23, 2005.
[24] European Medicines Agency. Reflection paper: Formulations of choice for the
paediatric population, London, 28 July 2006 2006.
[25] D. Boxwell, K. Cao, L. Lewis, et al. Kaletra oral solution toxicity in neonates-
lopinavir, ethanol, and/or propylene glycol? In 18th CROI Conference on Retro-
viruses and Opportunistic Infections, February 27 - March 2, 2011.
[26] U.S. Department of Health, Human Services (Center for Drug Evaluation, and
Research (FDA)). Guidance for Industry: Fixed Dose Combinations, Co-Packaged
Drug Products, and Single-Entity Versions of Previously Approved Antiretrovirals
for the Treatment of HIV, 2006.
[27] J. Breitkreutz and J. Boos. Paediatric and geriatric drug delivery. Expert Opin
Drug Deliv, 4(1):37–45, 2007.
[28] Merck Sharp & Dohme Limited. Stocrin. Summary of product characteristics.
[29] R. ter Heine, H.J. Scherpbier, K.M. Crommentuyn, et al. A pharmacokinetic and
pharmacogenetic study of efavirenz in children: dosing guidelines can result in
subtherapeutic concentrations. Antivir Ther, 13(6):779–787, 2008.
[30] A.H. Salem, C.V. Fletcher, and R.C. Brundage. Pharmacometric characteriza-
tion of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-
infected children. Antimicrob Agents Chemother, 58(1):136–143, 2014.
[31] L.H. Wang, A.A. Wiznia, M.H. Rathore, et al. Pharmacokinetics and safety
of single oral doses of emtricitabine in human immunodeficiency virus-infected
children. Antimicrob Agents Chemother, 48(1):183–191, 2004.
[32] Gilead Sciences Inc. Emtriva. Label Information.
[33] N. Vanprapar, T.R. Cressey, K. Chokephaibulkit, et al. A chewable pediatric fixed-
dose combination tablet of stavudine, lamivudine, and nevirapine: pharmaco-
kinetics and safety compared with the individual liquid formulations in human
immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J,
29(10):940–944, 2010.
[34] K. Chokephaibulkit, T.R. Cressey, E. Capparelli, et al. Pharmaco-
kinetics and safety of a new paediatric fixed-dose combination of zidovu-
dine/lamivudine/nevirapine in HIV-infected children. Antivir Ther, 16(8):1287–
1295, 2011.
[35] P. Kasirye, L. Kendall, K.K. Adkison, et al. Pharmacokinetics of antiretroviral
drug varies with formulation in the target population of children with HIV-1. Clin
Pharmacol Ther, 91(2):272–280, 2012.
[36] N. Bouazza, D. Hirt, C. Bardin, et al. Is the recommended once-daily dose of
lamivudine optimal in West African HIV-infected children? Antimicrob Agents
Chemother, 54(8):3280–3286, 2010.
How to improve antiviral drug treatment for children 129
References
[37] N. Bouazza, D. Hirt, S. Blanche, et al. Developmental pharmacokinetics of lamivu-
dine in 580 pediatric patients ranging from neonates to adolescents. Antimicrob
Agents Chemother, 55(7):3498–3504, 2011.
[38] D.M. Burger, G. Verweel, N. Rakhmanina, et al. Age-dependent pharmacokinetics
of lamivudine in HIV-infected children. Clin Pharmacol Ther, 81(4):517–520, 2007.
[39] A.H. Tremoulet, M. Nikanjam, T.R. Cressey, et al. Developmental pharmaco-
kinetic changes of lamivudine in infants and children. J Clin Pharmacol,
52(12):1824–1832, 2012.
[40] G.J. Yuen, D.M. Morris, P.K. Mydlow, et al. Pharmacokinetics, absolute
bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol,
35(12):1174–1180, 1995.
[41] A.H. Corbett, M.C. Hosseinipour, J. Nyirenda, et al. Pharmacokinetics of generic
and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected
Malawian children. Antivir Ther, 15(1):83–90, 2010.
[42] F. Esseku, A. Joshi, Y. Oyegbile, et al. A randomized Phase I bioequivalence
clinical trial of a paediatric fixed-dose combination antiretroviral reconstitutable
suspension in healthy adult volunteers. Antivir Ther, 18(3):205–212, 2013.
[43] T. Monif, S. Reyar, H.K. Tiwari, et al. A single-dose, randomized, open-label, two-
period crossover bioequivalence study comparing a fixed-dose pediatric combina-
tion of lamivudine and stavudine tablet for oral suspension with individual liquid
formulations in healthy adult male volunteers. Arzneimittelforschung, 59(2):104–
108, 2009.
[44] T. Monif, N. Rao Thudi, S. Koundinya Tippabhotla, et al. A single-dose,
randomized, open-label, two-period crossover bioequivalence study of a fixed-dose
pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-
mg tablet for oral suspension with individual liquid formulations in healthy adult
male volunteers. Clin Ther, 29(12):2677–2684, 2007.
[45] C. Piana, W. Zhao, K. Adkison, et al. Covariate effects and population pharmaco-
kinetics of lamivudine in HIV-infected children. Br J Clin Pharmacol, 77(5):861–
872, 2014.
[46] E.G. Rhee, M.L. Rizk, D.M. Brainard, et al. A pharmacokinetic comparison of
adult and pediatric formulations of raltegravir in healthy adults. Antivir Ther,
2014.
[47] N.R. Hartman, R. Yarchoan, J.M. Pluda, et al. Pharmacokinetics of 2’,3’-
dideoxyinosine in patients with severe human immunodeficiency infection. II. The
effects of different oral formulations and the presence of other medications. Clin
Pharmacol Ther, 50(3):278–285, 1991.
[48] B.D. Damle, S. Kaul, D. Behr, et al. Bioequivalence of two formulations of didano-
sine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers
and HIV-infected subjects. J Clin Pharmacol, 42(7):791–797, 2002.
[49] D. Burger, P. Meenhorst, J. Mulder, et al. Substitution of didanosine sachets
by chewable tablets: a pharmacokinetic study in patients with AIDS. J Acquir
Immune Defic Syndr Hum Retrovirol, 10(2):163–168, 1995.
[50] D. Zucman, S. Camara, J. Gravisse, et al. Generic antiretroviral drugs in devel-
oping countries: friends or foes? AIDS, 28(4):607–609, 2014.
[51] B. Kaeser, J.E. Charoin, M. Gerber, et al. Assessment of the bioequivalence of two
nelfinavir tablet formulations under fed and fasted conditions in healthy subjects.
Int J Clin Pharmacol Ther, 43(3):154–162, 2005.
[52] Merck Sharp & Dohme Corp. Isentress. Label Information.
130 Making things easier
References
[53] S. Kaul, P. Ji, M. Lu, et al. Bioavailability in healthy adults of efavirenz capsule
contents mixed with a small amount of food. Am J Health Syst Pharm, 67(3):217–
222, 2010.
[54] J. King, M. McCall, A. Cannella, et al. A randomized crossover study to determine
relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-
dose combination tablet compared with a compounded oral liquid formulation
derived from the tablet. J Acquir Immune Defic Syndr, 56(5):e130–132, 2011.
[55] T.N. Kakuda, C. Berckmans, G. De Smedt, et al. Single-dose pharmacokinetics
of pediatric and adult formulations of etravirine and swallowability of the 200-mg
tablet: results from three Phase 1 studies. Int J Clin Pharmacol Ther, 51(9):725–
737, 2013.
[56] B.M. Best, E.V. Capparelli, H. Diep, et al. Pharmacokinetics of lopinavir/ritonavir
crushed versus whole tablets in children. J Acquir Immune Defic Syndr, 58(4):385–
391, 2011.
[57] S. Innes, J. Norman, P. Smith, et al. Bioequivalence of dispersed stavudine:
opened versus closed capsule dosing. Antivir Ther, 16(7):1131–1134, 2011.
[58] A.A. Mathias, J. Hinkle, M. Menning, et al. Bioequivalence of
efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. J
Acquir Immune Defic Syndr, 46(2):167–173, 2007.
[59] C.E. Klein, Y.L. Chiu, W. Awni, et al. The tablet formulation of
lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule
formulation with less pharmacokinetic variability and diminished food effect. J
Acquir Immune Defic Syndr, 44(4):401–410, 2007.
[60] M.G. Mooij, B.A. de Koning, M.L. Huijsman, et al. Ontogeny of oral drug absorp-
tion processes in children. Expert Opin Drug Metab Toxicol, 8(10):1293–1303,
2012.
[61] H.K. Batchelor, R. Kendall, S. Desset-Brethes, et al. Application of in vitro
biopharmaceutical methods in development of immediate release oral dosage forms
intended for paediatric patients. Eur J Pharm Biopharm, 85(3 Pt B):833–842,
2013.
[62] G. Charkoftaki, A. Dokoumetzidis, G. Valsami, et al. Elucidating the role of
dose in the biopharmaceutics classification of drugs: the concepts of critical dose,
effective in vivo solubility, and dose-dependent BCS. Pharm Res, 29(11):3188–
3198, 2012.
[63] E. Rinaki, G. Valsami, and P. Macheras. Quantitative biopharmaceutics classifi-
cation system: the central role of dose/solubility ratio. Pharm Res, 20(12):1917–
1925, 2003.
[64] S. Welch, M. Sharland, E.G. Lyall, et al. PENTA 2009 guidelines for the use of
antiretroviral therapy in paediatric HIV-1 infection. HIV Med, 10(10):591–613,
2009.
[65] P. Nahirya-Ntege, A. Cook, T. Vhembo, et al. Young HIV-infected children and
their adult caregivers prefer tablets to syrup antiretroviral medications in Africa.
PLoS One, 7(5):e36186, 2012.
[66] G.E. Chittick, C. Gillotin, J.A. McDowell, et al. Abacavir: absolute bioavailability,
bioequivalence of three oral formulations, and effect of food. Pharmacotherapy,
19(8):932–942, 1999.
[67] V. Jullien, S. Urien, H. Chappuy, et al. Abacavir pharmacokinetics in human
immunodeficiency virus-infected children ranging in age from 1 month to 16 years:
A population analysis. J Clin Pharmacol, 45(3):257–264, 2005.
How to improve antiviral drug treatment for children 131
References
[68] W. Zhao, C. Piana, M. Danhof, et al. Population pharmacokinetics of abacavir in
infants, toddlers and children. Br J Clin Pharmacol, 75(6):1525–1535, 2013.
[69] R.F. L’Homme, T. Dijkema, A. Warris, et al. Pharmacokinetics of two generic
fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune
Junior) are similar to the branded products in healthy adults. J Antimicrob
Chemother, 59(1):92–96, 2007.
[70] V. Jullien, A. Rais, S. Urien, et al. Age-related differences in the pharmacokinetics
of stavudine in 272 children from birth to 16 years: a population analysis. Br J
Clin Pharmacol, 64(1):105–109, 2007.
[71] R.H. Drew, S. Weller, H.A. Gallis, et al. Bioequivalence assessment of zidovu-
dine (Retrovir) syrup, solution, and capsule formulations in patients infected with
human immunodeficiency virus. Antimicrob Agents Chemother, 33(10):1801–1803,
1989.
[72] F. Fauchet, J.M. Treluyer, P. Frange, et al. Population pharmacokinetics study
of recommended zidovudine doses in HIV-1-infected children. Antimicrob Agents
Chemother, 57(10):4801–4808, 2013.
[73] P.W. Hugen, D.M. Burger, H.J. ter Hofstede, et al. Development of an indinavir
oral liquid for children. Am J Health Syst Pharm, 57(14):1332–1339, 2000.
[74] V. Jullien, S. Urien, D. Hirt, et al. Population analysis of weight-, age-, and sex-
related differences in the pharmacokinetics of lopinavir in children from birth to
18 years. Antimicrob Agents Chemother, 50(11):3548–3555, 2006.
[75] N. Rakhmanina, J. van den Anker, A. Baghdassarian, et al. Population pharmaco-
kinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-
experienced human immunodeficiency virus-infected children. Antimicrob Agents
Chemother, 53(6):2532–2538, 2009.
[76] M.B. Regazzi, E. Seminari, P. Villani, et al. Nelfinavir suspension obtained
from nelfinavir tablets has equivalent pharmacokinetic profile. Journal of
Chemotherapy, 13(5):569–574, 2001.
[77] J.F. Marier, M. Borges, G. Plante, et al. Bioequivalence of abacavir generic and
innovator formulations under fasting and fed conditions. Int J Clin Pharmacol
Ther, 44(6):284–291, 2006.
[78] S. Schramm Andrade, E.K. Kano, T.M. de Lima Souza Brioschi, et al. Bioavail-
ability study of two oral formulations of didanosine in healthy volunteers.
Arzneimittelforschung, 56(5):359–364, 2006.
[79] C. Estrela Rde, M.C. Salvadori, R.S. Raices, et al. Determination of didanosine
in human serum by on-line solid-phase extraction coupled to high-performance
liquid chromatography with electrospray ionization tandem mass spectrometric
detection: application to a bioequivalence study. J Mass Spectrom, 38(4):378–
385, 2003.
[80] E.K. Kano, C.H. dos Reis Serra, E.E. Koono, et al. Determination of lamivudine
in human plasma by HPLC and its use in bioequivalence studies. Int J Pharm,
297(1-2):73–79, 2005.
[81] V.S. Narang, A. Lulla, G. Malhotra, et al. Pharmacokinetic profiling and bioequiv-
alence evaluation of 2 lamivudine tablet formulations after single oral admin-
istration in healthy human Indian volunteers. J Acquir Immune Defic Syndr,
38(5):566–569, 2005.
[82] N.S. Santos-Magalhaes, A. Pontes, R.M. Cavalcante, et al. Bioequivalence of two
lamivudine tablet formulations. Arzneimittelforschung, 51(4):310–314, 2001.
132 Making things easier
References
[83] G. Bahrami, S. Mirzaeei, A. Kiani, et al. High-performance liquid chromatographic
determination of lamivudine in human serum using liquid-liquid extraction; appli-
cation to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life
Sci, 823(2):213–217, 2005.
[84] T. Monif, S.K. Tippabhotla, M. Garg, et al. Comparative bioavail-
ability/bioequivalence of two different stavudine 40 mg capsule formulations: a
randomized, 2-way, crossover study in healthy volunteers under fasting condition.
Int J Clin Pharmacol Ther, 45(8):469–474, 2007.
[85] V.S. Narang, A. Lulla, G. Malhotra, et al. Bioequivalence evaluation of two
marketed brands of stavudine 40 mg capsules in healthy human South African
volunteers. Pharmacological Research, 50(5):511–516, 2004.
[86] R.S. Raices, M.C. Salvadori, E.E.R. de Cassia, et al. Determination of stavudine in
human serum by on-line solid-phase extraction coupled to high-performance liquid
chromatography with electrospray ionization tandem mass spectrometry: applica-
tion to a bioequivalence study. Rapid Commun Mass Spectrom, 17(14):1611–1618,
2003.
[87] G.A. Yerino, E.K. Halabe, E. Zini, et al. Bioequivalence study of two oral
tablet formulations containing tenofovir disoproxil fumarate in healthy volunteers.
Arzneimittel-Forschung/Drug Research, 61(1):55–60, 2011.
[88] M. Yadav, T. Mishra, P. Singhal, et al. Rapid and specific liquid chromatographic
tandem mass spectrometric determination of tenofovir in human plasma and its
fragmentation study. J Chromatogr Sci, 47(2):140–148, 2009.
[89] C.H. Dos Reis Serra, E.E. Mori Koono, E.K. Kano, et al. Bioequivalence and
pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers:
an open-label, randomized, single-dose, two-way crossover study. Clin Ther,
30(5):902–908, 2008.
[90] S. Chompootaweep, J. Poonsrisawat, and P. Xumseang. Evaluation of the
bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers.
J Med Assoc Thai, 89 Suppl 3:S79–85, 2006.
[91] J.F. Marier, H. Manthos, S. Kebir, et al. Comparative bioavailability study of
zidovudine administered as two different tablet formulations in healthy adult
subjects. Int J Clin Pharmacol Ther, 44(5):240–246, 2006.
[92] J.F. Marier, I. Morin, D. Al-Numani, et al. Comparative bioavailability of a
generic capsule formulation of the reverse transcriptase inhibitor efavirenz and
the innovator product. Int J Clin Pharmacol Ther, 44(4):180–184, 2006.
[93] T.L. Laurito, V. Santagada, G. Caliendo, et al. Nevirapine quantification in
human plasma by high-performance liquid chromatography coupled to electro-
spray tandem mass spectrometry. Application to bioequivalence study. J Mass
Spectrom, 37(4):434–441, 2002.
[94] V.S. Narang, A. Lulla, G. Malhotra, et al. Pharmacokinetic profiling and bioequiv-
alence assessment of two marketed brands of nevirapine tablets in healthy Indian
volunteers. Arzneimittel-Forschung/Drug Research, 55(10):598–603, 2005.
[95] Y. Zhu, Q. Zhang, C. Yu, et al. Relative bioavailability of two formulations
of nevirapine 200-mg tablets in healthy Chinese male volunteers: a single-
dose, randomized-sequence, open-label, two-way crossover study. Clin Ther,
32(13):2258–2264, 2010.
[96] A. Tarinas, R.D. Tapanes, D. Gonzalez, et al. Bioequivalence study of
two nevirapine tablet formulations in human-immunodeficiency-virus-infected
patients. Farm Hosp, 31(3):165–168, 2007.
How to improve antiviral drug treatment for children 133
References
[97] M. Yadav, V. Trivedi, V. Upadhyay, et al. Comparison of extraction procedures for
assessment of matrix effect for selective and reliable determination of atazanavir
in human plasma by LC-ESI-MS/MS. J Chromatogr B Analyt Technol Biomed
Life Sci, 885-886:138–149, 2012.
[98] A. Gupta, P. Singhal, P.S. Shrivastav, et al. Application of a validated ultra
performance liquid chromatography-tandem mass spectrometry method for the
quantification of darunavir in human plasma for a bioequivalence study in Indian
subjects. J Chromatogr B Analyt Technol Biomed Life Sci, 879(24):2443–2453,
2011.
[99] S. Chulavatnatol, K. Malathum, S. Kiertiburanakul, et al. Bioequivalence of
indinavir capsules in healthy volunteers. Asian Biomedicine, 4(1):98–101, 2010.
[100] C. Zala, C.S. Alexander, C. Ochoa, et al. Comparable pharmacokinetics of
generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with
ritonavir [1]. Journal of Acquired Immune Deficiency Syndromes, 38(3):363–364,
2005.
[101] S.K. Tippabhotla, N.R. Thudi, R. Raghuvanshi, et al. A bioequivalence study
comparing two formulations of lopinavir/ritonavir capsules. Int J Clin Pharmacol
Ther, 46(4):204–210, 2008.
[102] S. Chachad, A. Lulla, G. Malhotra, et al. Bioequivalence study of two fixed dose
combination tablet formulations of lopinavir and ritonavir in healthy volunteers.
Arzneimittel-Forschung/Drug Research, 59(5):263–268, 2009.
[103] T. Das Mishra, H. Kurani, P. Singhal, et al. Simultaneous quantitation of HIV-
protease inhibitors ritonavir, lopinavir and indinavir in human plasma by UPLC-
ESI-MS-MS. J Chromatogr Sci, 50(7):625–635, 2012.
[104] R.A. Ramautarsing, J. van der Lugt, M. Gorowara, et al. Neither branded
nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a
reduced dose of 200/50 mg twice daily. J Acquir Immune Defic Syndr, 59(1):55–
58, 2012.
[105] M.W. Hull, M. Harris, V. Lima, et al. Lopinavir/ritonavir pharmacokinetics
in a substitution of high-dose soft-gelatin capsule to tablet formulation. J Clin
Pharmacol, 49(2):155–161, 2009.
[106] J. van der Lugt, J. Lange, A. Avihingsanon, et al. Plasma concentrations of generic
lopinavir/ritonavir in HIV type-1-infected individuals. Antivir Ther, 14(7):1001–
1004, 2009.
[107] T. Puthanakit, K. Chokephaibulkit, P. Suntarattiwong, et al. Therapeutic
drug monitoring of lopinavir in human immunodeficiency virus-infected children
receiving adult tablets. Pediatr Infect Dis J, 29(1):79–82, 2010.
[108] R.A. Ramautarsing, J. van der Lugt, M. Gorowara, et al. Pharmacokinetics and
48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected
patients. Antivir Ther, 18(2):249–252, 2013.
[109] K. Derakhshandeh and A. Sohrabi. Pharmacokinetic study and comparative
bioavailability of two nelfinavir tablet formulations in Iranian healthy volunteers
after a low-dose administration (full text not available). Int J Clin Pharmacol
Ther, 47(7):491–498, 2009.
[110] B. Bittner, M. Riek, B. Holmes, et al. Saquinavir 500 mg film-coated tablets
demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted
with twice-daily ritonavir in healthy volunteers. Antivir Ther, 10(7):803–810,
2005.
134 Making things easier
References
[111] A. Winston, P.W.G. Mallon, C. Satchell, et al. The safety, efficacy and pharmaco-
kinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and
atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Clinical
Infectious Diseases, 44(11):1475–1483, 2007.
[112] G.A. Yerino, E.K. Halabe, E. Zini, et al. Bioequivalence study of two oral tablet
formulations containing saquinavir mesylate boosted with ritonavir in healthy
male subjects. Arzneimittel-Forschung/Drug Research, 61(8):481–487, 2011.
[113] G.J. Yuen, Y. Lou, N.F. Thompson, et al. Abacavir/lamivudine/zidovudine as
a combined formulation tablet: bioequivalence compared with each component
administered concurrently and the effect of food on absorption. J Clin Pharmacol,
41(3):277–288, 2001.
[114] A.C. Cremieux, C. Katlama, C. Gillotin, et al. A comparison of the steady-state
pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a
triple combination tablet and as abacavir plus a lamivudine-zidovudine double
combination tablet by HIV-1-infected adults. Pharmacotherapy, 21(4):424–430,
2001.
[115] V.S. Narang, A. Lulla, G. Malhotra, et al. A combined-formulation tablet
of lamivudine/nevirapine/stavudine: Bioequivalence compared with concurrent
administration of lamivudine, nevirapine, and stavudine in healthy Indian
subjects. J Clin Pharmacol, 45(3):265–274, 2005.
[116] P. Byakika-Kibwika, M. Lamorde, F. Kalemeera, et al. Steady-state pharmaco-
kinetic comparison of generic and branded formulations of stavudine, lamivu-
dine and nevirapine in HIV-infected Ugandan adults. Journal of Antimicrobial
Chemotherapy, 62(5):1113–1117, 2008.
[117] J. Byakika-Tusiime, L.W. Chinn, J.H. Oyugi, et al. Steady state bioequivalence
of generic and innovator formulations of stavudine, lamivudine, and nevirapine in
HIV-infected Ugandan adults. PLoS ONE, 3(12):e3981, 2008.
[118] M.C. Hosseinipour, A.H. Corbett, C. Kanyama, et al. Pharmacokinetic compar-
ison of generic and trade formulations of lamivudine, stavudine and nevirapine in
HIV-infected Malawian adults. AIDS, 21(1):59–64, 2007.
[119] T. Monif. Nevirapine/lamivudine/stavudine as a combined-formulation tablet:
bioequivalence study compared with each component administered concurrently
under fasting condition. Int J Clin Pharmacol Ther, 44(6):276–283, 2006.
[120] J.F. Marier, M. Dimarco, R. Guilbaud, et al. Pharmacokinetics of lamivudine,
zidovudine, and nevirapine administered as a fixed-dose combination formula-
tion versus coadministration of the individual products. J Clin Pharmacol,
47(11):1381–1389, 2007.
[121] H.E. Vezina, K. Henry, G.D. Ravindran, et al. A randomized crossover study
to determine bioequivalence of generic and brand name nevirapine, zidovudine,
and lamivudine in HIV-negative women in India. Journal of Acquired Immune
Deficiency Syndromes, 41(2):131–136, 2006.
[122] S. Chachad, A. Lulla, G. Malhotra, et al. Bioequivalence evaluation of a fixed
dose combination lamivudine + stavudine tablet with concurrent administration
of lamivudine tablet and stavudine capsule in healthy volunteers. Arzneimit-
telforschung, 59(10):537–540, 2009.
[123] T. Wattananat, I.O. Prasanchaimontri, and W. Akarawut. Simultaneous determi-
nation of stavudine and lamivudine in human plasma by high performance liquid
chromatography and its application to a bioavailability study. Southeast Asian J
Trop Med Public Health, 41(2):369–377, 2010.
How to improve antiviral drug treatment for children 135
References
[124] C. Feleder Ethel, A. Yerino Gustavo, K. Halabe Emilia, et al. Single-dose
bioequivalence of a new fixed-dose combination tablet containing tenofovir
disoproxil fumarate and lamivudine. Journal of Bioequivalence and Bioavailability,
3(10):236–243, 2011.
[125] K.H. Moore, S. Shaw, A.L. Laurent, et al. Lamivudine/zidovudine as a combined
formulation tablet: bioequivalence compared with lamivudine and zidovudine
administered concurrently and the effect of food on absorption. J Clin Pharmacol,
39(6):593–605, 1999.
[126] C. Estrela Rde, M.C. Salvadori, and G. Suarez-Kurtz. A rapid and sensitive
method for simultaneous determination of lamivudine and zidovudine in human
serum by on-line solid-phase extraction coupled to liquid chromatography/tandem
mass spectrometry detection. Rapid Commun Mass Spectrom, 18(10):1147–1155,
2004.
[127] E. Kayitare, C. Vervaet, J.D. Ntawukulilyayo, et al. Development of fixed dose
combination tablets containing zidovudine and lamivudine for paediatric applica-
tions. Int J Pharm, 370(1-2):41–46, 2009.
136 Making things easier
6 Pharmacokinetics of pediatric lopinavir/ritonavir
tablets in children when administered twice daily
according to FDA weight bands
Diane E.T. Bastiaans, Silvia Forcat, Hermione Lyall, Tim R. Cressey,
Rawiwan Hansudewechakul, Suparat Kanjanavanit, Antoni Noguera-
Julian, Christoph Ko¨nigs, Jamie R.J. Inshaw, Suwalai Chalermpant-
metagul, Yacine Sa¨ıdi, Alexandra Compagnucci, Lynda M. Harper, Carlo
Giaquinto, Angela P.H. Colbers, and David M. Burger, on behalf of
PENTA18/KONCERT Study Group
The Pediatric Infectious Disease Journal 2013; 33(3):301–305
How to improve antiviral drug treatment for children 137
6 Pharmacokinetics of pediatric lopinavir/ritonavir tablets
Abstract
Background
Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) are approved
by the United States Food and Drug Administration (FDA) and European
Medicines Agency (EMA) as part of combination antiretroviral therapy.
Dosing is based on body weight bands or body surface area under FDA
approval and only body surface area by the EMA. This can lead to a
different recommended dose. In addition, weight band-based dosing has
not been formally studied in the target population. We evaluated the
pharmacokinetics (PK) of LPV/r in children, administered twice daily
according to the FDA weight bands, using pediatric tablets.
Methods
Fifty-three HIV-infected children were included in the PK substudy of
the Paediatric European Network for the Treatment of AIDS 18 trial
(KONCERT). In this study, children were randomized to receive LPV/r
twice or once daily, according to FDA weight bands. A PK assessment was
performed in 17, 16 and 20 children in the 15–25 kg, 25–35 kg and > 35 kg
weight band, respectively, while children took the tablets twice daily. Rich
sampling was performed, and PK parameters were calculated by noncom-
partmental analysis. Given the high percentage of Asian children, it was
also tested whether there was a difference in PK parameters between Asian
and non-Asian children.
Results
For the total group, LPV geometric mean AUC0−12, Cmax and C12 were
106.9 h×mg/l, 12.0 mg/l and 4.9 mg/l, respectively. There were no signif-
icant differences in LPV PK parameters between the weight bands. In
addition, weight was not found to be associated with variability in Cmax,
C12 or AUC0−12 for the LPV PK parameters.
Conclusion
FDA weight band-based dosing recommendations provide adequate
exposure to LPV when using LPV/r pediatric tablets.
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Introduction
HIV-infected children require lifelong treatment with combination
antiretroviral therapy (cART). Currently, the preferred cART regimen
recommended for antiretroviral treatment-naive children with no resistance
to antiretroviral drugs comprises a backbone of two nucleoside reverse
transcriptase inhibitors plus either a nonnucleoside reverse transcriptase
inhibitor (NNRTI) or a ritonavir (RTV)-boosted protease inhibitor [1–3].
Lopinavir boosted with low-dose ritonavir (LPV/r) is used worldwide in
HIV-infected children as part of first- and second-line treatments [1, 2]. It
is licensed to be taken twice daily for children from the age of 2 years by
the European Medicines Agency (EMA) and from the age of 14 days by
the United States Food and Drug Administration (FDA). There are several
LPV/r formulations available: a liquid formulation (LPV/r 80/20 mg/ml),
adult tablets (LPV/r 200/50 mg) and pediatric tablets (LPV/r 100/25
mg). The pediatric tablet (100/25 mg) was approved by the FDA in 2007
and by the EMA in 2008; however, the posology in the product labels
approved by these two agencies is not the same. The dose for an individual
is based on body surface area only as recommended by the EMA, while it
is based on body weight bands or body surface area as recommended by
the FDA. Dosing based on body weight bands versus body surface area
may lead to differences in the number of tablets recommended for a child
with a certain weight, which is confusing and undesirable from a global
perspective. The FDA-recommended weight band dosing has been derived
from pharmacokinetic (PK) modeling but has not been formally studied
in the target population. To validate the FDA weight band-based dosing
recommendations, we evaluated the PK of LPV/r administered twice daily,
using the pediatric 100/25 mg tablet, in HIV-infected children.
6.1 Methods
This PK study is part of the ongoing Paediatric European Network for
the Treatment of AIDS (PENTA)-18 trial or KONCERT trial: A Kaletra
ONCE daily Randomized Trial of the pharmacokinetics, safety and efficacy
of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight
as part of combination antiretroviral therapy in HIV-1 infected children
(NCT01196195). KONCERT is a phase II/III, prospective, randomized,
open-label, international, multicenter trial in virologically suppressed HIV-
1-infected children. Children were eligible when they were younger than
18 years, 15 kg in weight, receiving cART that includes LPV/r and had
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an HIV-1 RNA < 50 copies/ml for at least 24 weeks and were able to
swallow tablets. Children receiving an NNRTI or a PI other than LPV/r
were excluded. The use of concomitant drugs, except for prophylaxis, was
not allowed unless permission was granted by the trial team. Children
were randomized (1 : 1) to either continue the same ART regimen with
LPV/r tablets taken twice daily (n = 80) or to switch to LPV/r tablets
dosed once daily (n = 80). The KONCERT trial has been approved by
the regulatory bodies and ethics committees for all participating countries
and sites. KONCERT is being conducted in full conformance with the
principles of the current version of the Declaration of Helsinki and with the
local laws and regulations concerning clinical trials.
6.1.1 Population and treatment
Children were enrolled in KONCERT in one of three weight bands: ≥ 15
to ≤ 25 kg (low), > 25 to ≤ 35 kg (middle) and > 35 kg body weight
(high). In the first phase of the trial, children who consented were selected
to participate in a PK substudy, until a minimum of 16 children in each
weight band had evaluable PK data. If needed, the LPV/r formulation
was changed to the pediatric tablet at the screening visit and the dose
adjusted to follow the recommended FDA dosing plan based on body weight
bands (see Table 6.1). It was required that tablets be swallowed whole
and could be taken with or without food. Adherence was assessed by
pill counts and a questionnaire at screening and on the day of the PK
assessment. During the trial, an amendment to the protocol was made to
ensure ethnic representativeness within the PK study. At that time, the
highest weight band already had 12 children from Thailand and further
inclusion into the PK study from this country was stopped. Enrollment of
subsequent participants continued to have 8 children from countries other
than Thailand in each of the weight bands.
6.1.2 Sample size
Based on plasma LPV PK data from an adult study on tablet formulation,
the estimated variance of log10 area under the curve (AUC) for pediatric
tablets was approximately 0.2 (internal Abbott data). Forty-eight children
(16 in each weight band) providing plasma LPV PK data on twice-daily
tablet regimens was estimated to provide at least 80% power for the width
of the 90% confidence interval for the mean log10 AUC on twice-daily dosing
to be < 0.230 on the log10 scale. Therefore, to confirm FDA body weight-
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Table 6.1: FDA recommended dosing plan based on body weight band for
lopinavir/ritonavir 100/25 mg tablets twice-daily (not given with
non-nucleoside reverse transcriptase inhibitors, fosamprenavir or
nelfinavir)
Weight (kg) Number of Exposure Approximate Exposure
tablets twice daily equivalent twice daily
twice daily (mg/kg) BSA (m2) (mg/m2)
≥ 15 to ≤ 25 2 8 to 13 ≥ 0.65 to ≤ 0.92 217 to 308
> 25 to ≤ 35 3 9 to 12 > 0.92 to ≤ 1.2 250 to 326
> 35 4 < 11 > 1.2 < 333
based dosing recommendations of twice-daily LPV/r 100/25 mg tablets, 48
children was considered to be sufficient for the estimation of interpatient
variability.
6.1.3 Pharmacokinetic assessment
Full 12-hour PK assessment of LPV/r was conducted prior to random-
ization. Children must have been receiving the pediatric tablets twice
daily at the FDA-recommended weight band-based dose for at least 7 days
prior to the PK assessment. On the PK day, the child’s medications were
intended to be administered before taking breakfast. Depending on the
country and hospital, breakfast according to local custom was served (e.g.,
pork/chicken/fish soup, rice and a cup of milk; cereal, toast, cooked eggs
and scones; or bread roll with butter, ham, cheese, jam or hazelnut spread).
Blood samples (2 ml/time point) were taken in ethylenediaminetetraacetic
acid (EDTA) tubes at 0 (predose, before morning dose), 2, 4, 6, 8 and 12
hours after an observed intake.
6.1.4 Pharmacokinetics
Lopinavir (LPV) and RTV PK parameters were determined using noncom-
partmental analysis (WinNonlinr, version 5.3., Pharsightr Corporation,
Mountain View, CA): AUC0−12 (area under the plasma concentration-time
curve calculated (linear-log trapezoidal method) over a dosing interval from
time 0 to 12 hours after dosing), Cmax (maximum observed plasma concen-
tration) and C12 (drug concentration 12 hours postdose).
How to improve antiviral drug treatment for children 141
6 Pharmacokinetics of pediatric lopinavir/ritonavir tablets
6.1.5 Measurement of plasma drug concentration
Samples were processed within 3 days of collection, and plasma was stored
immediately at −80◦C. Plasma concentrations of LPV and RTV were deter-
mined using a validated ultrahigh performance liquid chromatography assay
with ultraviolet detection derived from the previously published assay [4].
The analysis was performed at the Department of Pharmacy, Radboud
University Nijmegen Medical Centre, and this laboratory participates in
an international interlaboratory quality control program for therapeutic
drug monitoring of antiretroviral drugs [5]. The analytical range of the
assay for LPV was 0.109–31.2 mg/l and for RTV 0.044–29.4 mg/l. The
intraday and interday precision for both assays ranged from 0.6% to 4.2%
(coefficient of variation) and 0.3% to 1.8%, respectively. The percentage
accuracy of the assay ranged from 98.2% to 105.6%.
6.1.6 Statistical analysis
To validate dosing by the FDA weight bands, linear regression of the PK
parameters against dose (mg/kg body weight) was performed. Analysis of
variance (ANOVA) was used to compare the geometric means of each PK
parameter between the three different weight bands. This was further tested
by regression of logtransformed parameters against weight as a continuous
variable. Comparison of the PK parameters between different ethnic groups
(Asian vs. non-Asian children) was performed using an independent t test
on logtransformed values. Statistical analysis was performed using SPSS
software version 20.0.0.1 (IBMr SPSSr 1989, 2011).
6.2 Results
6.2.1 Population
Fifty-three children were enrolled in the PK study between August 2010
and December 2011: 17, 16 and 20 children in the 15 to ≤ 25 kg, > 25 to
≤ 35 kg and > 35 kg weight bands, respectively. Median (range) age of the
children was 11.0 (4.4, 17.7) years. Twenty-two (42%) were male children.
Further demographic data of the patients are presented in Table 6.2.
The use of concomitant medication was reported for 5 children.
According to the literature, none of the concomitant medication used is
known to influence the metabolism of LPV or RTV. No use of natural
products or herbs was reported. None of the children vomited either the
day before or on the day of the PK assessment. The median (range) LPV
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Table 6.2: Demographic data of children in KONCERT pharmacokinetic
substudy
All children 15–25 kg 25–35 kg > 35 kg
(n = 53) (n = 17) (n = 16) (n = 20)
Male 22 (42%) 5 10 7
Age (y) median, 11.0 7.4 10.9 15.0
(IQR) (8.8, 14.7) (6.8, 8.8) (10.1, 13.9) (13.7, 15.7)
Weight (kg) median, 31.0 20.5 30.2 41
(IQR) (23.6, 40.0) (19.3, 23.5) (29.1, 32.1) (38.3, 49.5)
Ethnicity
Asian 29 (55%) 8 8 13
Black African 14 (26%) 6 6 2
White 6 (11%) 2 1 3
Mixed black/white 2 (4%) 1 1 0
Other 2 (4%) 0 0 2
dose taken by the children was 9.8 (5.5, 13.3) mg/kg or 270 (215, 329)
mg/m2.
6.2.2 Lopinavir pharmacokinetics
For the total group, the LPV geometric mean (95%CI) AUC0−12 was 106.9
(97.8, 116.9) h×mg/l, Cmax 12.0 (11.1, 12.9) mg/l and C12 was 4.9 (4.1,
5.8) mg/l. The geometric mean plasma LPV concentration-time profile for
the total group and the profiles per weight band are shown in Figure 6.1.
The geometric means of the PK parameters for each weight band and the
total group are presented in Table 6.3.
Because the PK parameters of LPV were not normally distributed, statis-
tical analysis was performed on the logtransformed data. Linear regression
showed no correlation of the LPV PK parameters AUC0−12 (P = 0.062),
C12 (P = 0.87) and CL/F (P = 0.20) against the weight-based dose (mg/kg
body weight). Linear regression did show a correlation between the weight-
based dose of LPV and Cmax (P = 0.039).
There were no significant differences when comparing LPV PK param-
eters between the weight bands (AUC0−12, P = 0.42; Cmax, P = 0.17;
C12, P = 0.46 and CL/F, P = 0.75). Weight was also not associated
with variability in the LPV PK parameters (AUC0−12, P = 0.44; Cmax,
P = 0.12; C12, P = 0.33 and CL/F, P = 0.25).
One of the 53 children (1.9%) had an LPV C12 < 1.0 mg/l (0.56 mg/l).
This child received an LPV dose of 11.5 mg/kg, which was higher than the
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Figure 6.1: Plasma lopinavir concentration versus time for the total group
and for each weight band (data presented as geometric means).
Table 6.3: Pharmacokinetic parameters of lopinavir and ritonavir
Geometric mean (95%CI) n Lopinavir Ritonavir
AUC0−12 (h×mg/l) total 53 106.9 (97.8, 116.9) 5.9 (5.28, 6.65)
Weight (kg)
≥ 15 to ≤ 25 17 104.1 (84.9, 127.5) 5.7 (4.71, 6.84)
> 25 to ≤ 35 16 116.9 (100.6, 135.8) 6.8 (5.27, 8.65)
> 35 20 101.9 (89.1, 116.6) 5.5 (4.53, 6.76)
Cmax (mg/l) total 53 12.0 (11.1, 12.9) 0.88 (0.78, 1.00)
Weight (kg)
≥ 15 to ≤ 25 17 12.2 (10.4, 14.5) 0.87 (0.71, 1.06)
> 25 to ≤ 35 16 13.0 (11.4, 14.8) 1.02 (0.76, 1.35)
> 35 20 11.0 (10.0, 12.2) 0.80 (0.67, 0.95)
C12 (mg/l) total 53 4.9 (4.14, 5.80) 0.18 (0.15, 0.21)
Weight (kg)
≥ 15 to ≤ 25 17 4.2 (3.07, 5.78) 0.16 (0.12, 0.20)
> 25 to ≤ 35 16 5.1 (3.53, 7.36) 0.18 (0.14, 0.24)
> 35 20 5.4 (4.16, 6.97) 0.19 (0.13, 0.28)
Clearance (l/(h×kg)) total 53 0.089 (0.081, 0.097) 0.400 (0.356, 0.450)
Weight (kg)
≥ 15 to ≤ 25 17 0.092 (0.078, 0.109) 0.422 (0.358, 0.497)
> 25 to ≤ 35 16 0.085 (0.071, 0.100) 0.366 (0.281, 0.477)
> 35 20 0.089 (0.077, 0.104) 0.411 (0.333, 0.508)
Clearance (CL/F/kg) = dose (mg)/[AUC0−12 (h×mg/l) × body weight (kg)].
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median value in this study (9.8 mg/kg). Remarkably, the predose morning
level of this child was 8.1 mg/l. The last dose was reported to be taken
approximately 12 hours prior to the observed intake on the day of PK
assessment. No explanation could be found for this difference, other than
the possible diurnal variation in absorption, distribution, metabolism and
excretion [6].
Given the high percentage of Asian children within the PK study popula-
tion, it was tested whether there was a difference in PK parameters between
Asian and non-Asian children. Significant influence of ethnicity was found
on CL/F (P = 0.021), with Asian children having a higher clearance. There
were no significant differences in the other PK parameters between Asian
and non-Asian children (AUC0−12, P = 0.17; Cmax, P = 0.089 and C12,
P = 0.18). The geometric mean plasma LPV concentration-time profiles
for the Asian children and non-Asian children are shown in Figure 6.2.
Figure 6.2: Plasma lopinavir concentration versus time of Asian and non-
Asian children (data are presented as geometric means and
arrow bars show standard error of the mean).
6.3 Discussion
This study conducted in 53 HIV-infected children found adequate LPV
exposure when LPV/r 100/25 mg tablets were administered according to
the FDA-recommended weight band-based dose. No significant differences
of PK parameters for LPV were observed between the three weight bands.
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The current recommendation for the LPV trough concentration in HIV-
infected patients with no evidence of resistance is 1.0 mg/l [3]. Fifty-two
(98%) of the children achieved a trough concentration of 1.0 mg/l or higher.
Therefore, the weight band-based dosing described by the FDA can be used
to treat HIV-infected children with the LPV/r pediatric tablets.
In this study, the geometric mean LPV AUC0−12 was 106.9 h×mg/l,
Cmax 12.0 mg/l and C12 4.9 mg/l. The LPV AUC0−12, Cmax and C12
were all higher than that observed in children receiving 230/57.5 mg/m2
of the LPV/r solution described in the summary of product characteris-
tics (AUC0−12 72.6 h×mg/l, Cmax 8.2 mg/l and C12 3.4 mg/l) [7]. This
can mostly be explained by the higher dose that is used in our population
(median dose 270 mg/m2). The clinical relevance of this higher exposure
(i.e., side effects) is being assessed in the ongoing main trial. A summary
of LPV/r PK parameters reported from 10 studies in HIV-infected children
(n > 10) is shown in Table 6.4 [7–15]. Studies in which some of the children
used an NNRTI are included, but unfortunately results were not always
specified for concomitant use of an NNRTI. When comparing results of
these PK studies, it is important to realize that different formulations of
LPV/r may have been used, which could lead to differences in PK param-
eters. The AUCτ and AUC∞ of the soft gel capsule and oral solution are
18% lower compared with the 200/50 mg tablet formulation in healthy
volunteers, although the 90%CI of the geometric mean ratio is within the
bioequivalence range of 80–125% [16]. A study in HIV-infected adults
showed that the mean Clast was higher with a generic tablet compared
with the soft gel capsule formulation [17]. A 45% decrease in LPV AUC0−12
was observed in HIV-infected children when LPV/r tablets were crushed
compared with administration of whole tablets [8]. The formulation used
is also significantly associated with the absorption lag time: the lag time in
HIV-infected children using the solution was half the lag time in children
using capsules [13]. PK parameters found in a study evaluating the PK of
LPV/r in Thai adolescents using the 200/50 mg tablet formulation were
comparable with our results [11].
Diet can also influence the PK of LPV. Differences in LPV AUCτ and
Cmax have been shown when the LPV/r tablet formulation is administered
under fasting conditions or with a moderate or high-fat meal. Compared
with administration of LPV/r under fasting conditions, the LPV AUCτ
and Cmax increased, respectively, by 26.9% and 17.6%, with a moderate-fat
meal. When administered with a high-fat meal, the LPV AUCτ increased
by 18.9% and Cmaxwas unchanged [16].
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This is the first PK study in which the PK parameters of LPV in a
large group of Asian children can be directly compared with the results
of children of other ethnic origins. However, this should be done with
caution because the baseline characteristics of both groups are different.
Mean age of the Asian patients is significantly higher than that of non-
Asian patients. Furthermore, the weight for age is significantly lower in
the Asian children. Regarding the PK parameters, a significant differ-
ence in LPV clearance (CL/F) was observed between Asian and non-
Asian children. The CL/F of LPV in Asian children was on average 21%
higher than in non-Asian children: 0.097 versus 0.080 l/h×kg (P = 0.021).
This result was unexpected, as usually lower clearance is expected, and
therefore, a lower LPV/r dose has previously been investigated in Thai
children [11,12]. However, plasma half-life of LPV of Asian and non-Asian
children was the same for both groups (6.5 hours). A comparison of CL/F
of Thai children and a group of mainly (78%) African-American children
showed similar clearance in both groups: median (IQR) CL/F 1.7 (1.0,
3.5) and 1.8 (1.0, 2.6) l/h, respectively [12, 13, 18]. Despite the signifi-
cantly higher CL/F in Asian children in our study, there was no signifi-
cant difference in AUC0−12 between Asian and non-Asian children, which
can be explained by the relatively higher dose in the Asian children on
a mg/kg basis [9.8 vs. 9.1 mg/kg (median dose)]. A possible explana-
tion for these observations could be a difference in diet and more Asian
children in our study taking their medication under fasting conditions at
the day of PK assessment: 52% versus 13% of the non-Asian children.
Differences between ethnic groups in expression of cytochrome P450A
(CYP3A) isoenzymes could explain interpatient variability in the PK of
LPV [14,19–21]. For instance, wild-type CYP3A, which is associated with
more rapid metabolism, is more frequently expressed in Southeast Asians
compared with Caucasians [22–24]. Another mechanism possibly involved
in the PK of LPV relates to transporter proteins, such as the permeability
glycoprotein (P-gp; MDR1, ABCB1), the multidrug resistance protein 2
(MRP2; ABCC2) and the organic anion transporters (OATP; SLCO1B1)
[14,20,21,25–28]. Genotype frequencies of these transporter proteins differ
between ethnic groups [29, 30], but data from Asian patients are lacking.
Unfortunately, no genetic testing was performed in our patients, and the
influence of these polymorphisms on the PK of LPV cannot be explored. It
must be noted that despite potential ethnic influences on LPV PK, exposure
in all subgroups was adequate.
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Table 6.4: Pharmacokinetic studies of twice-daily lopinavir in HIV-infected
children
Author n Age LPV dose AUC0−12 Cmax
(year,range) (mean, (mg×h/l) (mg/l)
mg/m2)
Current study2 53 4.4–17.7 270 106.9 12.0
Best 20113 [8] 12 10–16 275 144 11.3
Foissac 20114 [9] 45 0.5–19 266 116 –
Jullien 20064 [10] 157 0–18 281 108 9.6
Klinklom 20123 [11] 23 IQR: 12–15 208 86.7 10.5
24 IQR: 12–15 290 102.7 11.4
Puthanakit 20093 [12] 11 IQR: 6.7–11.8 194 83.8 10.1
11 IQR: 8.4–14.7 279 117.6 11.9
Rakhmanina 20093 [13] 50 5.3–17.5 275 96.1 10.3
Rakhmanina 20113 [14] 50 4.3–17.2 275 96.9 –
Rosso 20063 [15] 21 3.5–13.5 230 – 14.6
Saez Lloren 20034,5 [7] 12 230 72.6 8.2
15 300 116.4 12.5
1 tablet: 200/50 mg lopinavir/ritonavir, pediatric tablet: 100/25 mg lopinavir/
ritonavir, pediatric tablet: 100/25 mg lopinavir/ritonavir, SGC = soft gel capsule
2 geometric mean pharmacokinetic parameters are shown
3 median pharmacokinetic parameters are shown
4 mean pharmacokinetic parameters are shown
5 Study also with non-nucleoside reverse transcriptase inhibitors (NNRTI)
(efavirenz or nevirapine), data shown are from the children using no NNRTI
In conclusion, FDA weight band-based dosing recommendations provide
adequate exposure when using the pediatric LPV/r tablets. Hence, the
FDA-recommended dose for the weight bands of ≥ 15 to ≤ 25 kg, > 25 to
≤ 35 kg and > 35 kg body weight can be used to achieve adequate exposure
of LPV in HIV-infected children.
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Table 6.4: Pharmacokinetic studies of twice-daily lopinavir in HIV-infected
children (continued)
C12 NNRTI Formulation
1 Pharmacokinetic
(mg/l) use modeling method
4.9 no pediatric tablet noncompartmental
6.8 no tablet noncompartmental
8.5 part SGC, solution, (pediatric) tablet population
7.9 part SGC, solution population
3 no tablet noncompartmental
4.1 no tablet noncompartmental
3.4 no solution noncompartmental
4.9 no solution noncompartmental
5.9 unknown SGC, solution population
– part SGC, solution, tablet noncompartmental
7.9 no SGC, solution –
3.4 no solution noncompartmental
6.5 no solution noncompartmental
References
[1] S. Welch, M. Sharland, E.G. Lyall, et al. PENTA 2009 guidelines for the use of
antiretroviral therapy in paediatric HIV-1 infection. HIV Med, 10(10):591–613,
2009.
[2] World Health Organization. Antiretroviral therapy for HIV infection in infants and
children: towards universal access. Recommendations for a public health approach
- 2010 revision., 2010.
[3] Panel on Antiretroviral Therapy and Medical Management of HIV-
Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric
HIV Infection.
[4] J.A. Droste, C.P. Verweij-Van Wissen, and D.M. Burger. Simultaneous determi-
nation of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir,
nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma
by reversed-phase high-performance liquid chromatography. Ther Drug Monit,
25(3):393–399, 2003.
[5] D. Burger, M. Teulen, J. Eerland, et al. The International Interlaboratory Quality
Control Program for Measurement of Antiretroviral Drugs in Plasma: a global
proficiency testing program. Ther Drug Monit, 33(2):239–243, 2011.
[6] G.K. Paschos, J.E. Baggs, J.B. Hogenesch, et al. The role of clock genes in pharma-
cology. Annu Rev Pharmacol Toxicol, 50:187–214, 2010.
[7] X. Saez-Llorens, A. Violari, C.O. Deetz, et al. Forty-eight-week evaluation of
lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-
infected children. Pediatr.Infect.Dis.J., 22(3):216–224, 2003.
How to improve antiviral drug treatment for children 149
References
[8] B.M. Best, E.V. Capparelli, H. Diep, et al. Pharmacokinetics of lopinavir/ritonavir
crushed versus whole tablets in children. J Acquir Immune Defic Syndr, 58(4):385–
391, 2011.
[9] F. Foissac, S. Urien, D. Hirt, et al. Pharmacokinetics and virological efficacy after
switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected
children. Antimicrob Agents Chemother, 55(9):4320–4325, 2011.
[10] V. Jullien, S. Urien, D. Hirt, et al. Population analysis of weight-, age-, and sex-
related differences in the pharmacokinetics of lopinavir in children from birth to 18
years. Antimicrob Agents Chemother, 50(11):3548–3555, 2006.
[11] A. Klinklom, T. Puthanakit, M. Gorowara, et al. Low dose lopinavir/ritonavir
tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adoles-
cents. Antivir Ther, 17(2):283–289, 2012.
[12] T. Puthanakit, J. van der Lugt, T. Bunupuradah, et al. Pharmacokinetics and 48
week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. J Antimicrob
Chemother, 64(5):1080–1086, 2009.
[13] N. Rakhmanina, J. van den Anker, A. Baghdassarian, et al. Population pharmaco-
kinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-
experienced human immunodeficiency virus-infected children. Antimicrob Agents
Chemother, 53(6):2532–2538, 2009.
[14] N.Y. Rakhmanina, M.N. Neely, R.H. Van Schaik, et al. CYP3A5, ABCB1,
and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of
lopinavir/ritonavir in HIV-infected children. Ther Drug Monit, 33(4):417–424, 2011.
[15] R. Rosso, A. Di Biagio, C. Dentone, et al. Lopinavir/ritonavir exposure in
treatment-naive HIV-infected children following twice or once daily administration.
J Antimicrob Chemother, 57(6):1168–1171, 2006.
[16] C.E. Klein, Y.L. Chiu, W. Awni, et al. The tablet formulation of lopinavir/ritonavir
provides similar bioavailability to the soft-gelatin capsule formulation with less
pharmacokinetic variability and diminished food effect. J Acquir Immune Defic
Syndr, 44(4):401–410, 2007.
[17] J. van der Lugt, J. Lange, A. Avihingsanon, et al. Plasma concentrations of generic
lopinavir/ritonavir in HIV type-1-infected individuals. Antivir Ther, 14(7):1001–
1004, 2009.
[18] M.N. Neely and N.Y. Rakhmanina. Comment on: Pharmacokinetics and 48 week
efficacy of low-dose lopinavir/ritonavir in HIV-infected children. J Antimicrob
Chemother, 65(4):808–809; author reply 809–810, 2010.
[19] R.C. Estrela, A.B. Santoro, P.F. Barroso, et al. CYP3A5 genotype has no impact on
plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.
Clin.Pharmacol.Ther., 84(2):205–207, 2008.
[20] R. Lubomirov, I.J. di, A. Fayet, et al. ADME pharmacogenetics: investigation of the
pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Pharmacogenet.Genomics, 20(4):217–230, 2010.
[21] R.A. van Waterschoot, R. ter Heine, E. Wagenaar, et al. Effects of cytochrome
P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1)
and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol,
160(5):1224–1233, 2010.
[22] P. Kuehl, J. Zhang, Y. Lin, et al. Sequence diversity in CYP3A promoters and
characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet,
27(4):383–391, 2001.
150 Making things easier
References
[23] M.K. Ma, M.H. Woo, and H.L. McLeod. Genetic basis of drug metabolism. Am J
Health Syst Pharm, 59(21):2061–2069, 2002.
[24] S.J. Lee, K.A. Usmani, B. Chanas, et al. Genetic findings and functional studies
of human CYP3A5 single nucleotide polymorphisms in different ethnic groups.
Pharmacogenetics, 13(8):461–472, 2003.
[25] E.L. Woodahl, Z. Yang, T. Bui, et al. MDR1 G1199A polymorphism alters perme-
ability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells.
AIDS, 19(15):1617–1625, 2005.
[26] L. Elens, J.C. Yombi, D. Lison, et al. Association between ABCC2 polymorphism
and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected
patients. Pharmacogenomics, 10(10):1589–1597, 2009.
[27] R.C. Hartkoorn, W.S. Kwan, V. Shallcross, et al. HIV protease inhibitors are
substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concen-
trations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics,
20(2):112–120, 2010.
[28] A. Schipani, D. Egan, L. Dickinson, et al. Estimation of the effect of SLCO1B1
polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antivir
Ther, 17(5):861–868, 2012.
[29] C. Marzolini, E. Paus, T. Buclin, et al. Polymorphisms in human MDR1 (P-
glycoprotein): recent advances and clinical relevance. Clin.Pharmacol.Ther.,
75(1):13–33, 2004.
[30] K. Kurose, E. Sugiyama, and Y. Saito. Population differences in major functional
polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern
Asians and Europeans: implications in the clinical trials for novel drug development.
Drug Metab Pharmacokinet, 27(1):9–54, 2012.
How to improve antiviral drug treatment for children 151
7 Development of a new paediatric formulation of valaciclovir
152 Making things easier
7 A new paediatric formulation of valaciclovir:
development and bioequivalence assessment
Diane E.T. Bastiaans, Carli M. Wilmer, Angela P.H. Colbers, Claudia
A.W. Heijens, Kirsten Velthoven-Graafland, Oscar S.N.M. Smeets, Nicole
Vink, Veroniek E.M. Harbers, Adilia Warris, David M. Burger
Archives of Disease in Childhood 2016; 101(10):971–972
How to improve antiviral drug treatment for children 153
7 Development of a new paediatric formulation of valaciclovir
Abstract
Background
The aim of this study was to develop a new paediatric formulation of valaci-
clovir and to assess the bioequivalence of the new formulation compared to
valaciclovir tablets.
Methods
A new paediatric formulation was developed with good pharmaceutical
quality and stability, and with the possibility of flexible dosing. Bioequiv-
alence of the new formulation compared to the innovator product (tablet)
was tested in a randomized, single-dose (500 mg), open label, two-period
crossover, phase-I trial in fasting healthy adult volunteers.
Results
A solution with 20 mg/ml valaciclovir with a shelf life of at least nine
months was developed. The geometric mean ratio of the test versus refer-
ence formulation was 106% (90%CI 100 to 112%) for AUC0−12 and 122%
(90%CI 110 to 133%) for Cmax. The 90% confidence interval for the ratio
of the AUC0−12 was within the acceptance range for bioequivalence. The
upper limit of the ratio for the Cmax was above the limit of 125%.
Conclusion
The newly developed valaciclovir solution has a comparable exposure to the
innovator product and is therefore an alternative formulation for (paedi-
atric) patients who experience difficulties with the intake of valaciclovir
tablets.
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7.1 Introduction
7.1 Introduction
Valaciclovir is an oral prodrug of aciclovir and is used for the treatment
and prophylaxis of herpes simplex virus (HSV) and varicella zoster virus
(VZV) infections [1]. Valaciclovir has a higher and more reliable bioavail-
ability than aciclovir with at least equal efficacy, a similar safety profile and
the advantage of decreased dosing frequency [2–4]. In adults, valaciclovir
has replaced aciclovir in many clinical scenarios. Valaciclovir is approved
by the European medicines agency (EMA) to be used in children from
the age of 12 years and above for the treatment of certain herpes infec-
tions. Pharmacokinetic studies performed in children from 0 to 18 years of
age, have shown that bioavailability is 2- to 5-fold higher compared to oral
aciclovir and comparable plasma levels can be achieved as in adults [5–8].
Although these studies were performed with various formulations (adult-
dose tablets, crushed tablets and an extemporaneous solution of valaci-
clovir), the results support the use of oral valaciclovir instead of aciclovir
in children.
The extemporaneous formulation made from crushed tablets as described
in the FDA label information is in our opinion a suboptimal formula-
tion for several reasons [9]. First, crushing tablets can result in hetero-
geneous particle size associated with differences in sedimentation of the
drug compound in a suspension, with a resulting difficulty in redispersing
the suspension upon agitation. This may lead to dosing errors and practical
problems such as obstruction of feeding tubes. Secondly, the valaciclovir
formulation from crushed tablets has to be discarded after 28 days, which
for practical reasons is too short. A paediatric formulation with accept-
able palatability, good pharmaceutical quality and stability, and with the
possibility of flexible dosing is currently not available.
The aim of this study was to develop a paediatric formulation of valaci-
clovir and to assess the bioequivalence of the new formulation compared to
the brand named valaciclovir tablets.
7.2 Methods
7.2.1 Formulation development
We chose to develop an oral liquid due to the need of flexible dosing in
the paediatric population and because this is generally considered accept-
able for use in both young infants and children [10]. A liquid can also be
used in children and adults dependent on feeding tubes. Next to this, most
pharmacies are adequately equipped to prepare oral liquids. The formula-
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tion had to meet the following criteria: accurate dosing from first to last
dose, non-toxic excipients, acceptable palatability, and good pharmaceu-
tical stability for an acceptable period of time. Appropriateness for admin-
istration to neonates was also taken into account during development of
the formulation.
Valaciclovir HCl.1 H2O (Duchefa Farma, Haarlem, the Netherlands)
was used as active pharmaceutical ingredient. Stability testing included:
inspection of clarity and colour of the solution, pH-measurement, and deter-
mination of the concentration of valaciclovir using a stability indicating
validated HPLC method. The valaciclovir solution was stored in brown
polyethylene terephthalate (PET) bottles. For primary stability testing
the valaciclovir solution was stored both at room temperature and at
4◦C. At each predefined time point two previously unopened bottles were
analysed. For definitive stability testing, six previously unopened bottles
per time point were analysed. The new paediatric valaciclovir formulation
was prepared in accordance with Good Manufacturing Practice (GMP).
7.2.2 Bioequivalence assessment
Bioequivalence of the new paediatric formulation compared to the innovator
product was tested in a randomized, single-dose, open label, two-period
crossover, phase-I trial in fasting healthy adult volunteers, according to the
EMA guideline for bioequivalence [11]. Valaciclovir is a highly soluble and
low permeable drug (biopharmaceutical class 3) and bioequivalence between
the two formulations needs therefore to be assessed in vivo [11,12]. The trial
was approved by the medical ethical committee of the Radboud University
Medical Center (Radboudumc, CMO Arnhem-Nijmegen, NCT01689285).
The trial was conducted in conformance with the principles of the current
version of the Declaration of Helsinki and with regulations concerning
clinical trials. All subjects provided written informed consent.
A total of 16 healthy adult volunteers were randomly assigned to one
of two treatment groups. Treatment order was randomly allocated using
random values created with SPSS software version 18.0.2 [SPSS Inc., 1993–
2007]. Randomisation was stratified for sex. Group A received the reference
formulation (valaciclovir tablet 500 mg (Zelitrexr)) on day 1 and after a
wash-out of seven days the same dose as the new paediatric formulation
(valaciclovir 500 mg (=25 ml) test formulation). Group B received the
test formulation at day 1 and the reference on day 8. Food was restricted
from 8 h before and 2 h after intake of the study medication. Tablets were
swallowed intact and consumed with 200 ml water, while the new paedi-
156 Making things easier
7.3 Pharmacokinetic and statistical analysis
atric formulation (25 ml) was consumed with 175 ml water. Because of the
difference in appearance of the test and reference formulation, subjects and
investigators could not be blinded for the treatment. After observed intake
blood samples were drawn at the following time points: t=0 (pre-dose),
0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12 hours. Indwelling
venous catheters were used for blood collection during the stay at the
clinical research centre.
7.2.3 Safety
To determine the safety profile of a single dose of the new valaciclovir
formulation, adverse events were collected. Next to this, blood samples were
drawn at screening and 12 hours post dosing to determine possible changes
in biochemistry and haematology (liver and kidney function parameters
and blood cell counts).
7.3 Pharmacokinetic and statistical analysis
Valaciclovir is rapidly hydrolysed to aciclovir, and Cmax of valaciclovir is
only 4% of Cmax of aciclovir. Therefore analysis of exclusively aciclovir
is justified to investigate bioequivalence. Aciclovir plasma concentrations
were determined using a validated ultra performance liquid chromatog-
raphy assay with ultraviolet detection, with a lower limit of quantification
of 0.03 mg/l and a higher limit of quantification of 30 mg/l. The coeffi-
cient of variation for intraday precision ranged from 0.6% to 3.8% and for
interday precision from 0.0% to 2.0%. The percentage accuracy of the assay
ranged from 91.7% to 105.7%. The analysis was performed by the labora-
tory of the department of pharmacy of the Radboud University Medical
Center, Nijmegen, the Netherlands.
Bioavailability (rate and extent of absorption) was determined by three
pharmacokinetic parameters: the area under the plasma concentration time
curve (AUC), the maximum plasma concentration (Cmax), and the time to
maximum plasma concentration (Tmax).
Pharmacokinetic parameters were calculated using non-
compartmental analysis with the linear up-log down calculation method
(WinNonlin/Phoenix v6.4. Pharsight Corporation, Mountain View, CA,
USA). Actual sampling times were used for pharmacokinetic analysis.
The primary comparison was made between aciclovir AUC0−12 and Cmax
values after intake of the valaciclovir new paediatric formulation (test)
versus intake of the valaciclovir tablets (reference). AUC0−12 is used,
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because with the sampling schedule and known pharmacokinetics in adults
it is expected to cover at least 80% of AUC0−∞ [1, 11]. The geometric
mean ratio for each pharmacokinetic parameter was calculated. Within
the WinNonLin software package 90% confidence intervals (90%CI) were
calculated using the bioequivalence crossover design tool approach with
fixed effects in the model specification. Both regimens were considered
bioequivalent if for AUC0−12 and Cmax the 90%CI for the ratio of the
test and reference product were contained within the 80–125% acceptance
interval [13].
Based on an inter-subject coefficient of variation in AUC of 15.8%, after
administration of 500 mg valaciclovir, and equal expected mean values of
AUC in the test and reference formulation, a sample size of 16 would be
sufficient to investigate bioequivalence with a desired power of 80% and to
account for possible dropouts [1, 11,14].
Comparison of pharmacokinetic parameters between the two treatment
groups was performed using an independent t test on log-transformed
values. Statistical analysis was carried out using SPSS software version
18.0.2 [SPSS Inc., 1993–2007].
7.4 Results
7.4.1 Formulation
A solution with 20 mg/ml valaciclovir was developed using glycerol (42.5%),
citric acid, disodium hydrogenphosphate and water as excipients, with pH
3.5 as target. Electronic tongue testing of the solution indicated that
the assumed bitter taste of valaciclovir could partly be masked with the
used excipients [15]. Primary stability testing showed that storage at room
temperature resulted in loss of almost 10% of the initial concentration of
valaciclovir in 3 months. This storage condition was therefore considered
not adequate and was no longer investigated. When the solution was stored
at 4◦C, a shelf life of at least nine months was observed (see Table 7.1).
7.4.2 Bioequivalence assessment
A total of 16 healthy volunteers were included in the study in June and
July 2015, of which 9 were male. Median age of the subjects was 31.5 years
(range 19, 55) and median body mass index was 23.7 (range 18.8, 29.9).
The two treatment groups consisted of each 8 subjects and had similar
demographic characteristics (equality of means, P > 0.10). The geometric
mean AUC0−12 of aciclovir after administration of the valaciclovir solution
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Table 7.1: Stability of valaciclovir 20 mg/ml solution (mean (± sd))
Primary stability testing (50 ml bottles)
week 0 week 4 week 8 week 12 –
Room temperature
pH 3.6 3.6 3.6 3.5
content (%) 99.5 (0.7) 97.2 (0.6) 94.2 (0.7) 92.8 (0.0)
Refrigerated (4◦C)
pH 3.6 3.6 3.6 3.6
content (%) 100.3 (0.1) 99.2 (0.2) 99.0 (0.1) 99.6 (0.1)
Definitive stability testing (200 ml bottles)
week 0 week 6 week 12 week 26 week 39
Refrigerated (4◦C)
pH 3.6 3.6 3.6 3.6 3.6
content (%) 102.5 (0.4) 102.1 (0.5) 100.3 (0.5) 99.6 (0.7) 99.0 (1.0)
was 10.6 (95%CI 9.65 to 11.7) h×mg/l compared to 9.96 (95%CI 8.71 to
11.4) h×mg/l for the reference formulation, and for Cmax these were 3.63
(95%CI 3.27 to 4.02) mg/l and 2.98 (95%CI 2.59 to 3.44) mg/l, respectively.
The geometric mean ratio of the test versus reference formulation was 106
(90%CI 100 to 112)% for AUC0−12 and 122 (90%CI 110 to 133)% for Cmax.
The 90%CI for the AUC ratio was within the 80 to 125% acceptance range.
The upper limit of the ratio for the Cmax (133%) was above the limit of
125%. (see also Table 7.2)
Table 7.2: Geometric mean values of aciclovir pharmacokinetic parameters
after administration of 500 mg valaciclovir
Parameter Test (solution) Reference (tablet) Ratio T/R (%)
(95%CI) (95%CI) (90%CI)
Cmax (mg/l) 3.63 (3.27, 4.02) 2.98 (2.59, 3.44) 121 (110, 133)
AUC0−12 (h×mg/l) 10.6 (9.56, 11.7) 9.96 (8.71, 11.4) 106 (100, 112)
AUC0−∞ (h×mg/l) 11.0 (9.95, 12.2) 10.4 (9.07, 12.0) –
Residual area (%) 3.9 (2.9, 5.1) 3.5 (2.3, 5.3) –
t1/2 (h) 2.75 (2.50, 3.02) 2.58 (2.23, 2.98) –
Tmax (h)
† 0.75 (0.75, 1.44) 1.25 (1.00, 1.94) –
† Tmax: median value and interquartile range
The mean plasma concentration-time profiles of aciclovir after adminis-
tration of the test and reference formulation are depicted in Figure 7.1.
Adverse events reported by the subjects which were possibly related to
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Figure 7.1: Mean (± sd) aciclovir plasma concentration-time profile of the
new valaciclovir solution and the reference formulation (tablet)
after administration of 500 mg valaciclovir.
the study drug were dizziness and fainting (n = 1, solution), and nausea,
lethargy and headache (n = 1, tablet). Both subjects recovered from the
adverse events within 24 hours after onset of the symptoms.
7.5 Discussion
The newly developed valaciclovir solution met the criteria for bioequiva-
lence regarding the AUC0−12. However, the upper limit of the 90%CI of
the ratio for Cmax was just above the 125% criterion. The higher mean Cmax
and shorter Tmax can be explained by a faster absorption rate of valaciclovir
from the new paediatric liquid formulation compared to the tablet. The
tablet needs to disintegrate first before the valaciclovir is solved and avail-
able for absorption. Because of the mild toxicity profile of (val)aciclovir,
it is not expected that the slightly higher Cmax will result in more adverse
events [1].
Bioequivalence studies in adults instead of paediatric populations are
preferred by regulatory agencies for bridging between adult and paediatric
formulations, when it can be assumed that absorption will be comparable
in children [16]. Extrapolation of adult biopharmaceutical properties of a
drug, such as solubility and permeability, to children should be done with
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caution. Biopharmaceutical methods applicable for paediatrics are being
developed [17–19]. Following Batchelor et al. it can be estimated that
valaciclovir needs to be solved in a relatively lower gastric volume in children
compared to adults, but will still be classified as a highly soluble drug.
Valaciclovir is absorbed through uptake by dipeptide transporters [20, 21].
It is not expected that the excipients used will influence uptake through
these transporters [22]. A possible influence of glycerol on the intestinal
transit time did not result in a lower absorption of valaciclovir from the
new paediatric formulation.
The preparation of a valaciclovir liquid as described in the FDA label
information was found not to be adequate for use in daily practice, because
of the need to use crushed tablets and the short shelf life [9, 23]. The
pharmacokinetics of an extemporaneously prepared suspension following
the FDA label information compared to the brand named tablet has been
investigated in a small paediatric study (n = 8) [24]. Comparison was not
made following the regulatory guidance for the assessment of bioequiva-
lence. The mean relative bioavailability of the suspension compared to the
tablets was 91.1% (sd, 33.1%). The newly developed valaciclovir formula-
tion reported here is a solution instead of a suspension, has a longer shelf
life (at least nine months) and has a bioavailability comparable to the brand
named tablets.
We acknowledge that the relatively low concentration of the developed
solution (20 mg/ml) might be a problem when higher doses have to be
administered. The EMA recommends a maximum volume of intake per
dosing time point depending on the age of a child: < 5 ml for children
< 5 years of age and < 10 ml for older children, corresponding to a valaci-
clovir dose of 100 mg and 200 mg, respectively. At the early stage of
development we tested a valaciclovir solution with a higher concentration
(50 mg/ml), but this formulation showed inferior stability and was not
investigated further. Available tablet strengths for valaciclovir are 250 mg
and 500 mg, and the new paediatric formulation has been developed specifi-
cally to administer low dosages, or through a feeding tube. Whether higher
dose volumes are acceptable, depends on the palatability of the formula-
tion [10]. Palatability influences the acceptability and compliance substan-
tially. Taste of the new paediatric formulation has been tested in vitro [15].
Palatability testing of this new formulation in children has been performed
and results and full details will be reported separately.
When an extemporaneous preparation is made by a pharmacist, either
by adapting an approved formulation or preparation from raw materials
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(unlicensed preparations), the compounding pharmacist is responsible for
the pharmaceutical quality of the formulation [25]. Standardization of the
formulation is recommended, if possible at an (inter)national level [26,27].
The preparation method and developmental aspects of the currently devel-
oped paediatric formulation have been included in the Formulary of the
Dutch Pharmacists (FNA) and are freely available upon request.
With the results of this study it can be concluded that the newly devel-
oped valaciclovir solution is an alternative formulation for (paediatric)
patients who experience difficulties with the administration of valaciclovir
tablets. The new formulation will facilitate to administer targeted dosages
to young children and patients depending on a feeding tube.
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Abstract
Background
Palatability testing of oral drug formulations in children is challenging,
although palatability is highly relevant for the acceptability of drug formu-
lations.
Methods
The palatability of a new paediatric formulation of valaciclovir in children
(aged 4 to 12 years) and their parents was assessed in a randomized, two-
period, multicentre, cross-over study. To support formulation development
and palatability testing electronic tongue measurements were applied. The
liking of the new valaciclovir formulation and the reference formulation was
scored on a 100 mm visual analogue scale (VAS). The mean difference in
VAS score of the test and reference formulation as indicated by the children
was the primary outcome measure.
Results
The electronic tongue measurement indicated taste-masking capabilities
for the three different formulations in the developmental phase. A glycerol-
based formulation was further tested and compared to the reference formu-
lation prepared out of crushed and suspended tablets. The mean (95%CI)
VAS scores as indicated by the children (n = 20) were 26 mm (18, 34) for
the test formulation and 24 mm (16, 32) for the reference formulation with
a mean difference (95%CI) of 2.4 (−8.5, 13) mm, in favour of the test formu-
lation. The mean (95%CI) VAS scores indicated by the parents (n = 20)
were 45 (36, 54) mm for the test formulation and 46 (37, 55) mm for the
reference formulation, and a mean difference (95%CI) of −0.9 (−12, 9.8)
mm.
Conclusion
The palatability of the new paediatric valaciclovir formulation was consid-
ered non-inferior to the reference formulation prepared out of crushed
tablets. We were able to optimize the study design and number of
children to be included in the palatability testing by using electronic tongue
measurements.
166 Making things easier
8.1 Introduction
8.1 Introduction
The palatability of oral drug formulations is a key characteristic for the
acceptability and compliance to drug therapy, especially for children [1–3].
This aspect was emphasized by the regulatory authorities in the ‘Guideline
on pharmaceutical development of medicines for paediatric use’, in which
a verification of the acceptability of a new paediatric formulation prior
to its approval is demanded [3]. Next to this, the Paediatric Regulation of
2006 requests the development of appropriate formulations for children, but
without performance of unnecessary clinical trials in children [4]. Palata-
bility testing should best be performed in the paediatric target population
due to high differences in taste preferences between adults and children, and
also between healthy and sick children [2]. However, the experience to test
the acceptability of drug formulations in children is still limited. In general,
palatability testing of drug formulations with human taste panels is reluc-
tantly chosen and hampered by ethical concerns, toxicological aspects, high
costs and poor reproducibility [5]. Taking all regulatory, ethical and statis-
tical requirements into account, in vitro methods for the taste assessment
of oral drug formulations might be a favourable alternative.
The electronic tongue is a promising tool used for in vitro taste assess-
ments [6]. These instruments are commonly equipped with a sensor array
and based on electrochemical measurement principles including potentiom-
etry, voltammetry and amperometry [7–9]. Most of the used electronic
tongue sensors are potentiometric membrane electrodes following the
Nernst law and their membrane potentials are correlated to at least one
reference electrode [5, 7, 8]. The sensor responses are caused by inter-
actions of the sample molecules with incorporated components of the
electrode membrane. Currently, two commercially available electronic
tongue systems are employed for the taste assessment of drug formulations,
the α-Astree (AlphaMOS, Toulouse, France) and the taste sensing systems
TS-5000Z and SB402B (Insent Inc., Atsugi-Shi, Japan) [8–10]. In case
of the TS-5000Z and SB402B, different sensors are dedicated to different
tastes, such as bitterness and sourness. The α-Astree and non-commercially
available electronic tongues work cross-selective, meaning that one sensor is
dedicated to a combination of different tastes [10]. Even though electronic
tongues are commonly used tools in the development of properly taste-
masked drug formulations, the obtained results are only a relative interpre-
tation of taste [6]. A relationship between electronic tongue measurements
with human taste has been shown to some extent in adults [7, 9, 11–13].
The aim of this study was to investigate the palatability of a new paedi-
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atric oral liquid formulation containing valaciclovir, compared with a formu-
lation of crushed and suspended tablets. Valaciclovir is used for the treat-
ment and prophylaxis of herpes simplex virus and varicella zoster virus
infections [14]. However, in Europe, its use is off-label in children below
the age of 12 years. The FDA label information describes the preparation of
an oral liquid formulation from crushed tablets [15]. To overcome practical
problems associated with the formulation prepared out of crushed tablets,
such as a short shelf life and obstruction of feeding tubes, we developed
a new paediatric valaciclovir formulation [16]. In vivo palatability testing
was performed in children and their parents. The electronic tongue was
applied for the formulation development as well as for the in vitro taste
assessment of the new formulation.
8.2 Materials and Methods
8.2.1 Materials
8.2.1.1 Electronic tongue
For the preparation of the standard and washing solutions for the electronic
tongue, potassium chloride (Grussing, Filsum, Germany), tartaric acid
(AppliChem, Darmstadt, Germany), potassium hydroxide (Gruessing,
Filsum, Germany), hydrochloric acid (Merck, Germany), and absolute
ethanol (VWR international, Darmstadt, Germany) were used. The
measurements were performed with a sensor array consisting of 8 commer-
cially available sensors (Insent Inc., Atsugi-Shi, Japan), each dedicated to a
defined taste: SB2AAE: umami, SB2CT0: saltiness, SB2AE1: astringency,
SB2CA0: sourness SB2AC0: bitterness (cationic substances), SB2AN0:
bitterness (cationic substances), SB2BT0: bitterness (cationic substances),
SB2C00: bitterness (anionic substances).
8.2.1.2 Valaciclovir formulations
Valaciclovir formulations were prepared based on valaciclovir hydrochloride
monohydrate (Duchefa Farma, Haarlem, the Netherlands), glycerol (Spruyt
Hillen, IJsselstein, the Netherlands), maltodextrin (Kleptoser Linecaps,
Roquette, France), citric acid (Duchefa Farma, Haarlem, the Netherlands),
disodium hydrogenphosphate (Spruyt Hillen, IJsselstein, the Netherlands),
OraSweetr SF (Paddock Laboratories LLC, Minneapolis, US) and purified
water. Samples for the formulation development comprised valaciclovir in
three different dosing vehicles, named liquid A, B and C. Liquid A contained
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glycerol as main excipient, liquid B maltodextrin and liquid C contained
both glycerol and maltodextrin as excipients (see Table 8.1).
Table 8.1: Composition of liquids tested by the electronic tongue A) in the
developmental phase and B) to support the in vivo palatability
testing
Composition of the formulation Abbreviation Valaciclovir
concentration
(mg/ml)
A) Liquids developmental phase
Liquid A: water, glycerol (42.5%), citric acid, A1/A2 0
disodium hydrogenphosphate Val20 A 20
Val50 A 50
Liquid B: water, maltodextrin (0.5:1 mol/mol B1/B2 0
valaciclovir), citric acid, disodium hydrogen- Val20 B 20
phosphate, sorbic acid Val50 B 50
Liquid C: water, glycerol (25.5%), maltodextrin C1/C2 0
(0.5:1 mol/mol valaciclovir), citric acid, Val20 C 20
disodium hydrogenphosphate Val50 C 50
water Val20 20
Val50 50
B) Liquids for in vivo palatability assessment
Liquid A: water, glycerol (42.5%), citric acid, Test 0
disodium hydrogenphosphate Val20 test 20
Val50 test 50
OraSweetr Reference 0
Val25 ref 25
Val50 ref 50
water Val20 20
The test formulation for the in vivo palatability assessment was chosen
based on the results of the first electronic tongue measurement combined
with the results of stability testing. The reference formulation was derived
from the extemporaneous liquid made from crushed innovator tablets as
described in the FDA label information with OraSweetr SF as suspension
vehicle [15, 17]. The mixed valaciclovir formulation was a 1 : 1 mixture of
the test and reference formulation.
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8.2.2 Methods
8.2.2.1 Electronic tongue
Electronic tongue measurements were performed using the taste sensing
system SA402B (Insent Inc.) and the measurement protocol according to
Woertz et al. [18]. Two electronic tongue measurements were performed:
A) one in the developmental phase and B) one to support the in vivo palata-
bility testing. Most reliable use of electronic tongues measurements for drug
formulation development requires a concentration dependent behaviour of
the applied sensors: if for example one of the bitter sensors detects a
reduced sensor signal for a drug formulation compared to the pure drug, a
taste-masking effect of the excipients can be assumed [6,8,19,20]. Therefore,
the behaviour of the sensors to different concentrations of pure valaciclovir
was determined prior to evaluating the drug formulations. For this purpose,
calibration samples containing 0, 0.2, 2, 20 and 50 mg/ml valaciclovir in
only water were analysed.
Samples with 0, 20 and 50 mg/ml valaciclovir in liquid A, B and C
were tested for the formulation development. The samples for the taste
assessment of the newly developed drug formulation comprised 20 mg/ml
and 50 mg/ml valaciclovir in the chosen liquid or 25 mg/ml and 50 mg/ml
in OraSweetr SF (Table 8.1). Each sample was measured four times, and
the last three measurements were used for the data evaluation.
8.2.2.2 In vivo palatability testing
8.2.2.2.1 Study population
Children were eligible if aged at least 4 and less than 12 years and having
received (val)aciclovir in the past, or using valaciclovir as prophylaxis at
that time, or had a high probability of future use, such as children with
primary immune deficiency or recipients of haematopoietic stem cell trans-
plantation. Children and one of their parents attending the outpatient
clinic of the Leiden University Medical Centre, Radboud University Medical
Centre or the University Medical Centre Utrecht in the Netherlands, were
asked for their participation. Children with a sensitivity or idiosyncrasy
to medicinal products or excipients were excluded, as were children with
any condition that influences taste sensation (such as upper respiratory
infection, mucositis or use of medication that influences taste perception).
The Central Committee on Research Involving Human Subjects
(CCMO) provided ethical approval for performance of the assessment
(NCT01682109). The trial was conducted conform the principles of the
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Declaration of Helsinki and regulations concerning clinical trials.
8.2.2.2.2 Palatability testing
The palatability assessment was a randomized, two-period, multicentre,
cross-over study. The design of the study was based on the EMA Reflection
Paper and description of conducting taste assessment trials in children [2,
21–24]. The main outcome was based on liking indicated by the subjects
on a 100 mm visual analogue scale (VAS) combined with five smiley faces
(Figure 8.1). Upon signed informed consent, the child and parent were
together taken to a private area. First, the 100 mm VAS-smiley scale was
explained and practiced by the child. To have the same ‘taste starting
point’ all subjects tasted 4 ml (children 4–8 years) or 8 ml (children 8–12
years and the parent) of the same mixed valaciclovir formulation. After
this, 4 ml or 8 ml of the test and reference formulation were presented to
the subject in a plastic medication cup in randomized order. To neutralize
taste before and between tastings, subjects ate a cracker and rinsed their
mouth with water. After tasting each of the three formulations the subject
rated their liking on the VAS-smiley scale. Parents were also asked to
record which formulation they thought their child would favour.
Figure 8.1: Applied combined 100 mm visual analogue/facial hedonic scale.
Treatment order was randomly allocated using random values created
with SPSSr software version 18.0.2 (SPSS Inc., 1993–2007). Randomisa-
tion was stratified for sex and age in blocks of four. After the mixed valaci-
clovir formulation, group A first received the test formulation followed by
the reference formulation, group B received the reference formulation first.
Correlating the results of an electronic tongue measurement with results
from a human taste panel increases the value of the information from both
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measurements. Since the ability to describe basic tastes develops during
the first decade of a child’s life, not the children but the parents were asked
to describe the basic tastes of the different valaciclovir formulations [25,26].
Parents could report all the tastes that were applicable: bitter, sweet, salt,
sour or other, regardless of the intensity of taste.
With an expected difference between VAS scores of the formulations of
10 mm, a standard deviation of the within subject differences of about
30 mm and a non-inferiority margin of 10 mm, a total of 20 children was
needed to reach a power of 80% to demonstrate non-inferiority of the test
formulation compared to the reference formulation.
8.2.2.3 Data analysis
8.2.2.3.1 Electronic tongue measurement
Data obtained by electronic tongue measurements were evaluated using
Microsoft Excelr, OriginPro 9.0G and Simca 13.0.2 (Umetrics, Sweden)
for univariate and multivariate data analysis. The sensor responses
were corrected with an external standard solution of 0.5 mM quinine
hydrochloride dihydrate (Buchler GmbH, Germany) and the mean values
and standard deviations were calculated. The results of the measurements
of the dosing vehicles without valaciclovir were used as a positive reference
for taste-masking efficiency. The pure drug solutions with 20 mg/ml and
50 mg/ml valaciclovir in water were used as a negative taste reference.
8.2.2.3.2 In vivo palatability testing
The mean difference in palatability of the test and reference formulation
as indicated by the children on the 100 mm VAS-smiley scale was used
as primary outcome measure. A difference of 10 mm or less was consid-
ered negligible. Non-inferiority was shown when the lower limit of the 95%
two-sided confidence interval (95%CI) for the difference in VAS scores of
the formulations was above −10 mm. The primary analysis was a model
without carry-over, with the formulation and period as fixed effects. A
model with carry-over effects (interaction period by formulation) was used
to verify whether an identical trend in the ordering of the formulations
was found and is regarded as a measure of the robustness of our findings.
The scores given by the parents were analysed in a similar way. To deter-
mine whether there was a correlation for the rating of the child and the
parent, the correlation coefficient with repeated observations within families
was calculated [27]. Subjects not able to evaluate all three liquids were
excluded from the data analysis. Statistical analysis was performed in
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SPSSr (software version 18.0.2, SPSS Inc., 1993–2007).
8.3 Results
8.3.1 Electronic tongue measurement
8.3.1.1 Electronic tongue supported formulation development
Concentration dependent sensor responses towards valaciclovir were
observed for all applied sensors. Sensors SB2CT0 (saltiness), SB2AE1
(astringency) and SB2BT0 (bitterness of cationic substances) were found
to be most sensitive, showing the best response towards the pure drug
substance.
The three different formulations (liquid A, B and C, Table 8.1),
each with different concentrations of valaciclovir, were analysed by the
employed sensor array. With respect to the resulting sensors response
pattern, the drug free and drug containing formulations were compared
to each other to derive differences in taste properties. Differences within
the sensors response pattern were also used to compare the three different
formulations regarding their capability to taste-mask valaciclovir. For
this purpose, a principal component analysis (PCA) was performed where
the formulations liquid A, B and C, the pure drug solutions (20 mg/ml
and 50 mg/ml valaciclovir in water) and the dosing vehicles (formulations
without valaciclovir) were included (Figure 8.2). The PCA was built
based on the first two principal components explaining 92% of the
information given by the sensor responses (principal component 1: 71.1%,
principal component 2: 20.9%, Figure 8.2). In this case, the first principal
component defines the bitterness of the investigated sample: samples
located on the left side of the map (dosing vehicles) are less bitter than
those located on the right side of the map (drug containing formulations).
Merging sensorial information in such a map helps assessing how different
samples are detected by the sensors. For example, it indicates a similar
taste for the drug formulations ‘Val20 A’ and ‘Val20 C’ (Figure 8.2). In
general, taste-masking of valaciclovir was observed in all investigated drug
formulations. As the formulations containing maltodextrin had an inferior
physical stability, liquid A was selected for further investigations.
8.3.1.2 Electronic tongue evaluation of formulations for in vivo palatability
testing
The in vitro taste-masking capability of the test formulation (liquid A)
was compared to the reference formulation (Table 8.1). The obtained
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Figure 8.2: PCA map for the formulation development of valaciclovir
(mean, n = 3, R2 = 0.920, Q2 = 0.508): Val20/50: valaciclovir
in water (20 and 50 mg/ml); A1/2, B1/2 and C1/2: dosing
vehicles; Val20/50 A/B/C: valaciclovir in dosing vehicles A, B,
and C (20 and 50 mg/ml)
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sensor responses were initially evaluated by multivariate data analysis by
performing a PCA with 2 principal components (Figure 8.3). The first
principal component described 88.2% of the sensor information. No differ-
entiation as aforementioned was possible (right side: bitter, left side: less
bitter). In this case main information along the x-axis differentiates the
two vehicles, which is most probably due to the different viscosity (viscous
located on the left side, less viscous on the right side), while bitterness might
be differentiated along the y-axis. Thus, when assessing taste masking
based on the PCA map, both formulations have to be evaluated individu-
ally.
Figure 8.3: PCA map comparing the test and reference formulation
containing valaciclovir in different concentrations (mean, n = 3,
R2 = 0.990, Q2 = 0.932): Val20: valaciclovir in water (20
mg/ml); Test: dosing vehicle of test formulation; Reference:
dosing vehicle of reference formulation; Val20/50 test: valaci-
clovir test formulation (20 and 50 mg/ml); Val25/50 ref: valaci-
clovir reference formulation (25 and 50 mg/ml)
The small distances between samples ‘Val20 test’ and ‘test’ demonstrate
a good taste-masking effect of the dosing vehicle. On the contrary, the
test sample containing 50 mg/ml valaciclovir (Val50 test) was located close
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to the pure drug solution (Val20), indicating only a minor taste-masking
effect. The reference formulations (Val25 ref and Val50 ref) were located
close to each other but further away from their corresponding dosing vehicle
(reference). This indicated differences in taste sensation.
To individually quantify the differences in the taste pattern of the tested
samples, the Euclidean distances
d(p, q) =
√√√√ n∑
i=1
(qi − pi)2
were calculated (Figure 8.4 and Table 8.2). For the test and reference
formulations, the samples containing 20 mg/ml and 25 mg/ml valaciclovir
demonstrated a high taste-masking efficiency indicated by high distances
between the drug formulations to the pure drug solution and low distances
to their corresponding dosing vehicles. Both calculated Euclidean distances
of the reference formulations were higher than of the test formulations
(Table 8.2), meaning that the reference formulations were less similar in the
taste pattern to either the pure drug solution or the reference dosing vehicle.
Due to this contradictory outcome, the test formulation was assumed to
better taste mask valaciclovir than the reference formulation. As a result
a difference between liking of the test and reference formulation of approx-
imately 10 mm on the 100 mm VAS score in favour of the new paediatric
formulation was expected for the palatability assessment in children.
Table 8.2: Euclidean distances (mV) between formulations for the test and
reference formulations (n = 3, mean ± sd)
Formulation Dosing vehicle Pure drug solution
vs formulation vs formulation
Test (liquid A)
20 mg/ml 0.94 ± 0.05 2.48 ± 0.08
50 mg/ml 2.18 ± 0.04 1.62 ± 0.05
Reference (OraSweetr) SF
25 mg/ml 3.36 ± 0.06 5.51 ± 0.04
50 mg/ml 4.63 ± 0.04 4.53 ± 0.03
8.3.2 In vivo palatability testing
Twenty-one children and 20 parents were included in the taste assessment.
One child tasted only two formulations, and the parents of another child
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Figure 8.4: Euclidean distances of the drug formulations compared either to
the corresponding dosing vehicle (black) or the corresponding
samples of valaciclovir in water (red) (mean ± sd, n = 3):
Val20/50 test: valaciclovir in dosing vehicle of test formulation
(20 and 50 mg/ml); Val25/50 ref: valaciclovir in dosing vehicles
of reference formulation (25 and 50 mg/ml)
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were not able to attend. Therefore, VAS scores of all three liquids from
20 children and 20 parents (19 child-parent pairs) could be included in the
analysis. Characteristics of the subjects and VAS scores are displayed in
Table 8.3. For the children, mean (95%CI) VAS scores were 26 mm (18, 34)
for the test formulation and 24 mm (16, 32) for the reference formulation
with a mean difference (95%CI) of 2.4 (−8.5, 13) mm, in favour of the test
formulation. The test formulation can herewith be considered non-inferior
to the reference formulation. Based on the VAS scores of the test and
reference formulation, 7 children (35%) preferred the test formulation, 4
(20%) the reference formulation and 9 (45%) children indicated a difference
of 10 mm or less between the formulations. Inclusion of the interaction of
period by formulation as a fixed effect did not have a significant effect
(P = 0.871) and therefore no carry-over effects were observed.
Table 8.3: Baseline characteristics and results from scores on the visual
analogue scale (VAS score)
Baseline characteristics Children Parents
(median, range)
n = 20 n = 20
age,years 8.7 (6.3, 11.9) 41 (34, 54)
sex (female/male) 6/14 11/9
underlying condition
primary immune deficiency 18
stem cell transplantation 2
VAS scores (mm)
(mean, 95%CI)
test formulation 26 (18, 34) 45 (36, 54)
reference formulation 24 (16, 32) 46 (37, 55)
test – reference formulation 2.4 (–8.5, 13) –0.9 (–12, 9.8)
For the parents, mean (95%CI) VAS scores were 45 (36, 54) mm for the
test formulation and 46 (37, 55) mm for the reference formulation and a
mean difference (95%CI) of −0.9 (−12, 9.8) mm, in disadvantage of the
test formulation. Based on the VAS scores of the formulations, 6 parents
(30%) preferred the test formulation, 7 (35%) the reference formulation and
7 (35%) indicated a difference of 10 mm or less between formulations. The
test for the interaction of period by formulation showed a P -value of 0.074
and therefore carry-over effects cannot be ruled out for the parents. When
only the results from the first period are analysed: 11 parents tasted the test
formulation and 9 the reference formulation. In this way, the mean (95%CI)
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difference between the VAS scores of the formulations was 12 (−4.5, 28.6)
in favour of the test formulation.
VAS scores of the children and the parents did not show a correla-
tion (correlation coefficient = −0.03, P = 0.91). Predictions made by
18 parents which formulation would be preferred by their child showed
6 (33%) correctly predicting their child’s preference and 10 (56%) choosing
a different formulation. Two children were not able to show a preference.
Nineteen parents assigned basic tastes to the formulations (Table 8.4).
The predominantly chosen basic tastes by the parents for both the reference
and the test formulation were bitterness and sweetness. Twelve parents
(63%) thought the reference formulation had a bitter taste and 8 parents
(42%) thought the test formulation had a bitter taste. This indicates that
the bitter taste was better masked with the test formulation. The high
percentage of parents tasting bitter corresponds to the results found by the
electronic tongue, in which the bitter sensor (SB2BT0) was most distinctive
for valaciclovir, together with sensor signals of the saltiness and astringency
receptor. The parents did not predominantly choose the saltiness taste.
Twelve parents (63%) indicated the reference formulation as being sweet
and eleven parents (58%) for the test formulation.
Table 8.4: Basic tastes assigned to the tested valaciclovir formulations by
the parents (n = 19)
Taste Reference (n, %) Test (n, %)
Bitter 12 (63%) 8 (42%)
Sweet 12 (63%) 11 (58%)
Salt 1 ( 5%) 2 (11%)
Sour 3 (16%) 8 (42%)
Other 0 ( 0%) 1 ( 5%)
8.4 Discussion
The palatability of the newly developed paediatric valaciclovir formulation
was non-inferior to the reference formulation in children. No significant
differences were found between the liking of the new paediatric formulation
of valaciclovir, compared to crushed and suspended tablets. Non-inferiority
was shown for the children, but not for the parents, since the lower margin
of the 95% confidence interval was just below −10% (−11.6%). This can
be explained by the higher mean VAS score of the reference formulation
compared to the test formulation, and the somewhat higher variance in VAS
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scores of the parents, compared with the children. Variability in prefer-
ence of the test or reference formulation was also observed between the
subjects: 35% of the children and 30% of the parents preferred the test
formulation and 20% of the children and 35% of the parents preferred the
reference formulation. No carry-over effects were observed for the children,
but carry-over effects for the parents could not be ruled out. When only the
results from the first period are analysed, non-inferiority of the reference
formulation was observed, also for the parents. When carry-over effects are
observed, an alternative for an AB cross-over design should be chosen [28].
However, this would imply a possible larger burden of the assessment such
as a longer assessment, more visits or more subjects, which are undesirable
in studies involving paediatric patients.
No correlation was found between the liking of the formulations by the
children and their parents. Only a minority of the parents was able to
correctly predict the preferred formulation for their child. This confirms
that taste assessments of (new) paediatric formulations should be performed
in children [2].
This is the first study in which results from palatability testing in children
and adults as well as results from an electronic tongue assessment are
simultaneously available. Based on the results from the electronic tongue
measurement, it was expected that the test formulation would have a
slightly better palatability than the reference formulation. Without the
use of the electronic tongue in the palatability testing, no difference in VAS
scores would be expected and the number of children to be included would
have been more than 3.5 fold higher. The expected difference of 10 mm
in VAS score between the formulations could not be confirmed, nor ruled
out. An explanation could be the complexity of tastes of both formula-
tions. The pure active pharmaceutical ingredient valaciclovir has a bitter
taste. The test and reference formulation both contain citric acid, which
has a sour taste, and both contain sweet tasting substances. Next to this,
sensors to capture the complexity of sweetness were not available. Sweet-
ness could thus not be measured with the electronic tongue. Especially
children mostly like sweetness, but it is generated by substances with a wide
molecular diversity. Sweetness sensors for selected sweet tasting substances
have been developed and development is extended to more complicated
molecules [7,29,30]. Validated sensors to measure sweetness are needed for
optimal in vitro evaluation of paediatric drug formulations.
Besides the taste also texture, smell and appearance of a formulation can
influence acceptability [2, 3]. These aspects were not scored nor measured
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during the assessment. However, for acceptability, solutions are generally
preferred over suspensions [31]. The new formulation of valaciclovir is a
solution, which would for that reason be preferred over the suspension out
of crushed tablets.
One of the strengths of this study is that we were able to perform palata-
bility testing in a paediatric target population using valaciclovir, or with a
high probability of future use. A different paediatric population who could
benefit from the new paediatric formulation of valaciclovir are (premature)
neonates. Because of the possible burden of the trial assessments and the
lack of experience with methods for acceptability testing of drug formula-
tions in neonates, they were not included in the study.
Debatable is the difference in valaciclovir concentration between the test
and reference formulation (20 vs. 25 mg/ml, respectively). As was shown
with the electronic tongue measurement a higher concentration of valaci-
clovir in water results in a higher sensor signal and an assumed more bitter
tasting formulation, which would be unfavourable for the reference formu-
lation. However, it was chosen to use concentrations that would be used
in clinical practice. The concentration for the test formulation was based
on pharmaceutical stability testing and expected ease of calculation of the
volume to be administered. The concentration of the reference formulation
was as included in the FDA label information, and would thus be used in
daily practice.
In conclusion, we found that in children the palatability of the new paedi-
atric valaciclovir formulation was non-inferior to the reference formulation
prepared out of crushed tablets. Next to a longer shelf life than crushed
and suspended tablets combined with a comparable exposure as tablets, the
results of this palatability study further support the use of the new paedi-
atric formulation as an alternative formulation for (crushed and suspended)
valaciclovir tablets. By applying an electronic tongue measurement during
the development and as screening for the in vivo palatability testing, we
were able to optimize effort and number of children to be included in a
clinical trial.
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9.1 Introduction
The results of the studies described in this thesis show that it is possible
to make antiviral drug treatment easier for children. The focus was on
orally administered drugs. Two main topics were investigated. At first,
the possibility to simplify antiretroviral dosing regimens was investigated
and secondly, a new paediatric formulation of valaciclovir was developed.
Different aspects were taken into account when searching for more child
friendly treatments. These included dosing frequency, appropriateness and
acceptability of a formulation, and the biopharmaceutical properties of a
drug.
9.2 Research in children
9.2.1 Clinical trials
Treatment options for children are often limited because of the lack of
evidence on safe and effective dosing regimens, and the availability of
appropriate formulations. One of the ways to collect more information
on the appropriate use of medicines in paediatrics is to include children in
clinical trials. However, to include children as subjects in (medical) scien-
tific research has long been deemed unethical which consequently resulted
in the lack of information on safe and effective use of medicines in children.
Slowly this changed to the opinion that it is unethical to exclude children
from medical research, and thus denying the opportunity to search for
better treatment options [1]. The Dutch law on medical research involving
human subjects states it is not allowed to include children in medical-
scientific research, unless the research will directly benefit the child, or
unless the burden of the trial assessments is negligible for research needed
to be performed in a specific population. For example for new drugs, strict
application of the law results in the nearly impossible situation to perform
clinical trials with children. In 2009 the committee ‘Doek’ investigated
the Dutch situation and came forward with recommendations [2]. One of
the major recommendations was to change the law, from the ‘no, unless’
principle, into a ‘yes, if’ principle, where researchers have to meet several
criteria before they are allowed to perform medical research in children,
such as a clear description in the study protocol of the burden and risk of
participation. The protocol should also describe whether the subject might
benefit from participation. When the research is not directly of benefit
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for the subject, the risk and burden should be minimal compared to the
standard treatment. Based on the recommendations from the committee,
the House of Representatives agreed in 2015 to change the Dutch law
on medical research, extending the possibilities for performing research in
children. The new law will also encompass that children from an earlier age
on (16 instead of 18 years) have to give informed consent for participation
in medical scientific research. However, children below this age should also
be involved in deciding about participation in research. As agreed in the
United Nations Convention on the Rights of the Child, all children capable
of expressing a view, have the right to be heard in decisions affecting them.
Therefore, they should also be included as much as possible when they
participate in research and understandable information should be available
for them. From a broader perspective, children, and not only their parents,
can be part of research networks focussing on certain research questions
within specific paediatric patient populations. Involvement of children and
their parents in the earliest stages when setting up research will lead to
additional research questions and improved acceptance and willingness to
participate.
The results of a large international clinical trial investigating the safety
and efficacy of a once-daily lopinavir/ritonavir containing antiretroviral
drug regimen in a large group of children (KONCERT, n = 173) is described
in chapter 1 [3]. In adults a once-daily dosing regimen with lopinavir was
already approved by the European Medicines Agency (EMA) in 2009. Early
pharmacokinetic studies in children indicated an adequate exposure when
children use lopinavir once daily [4–7]. To investigate the efficacy in HIV-
infected children of a once-daily lopinavir/ritonavir containing regimen,
results from a clinical trial were needed, but setting up clinical trials are
mostly very expensive and more difficult in paediatric than in adult popula-
tions. It took until 2014 for the results of the KONCERT trial to be
presented at an international conference [8]. More children treated with
once-daily lopinavir/ritonavir experienced viral load rebound within the
first 48 weeks: 14% compared to 8% in children treated with twice daily
lopinavir. The estimated difference between the two groups was 6%, with
a 90% confidence interval of −2 to 14%. The upper limit was above the
predetermined non-inferiority bound of 12%. Even after adjustment for
the difference in viral rebound between the two groups at baseline, the
upper bound of the confidence interval was 11%, only just within the
predefined 12% margin of non-inferiority. Based on these results the once-
daily dosing regimen has not been included as approved dosing regimen in
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the summary of product characteristics [9]. In the 2015 guideline of the
PENTA-network (Paediatric European Network for Treatment of AIDS),
other boosted protease inhibitors with proven efficacy when given once
daily, are preferred over lopinavir combined with ritonavir [10].
9.2.2 Real-world evidence
Next to clinical trials, alternative ways to collect information on safe and
effective use of medicines in children can be found. For example, there
is growing interest in the use of real-world evidence as part of adaptive
licensing, or adaptive pathways [11]. In real-world research, efficiency
rather than efficacy of a treatment is investigated. Applying adaptive
pathways is intended to result in more timely access to new medicines.
The observational cohort study reported in chapter 2 is an example
of investigating a once-daily lopinavir antiretroviral regimen using over
ten years of clinical experience in real-life setting. While awaiting perfor-
mance and results of a randomised controlled trial on lopinavir once daily
in children, several paediatricians already treated selected children with
this regimen. Since safety and efficacy were not yet investigated in a
clinical trial, children who switched to once-daily lopinavir were closely
monitored on clinical outcome and exposure to lopinavir. While on treat-
ment 82–100% of the children (n = 40) had an undetectable viral load
during yearly follow-up visits. The response rate is comparable to what
was found in the KONCERT trial and it supports PENTA’s statement
that selected, adherent HIV-infected children can be treated with once-
daily lopinavir/ritonavir when properly monitored. Although done with
caution, a comparison of the results from both studies supports the use of
real-life research as possible valuable alternative for the performance of a
clinical trial.
9.2.3 Off-label and on-label use in clinical practice
Studies show that off-label and unlicensed prescribing in children ranges
from 3 to 56% of the prescriptions in community practice, and from 36
to 100% in hospital settings [12]. Ethical issues arise when deciding to
treat children with an off-label regimen, especially when it is not part of
a clinical study. Current Dutch legislation obliges the clinician to discuss
with the patient (and/or its carers) the off-label use. Also, the intended
use should be described in authorised protocols, otherwise it should be
discussed with a pharmacist. The Dutch Knowledge Centre for Paediatric
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Pharmacotherapy (NKFK) was founded in 2005 with the main goal to
develop an evidence-based paediatric formulary. At the end of 2015 over
650 drugs have been reviewed by NKFK and are now included in the Dutch
paediatric formulary. From every drug listed in the formulary, the level
and kind of evidence for the dosing advice is given (summary of product
characteristics, published literature and/or expert opinion). The Dutch
Paediatric Association (NVK), Dutch Association of Hospital Pharmacists
(NVZA) and Royal Dutch Pharmacists Association (KNMP) recognize the
Dutch paediatric formulary as professional standard. On-label and off-label
use is thus supported for the most commonly used drugs in children in the
Netherlands. It is important to evaluate safety and efficacy or efficiency
when drugs are used off-label and to report the results found, as has been
done in chapter 1 and 2 for the once-daily use of lopinavir in children.
For darunavir a once-daily regimen has been approved for a subgroup
of HIV-infected children from the age of three years, first in January 2013
by the US FDA and at the end of 2014 by the EMA. Despite its approval
for once-daily use, guidelines at the end of 2015 advised against the use of
a once-daily regimen in children < 12 years of age, because of the lack of
data with respect to efficacy, safety and exposure. An odd situation thus
exists where an expected more convenient dosing regimen is approved, but
not yet recommended by professional guidelines. To support the approved
dosing regimen, exposure was measured in the first twelve children with
the age of 6–12 years in the Netherlands who switched to the once-daily
dosing regimen as described in the summary of the product characteris-
tics. The results are described in chapter 3. Exposure was significantly
lower than predicted based on population pharmacokinetics, but found
to be adequate. These findings highlight the need to validate suggested
dosing regimes in daily practice. In chapter 4, a population pharmaco-
kinetic model of lamivudine was used to suggest a new dosing regimen
for a subgroup of children in which the target exposure (area under the
curve) is not reached with the current dosing regimen. Both noncompart-
mental analysis and population pharmacokinetic analysis can be used to
evaluate dosing regimens. However, depending on the research question to
be answered and the data available, either one or a combination of the two
methods will be more suitable to evaluate and determine a well-founded
dosing regimen.
188 Making things easier
9.3 Paediatric formulations
9.3 Paediatric formulations
9.3.1 Regulation
The lack of appropriate formulations for children and information on dosing,
efficacy and safety has been recognized by regulators already decades ago.
This resulted in new regulation to stimulate the development of paediatric
formulations in the US by the FDA and in Europe by the EMA. In Europe
the Paediatric Regulation came into force at the end of 2006 [13]. Main
objectives of the regulation are to facilitate the development and acces-
sibility of medicinal products for use in children and to make sure that
use of these products are properly investigated and authorised for children.
These goals should be achieved without subjecting children to unnecessary
trials [13]. The Paediatric Regulation covers medicinal products already
authorised and products yet to be authorised. Certain obligations and
incentives, such as extension of patent protection, were deemed neces-
sary to stimulate the development and research on medicinal products for
children. For products already off patent a paediatric use marketing autho-
risation (PUMA) can be granted, which rewards 10 years of data protection.
The pharmaceutical company has to submit a paediatric investigation plan
(PIP) to the EMA to obtain an incentive. A waiver can be granted, mainly
when the disease for which the drug is intended to be approved does not
occur in children.
In 2012, a report was published describing the achievements of the
first five years after the paediatric regulation came into force [14]. The
proportion of clinical trials in children and neonates increased, and more
information relevant for the treatment of paediatric patients became avail-
able. Twenty-six new paediatric formulations were approved. Only one
PUMA was granted. Although EMA and others count the successes on
the first years of the paediatric regulation, others debate the success, also
because of the gap between development and what is most needed to treat
children properly [15–19]. The ten-year report is expected in 2017, for which
research networks are also approached to give input in whether information
stemming from PIPs is included in treatment guidelines. Despite all the
efforts so far, there is still a lack of appropriate formulations and informa-
tion on medicines for children in daily practice. Consequently, there is an
on-going need of pharmacists and clinicians to search for a safe, effective
and acceptable treatment for paediatric patients [20].
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9.3.2 Appropriateness
As also mentioned in the introduction of this thesis, the appropriateness
of a formulation is important for the success of the treatment with drugs
in children. An important document on the appropriateness of paediatric
formulations is the EMA Reflection paper: ‘Formulations of choice for the
paediatric population’ [21]. In this report requirements for formulations are
described, considering the different stages of growth and development, and
the different routes of administration. Separately described are the age
appropriateness of dosage forms, excipients and the importance of taste,
smell and texture. Next to what is described, the environment in which
the patient has to take the drug is important, as for example intravenous
administration is usually restricted to hospital settings. Requirements for
the development of medicines for paediatric use are described in a more
recent guideline [22]. A separate chapter in this guideline describes the need
to assess patient acceptability, highlighting the importance given by regula-
tors to the acceptability of drugs for children. The Netherlands Organisa-
tion for Health Research and Development (ZonMW) has recognized the
importance of the development of an appropriate paediatric formulation of
valaciclovir resulting in 2010 in a grant within the ‘Priority Medicines for
Children’ Programme for the VALID-project. Chapter 7 and chapter 8
describe the first results of the VALID-project, which are the develop-
ment, bioequivalence assessment and palatability testing of a new paediatric
formulation of valaciclovir.
9.3.3 Liquid paediatric formulations
Liquid formulations are generally considered appropriate for children from
birth. It can be challenging to develop liquid formulations with good palata-
bility and adequate stability. Excipients have to be used for preservation,
to mask bad taste and sometimes to increase solubility. Excipients can
give adverse effects and can also influence the pharmacokinetics of (co-
administered) drugs. The STEP database is a large database collecting all
information on the Safety and Toxicity of pharmaceutical Excipients for
Paediatrics [23]. Detailed information is available of almost thirty excip-
ients. Unfortunately, no such structured information is yet available of
the influence of different excipients on the absorption of drugs. For the
new valaciclovir paediatric formulation (chapter 7 and 8), it was chosen
to develop a liquid, mainly because of the appropriateness of a liquid for
young infants, children and patients dependent on feeding tubes, and the
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possibility of flexible dosing. Moreover, most pharmacies are adequately
equipped to prepare oral liquids, but not to prepare (mini) tablet formula-
tions.
9.3.4 Solid paediatric formulations
For the antiretroviral drug lopinavir/ritonavir paediatric tablets were devel-
oped, as alternative for the unpalatable liquid formulation that has to be
refrigerated. On approval by the FDA and EMA the posology in the
product labels differed: the dose was based on body surface area only
by the EMA, while it was based on body surface area or bodyweight by
the FDA. Dosing based on bodyweight is usually considered easier than
dosing on body surface area because the latter requires the use of a mathe-
matical equation with a higher chance on miscalculations. The bodyweight
based dosing recommendations with the new paediatric tablet, as described
in the FDA label, were evaluated in a large pharmacokinetic substudy
(n = 53) of the aforementioned KONCERT study. The results are described
in chapter 6. It was shown that exposure was higher when using the
paediatric tablets, compared to children receiving the liquid formulation,
but exposure was found to be adequate. As a result of these data the
European summary of product characteristics was updated by including the
bodyweight based dosing recommendations for the paediatric tablets [9].
9.3.5 Liquid versus solid paediatric formulations
Liquid and solid formulations both have their own advantages and disad-
vantages. In general, less excipients have to be used for solid formulations
and there are also less problems with stability of the active pharmaceu-
tical ingredient. Techniques to increase stability and mask bad taste can
easier be applied to solid compared to liquid formulations. On the other
hand, easier use through feeding tubes and the possibility of flexible dosing
are advantages of liquid formulations over solid formulations. Combining
advantages of both formulations can be possible in flexible solid dosage
forms. This type of dosage form has been recommended as most suitable
for children, particularly for developing countries, by a World Health organ-
isation expert forum in 2008 [24]. Examples are (orodispersible) minitablets
and orodispersible films. Promising results have been shown for minitablets
for which there is growing evidence that they are well accepted in the
youngest children including premature infants [25–30]. Acceptability was
equal, or even better, for uncoated minitablets compared to liquid placebo
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formulations in neonates and children 0.5–6 years [27,28]. Older children in
need of a higher dose can use more minitablets. Acceptability of different
numbers of minitablets and the preferred size of the minitablets has been
investigated in 2 and 3 year old children [30]. The ability to swallow 10
minitablets with a 3 mm diameter was very high: 75% and 93% in the 2 and
3 year olds, respectively. No significant differences were observed between
the number (5 or 10) and the size (2 or 3 mm) of the minitablets.
As described in chapter 5, the pharmacokinetics of a drug can be
different when different formulations, for example a liquid instead of a
tablet, are administered. Pharmacokinetics (mainly absorption) can also
be changed when formulations are manipulated. Pharmacists should know
that they are fully responsible for the quality of a formulation when drugs
are manipulated, but also for providing information on a possible change
in exposure. Taking into account the biopharmaceutical properties of a
drug, combined with the knowledge of pharmaceutical formulations and
the function of the excipients used, (possible) differences in exposure can
be explained or predicted. One needs to be aware that exposure can be
different between formulations, and also when manipulating formulations,
especially for drugs with a low aqueous solubility (biopharmaceutical classi-
fication system, class 2 and 4). Pharmacists are equipped with the knowl-
edge of all these areas of interest. They should be able to combine the
relevant information and translate it to a comprehensible advice for clini-
cians, patients and caregivers.
9.3.6 Extrapolation of adult data to children
In chapter 7 the bioequivalence of the new paediatric valaciclovir formu-
lation compared to the brand named tablet is described. For bridging
between adult and paediatric formulations, bioequivalence studies of paedi-
atric formulations are preferably performed in healthy adults, not in
children, but only when it can be assumed that absorption will be compa-
rable in children. It can be questioned whether we already know enough
about the differences in biopharmaceutics in children compared to adults.
We have to acknowledge that the same (general) biopharmaceutical princi-
ples might not be valid in children, since they are based on adult anatomy
and physiology data. An example is lamivudine, which is classified as a
highly water-soluble drug. In adults the administered dose will completely
dissolve in the gastro-intestinal fluid. The estimated gastro-intestinal
volume for adults to determine the solubility is 250 ml. Children have
a lower gastro-intestinal volume, and although a lower dose is adminis-
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tered, the dose is non-proportionally lower. The maximum solubility of
lamivudine is approached in the youngest children. Only when the drug is
dissolved, it will be available for absorption. In vitro models need to be
developed to better predict solubility and permeability in children. Some
groups have already proposed rules to determine a paediatric biopharma-
ceutical classification system, but consensus needs to be reached before it
can be applied by regulators [31–33].
9.3.7 Acceptability of paediatric formulations
With the new EMA guideline on the development on paediatric formula-
tions coming into force, acceptability has to be shown by applicants of a
new drug formulation to be approved [22]. However, it is debatable when
a drug formulation can be considered acceptable, and how acceptability
should best be tested in children [34]. Future research is needed to deter-
mine which methods are best to test for acceptability of different formula-
tions, for different diseases and for children with different ages and stages
of development. The definition of good acceptability will depend on the
patient population, the (severity of) disease, already available alternative
treatments, and possibilities for formulating the drug. Experience with
methods to test drug acceptability in children is limited [35–38].
For the new paediatric formulation of valaciclovir taste and acceptability
were tested with an in vitro method (electronic tongue) combined with
an in vivo method. Children and one of their parents performed the in
vivo taste assessment, where the palatability score of the children was
the primary outcome. Palatability testing of paediatric formulations can
best be performed in children, because of differences in taste perception
between adults and children [21]. Taste preferences are dependent on a lot
of factors, such as age, health status, sex, environment and previous experi-
ences. Taste preferences are already different between neonates, which can
partly be explained by the food intake of the mother during the pregnancy
and breastfeeding period [39]. Next to this, genetic differences determine
for example whether humans are able to taste bitter [40]. The electronic
tongue data suggested better taste-masking properties of the new paediatric
formulation of valaciclovir, compared to the reference valaciclovir formu-
lation. Based on these results the expected number of subjects needed to
be included in the in vivo taste assessment could be more than 3.5 fold
lower. To optimize the number of paediatric subjects needed for accept-
ability testing, more experience is needed with extrapolating results from
in vitro and animal to in vivo data.
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9.4 Future perspectives
Future developments in formulating drug products will be beneficial to
optimize dosing regimens and to improve the acceptance of paediatric drug
treatment. A large and fast developing area of research is nanotechnology
in medicine (nanomedicine) [41–43]. Nanotechnology can have several aims,
such as targeting drugs more specifically to the sites affected by the disease
and increasing solubility of mainly low solubility class drugs. Solubility of
drugs is a more critical factor for children and techniques to overcome this
issue can be of high value for paediatric drug development and treatment.
Improved pharmacokinetic profiles after oral administration of nanofor-
mulations of different non-nucleotide reverse transcriptase inhibitors and
protease inhibitors have been observed in preclinical studies [44]. More
examples for the antiretroviral treatment can be found in the development
of long acting drugs [45, 46]. One specific example is the development
of an injectable formulation of a combination of two antiretroviral drugs
(rilpivirine and cabotegravir) [47]. This combination is currently investi-
gated in a clinical trial in HIV-1 infected adults, where this formulation
is injected every 4 or 8 weeks (NCT02120352). Children mostly not favor
parenteral administration, but it might be an alternative for the intake of
a poor palatable drug every day.
When the new Dutch law on medical research involving human subjects
comes into force, it is expected that more research with paediatric subjects
can be performed in the Netherlands and that participation of Dutch
research groups in international research can be strengthened. Close collab-
oration is important to be able to further optimize methodology in paedi-
atric drug research. There will always be chances to intensify and broaden
existing collaborations and to create new research networks. In case of
research on acceptability of drug formulations in children, it can be benefi-
cial when not only researchers within the field of paediatric drug research
will cooperate, but also when we reap the benefits of the expertise devel-
oped by others in different areas of (paediatric) research. Examples are the
area of research where acceptability of food products by children is inves-
tigated and the area where in vitro methods are developed. Taking into
account differences in ethical and regulatory requirements, methods can be
modified and used in paediatric drug research to optimize testing of drugs.
The number of children needed to be included in clinical trials can thus
be limited and safe and efficacious treatments can be made more timely
available for children.
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Introduction
Paediatric patients cannot simply use the same drug formulations and
dosages as adult patients. The appropriateness of a formulation is deter-
mined by the characteristics of the patient to be treated with the drug, the
specific drug and the dose to be used, and the environment in which it has
to be administered. Oral administration of drugs is generally considered
the most convenient method to administer drugs, also for children. Since
the dose might have to be changed while children grow and develop, drug
formulations with the possibility of flexible dosing are preferred. Different
aspects determine acceptability, such as food restrictions, size of tablets,
amount of drug to be taken and the palatability. It can be expected that
the lower the acceptability of the drug formulation, the more important
also the dosing frequency is.
The aim of this thesis was to investigate how pharmacotherapy with
antiviral drugs can be optimized, to ensure safe and effective treatment for
children suffering from acute and chronic viral infections.
Part 1: Dosing regimen - pharmacokinetics
Children infected with human immunodeficiency virus (HIV) require
antiviral treatment to prevent the development of acquired immune
deficiency syndrome (AIDS). With current knowledge and treatment
options, HIV-infected children can expect to have full adult life, but
with the necessity to continue treatment lifelong. The need of combi-
nation therapy combined with the need of long-term adherence puts a
challenge on the patient and its caregivers. First-line antiretroviral therapy
as recommended by the PENTA network (Paediatric European Network
for Treatment of AIDS) is a dual or triple nucleoside reverse transcrip-
tase inhibitor (NRTI)-backbone together with either a ritonavir-boosted
protease inhibitor or a non-nucleoside reverse transcriptase inhibitor
(NNRTI).
The focus of the first part of this thesis is on how to simplify or optimize
the dosing schedule of antiretroviral drugs as part of combination antiretro-
viral therapy.
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Chapter 1
In this chapter the results of KONCERT are described. KONCERT
is the acronym for “Kaletra ONCE daily Randomised Trial of the
pharmacokinetics, safety and efficacy of twice-daily versus once-daily
lopinavir/ritonavir (lopinavir/r) tablets dosed by weight as part of combi-
nation antiretroviral therapy in HIV-1 infected children (PENTA 18).”
This large international clinical trial was performed within the PENTA-
network. Children could participate when they were at least 15 kg, able
to swallow intact tablets, treated with lopinavir/r twice daily, and were
virologically suppressed for at least 24 weeks. They were randomized to
continue lopinavir/r twice daily as part of their antiretroviral regimen,
or to change to once-daily treatment. The main outcome measure was
a confirmed viral load ≥ 50 copies/ml by 48 weeks (12% non-inferiority
margin). The main outcome measures for the pharmacokinetic substudy
were the pharmacokinetic parameters of lopinavir for once-daily compared
with twice-daily dosing in the same children.
One hundred seventy-three children were randomized in the KONCERT
trial, of which 86 were randomized to switch to once-daily treatment
with lopinavir/r. The rate of virological rebound was low in both
arms: 12 children on once-daily versus 7 on twice-daily lopinavir/r had
a confirmed viral load within 48 weeks. The estimated difference in
percentage with viral load rebound was 6% [90% confidence interval (–2,
14)]. Non-inferiority for viral load suppression on once-daily versus twice-
daily lopinavir/r could therefore not be demonstrated. This difference was
partially explained by the chance imbalance between arms in viral rebound,
which occurred between screening and baseline. Among 26 children in the
intra-subject lopinavir/r pharmacokinetic substudy, lower daily exposure
(area under the plasma-concentration time curve (AUC0−24) 161 h×mg/l
vs. 224 h×mg/l) and lower Clast (1.03 mg/l vs. 5.69 mg/l) were observed
with once-daily versus twice-daily dosing. Although these results do not
support routine use of once-daily lopinavir/r, lack of safety concerns or
resistance suggests that once-daily dosing remains an option in selected,
adherent children, with close viral load monitoring.
Chapter 2
The effectiveness of the off-label use of once-daily lopinavir/r in a real-
life setting is analysed and described in chapter 2. Several studies on
the pharmacokinetics and clinical efficacy of lopinavir/r once daily in
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HIV-infected children have been published in the past decade. Despite
frequently reported subtherapeutic trough levels, most children in these
studies showed good short-term outcomes (follow up 6–12 months). Two
of the pharmacokinetic studies on lopinavir/r once daily were initiated in
the Erasmus Medical Centre in 2002. After completion of these studies,
patients on lopinavir/r once daily were allowed to continue this treatment as
long as their viral loads were undetectable. Subsequently, selected children
were also offered to switch to lopinavir/r once daily. To ensure that children
had adequate exposure to lopinavir, therapeutic drug monitoring was used.
The long-term effectiveness of the once-daily lopinavir/r-containing regimen
was evaluated in HIV-1 infected children in clinical practice. The main
outcome measures were the percentage of patients with an undetectable
HIV-1 viral load each subsequent year after switch to lopinavir/r once daily
(on treatment and last observation carried forward (LOCF)), and virolog-
ical failure during follow-up (> 400 copies/ml twice within 6 months). Also
the exposure to lopinavir on the initial once-daily dosing regimen was deter-
mined.
Forty children with a median follow-up of 6.3 years (range 1.0, 10.3)
were included. During yearly follow-up, the percentage of children with an
undetectable viral load varied between 82–100% (on treatment) and 80–
93% (LOCF). Five children (12.5%) met the criteria for failure. Lopinavir
geometric mean AUC0−24 was 169.3 h×mg/l and Clast 1.35 mg/l. It
was concluded that a once-daily lopinavir/r-containing regimen in HIV-1
infected children with intensive clinical and therapeutic drug monitoring is
well tolerated and has good long-term clinical, virological, and immunolog-
ical outcome.
Chapter 3
For HIV-infected children 3–12 years old, once-daily dosing of darunavir/r
has been approved by the European medicines agency (EMA) at the end of
2014. Dosing recommendations for children 6–12 years old are based on a
modelling and simulation procedure by the company. Despite its approval
for once-daily use, guidelines at the end of 2015 advised against the use
of a once-daily regimen in children < 12 years of age, because of the lack
of data on efficacy, safety and exposure. This pharmacokinetic study was
designed to validate the proposed dosing recommendation for once-daily
darunavir/r in HIV-infected children 6–12 years of age.
Twelve children on a stable antiretroviral regimen with a viral load < 50
copies/ml were included. A 24h pharmacokinetic curve was collected after
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observed intake. The geometric mean (%CV) AUC0−24 was 63.1 (33%)
h×mg/l, Cmax 5.6 (34%) mg/l and Clast was 1.5 (44%) mg/l. It was prede-
fined that exposure would be adequate, when the lower limit of the 90% one
sided confidence interval (90%CI) of the geometric mean of the AUC0−24
was higher than 0.8 of the value of adults (0.8×89.7 = 71.8 h×mg/l). The
lower limit of the one sided 90%CI was 55.7 h×mg/l, which is 62% of the
adult value. Therefore, the target was not reached. The geometric mean
AUC0−24 was 70% of the AUC0−24found in adults. Ten out of the 12
children had an AUC0−24below the adult target value, of which seven had
an AUC below 0.8 of the adult target value. Clast of all of the children
was above 0.55 mg/l (range: 0.69, 2.38 mg/l), which is the target for
patients treated with protease inhibitors before. The AUC of darunavir in
children 6–12 years was substantially lower than predicted by the popula-
tion pharmacokinetic model that was submitted for approval of the once-
daily dosing regimen of darunavir/r in children. Since trough levels were
above the target value, the treatment was considered adequate.
Chapter 4
Lamivudine is a nucleoside reverse transcriptase inhibitor widely used as
part of antiretroviral treatment of children. Several issues have been raised
concerning the treatment with lamivudine, such as differences in bioavail-
ability between formulations and possible under dosing in the youngest age
group. Dosing in children should be based on the understanding of the
developmental changes in the pharmacokinetic and the pharmacodynamic
relation of drugs instead of applying the adult mg/kg dose to children. The
objectives of this study were to characterise age-related changes in lamivu-
dine pharmacokinetics in children and to test how well this model can be
generalized.
Based on the developed population pharmacokinetic model, lamivudine
exposure upon currently used dosing recommendations was evaluated and
a new dose was calculated for subgroups in which the target AUC0−24
was not reached. Bodyweight best predicted the developmental changes in
apparent clearance and volume of distribution of lamivudine. For children
with a bodyweight below 14 kg, the dose should be increased from 8 to 10
mg/kg/day if the adult target for AUC0−24 is aimed for.
202 Making things easier
Part 2: Paediatric formulations
Part 2: Paediatric formulations
Chapters 5 and 6
A multitude of antiretroviral drug formulations is available for the treat-
ment of HIV-infected adults and children. These formulations include
individual and co-formulated drugs, many of which are also supplied as
generic drugs. It is important to know whether a different type of formu-
lation such as a tablet and a liquid, or a new generic drug formulation
provides similar exposure compared to the innovator product. The rate
and extent of absorption from the gastrointestinal tract can be influenced
by the dissolution rate, solubility and permeability of the drug. Many
physiological factors are also important for absorption. A drug must be
dissolved before it can be absorbed. Physicochemical characteristics deter-
mine the solubility and permeability of a drug. The biopharmaceutics
classification system is used by regulators to determine whether in vivo
bioequivalence studies are necessary for the approval of new generic drug
products of solid immediate release dosage forms. According to this system,
the active pharmaceutical ingredient of a formulation can be classified into
one of four categories depending on its aqueous solubility and intestinal
permeability. Theoretically, it is expected that the influence of the formu-
lation on pharmacokinetics will be largest for drugs with low solubility.
Many antiretroviral drugs have a poor bioavailability and a low aqueous
solubility.
A review of studies assessing the pharmacokinetics of different antiretro-
viral drug formulations in adults and children is described in chapter 5.
For some antiretroviral drugs, differences in pharmacokinetics have been
described, with largest differences in exposure when a liquid formulation
is compared to a solid formulation (tablet or capsule). It is important to
realize that children sometimes use different formulations than adults.
If no appropriate formulations are available, existing formulations are
sometimes manipulated, for example tablets are cut or split to achieve a
different dose, and sometimes also crushed to ease administration. Devia-
tions from the optimal dose can occur when splitting or crushing tablets,
which can significantly impact drug efficacy and toxicity. Only a few studies
were found in which the effect of manipulating solid formulations was inves-
tigated. It is important to know whether exposure is still adequate. This is
relevant for children, but also for HIV-infected patients who (temporarily)
are not able to swallow solid drug formulations. Given the increasing
number of new formulations and drug combinations it is important to be
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aware that the formulation and excipients can significantly influence the
pharmacokinetics of antiretroviral drugs.
The results of the study investigating the pharmacokinetics of a new
paediatric tablet of lopinavir combined with ritonavir are described in
chapter 6. Lopinavir/r paediatric tablets (100 mg lopinavir and 25 mg
ritonavir) are approved by the US food and drug administration (FDA) and
EMA as part of combination antiretroviral therapy for children. However,
at time of start of the KONCERT trial, dosing was based on body weight
bands or body surface area under FDA approval, and only body surface
area by the EMA. This could lead to a different recommended dose. Also,
weight band based dosing was not yet formally studied in the target popula-
tion. The pharmacokinetics of lopinavir in children who used the paediatric
tablets twice daily was therefore studied in the first phase of the KONCERT
trial. The first children who consented were selected to participate in a
pharmacokinetic substudy, until a minimum of 16 children in each of three
dosing weight bands had evaluable pharmacokinetic data.
A total of 53 HIV-infected children were included. For the total group,
lopinavir geometric mean AUC0−12, Cmax and C12 were 106.9 h×mg/l,
12.0 mg/l and 4.9 mg/l, respectively. There were no significant differ-
ences in lopinavir pharmacokinetic parameters between the weight bands.
Weight was not found to be associated with variability in Cmax, C12 or
AUC0−12 for the lopinavir pharmacokinetic parameters. Given the high
percentage of Asian children, it was also tested whether there was a differ-
ence in pharmacokinetic parameters between Asian and non-Asian children.
Significant influence of ethnicity was found on CL/F, with Asian children
having on average a 21% higher CL/F than non-Asian children. Despite
the significantly higher CL/F in Asian children there was no significant
difference in AUC0−12, which can be partly explained by the relatively
higher dose in the Asian children on a mg/kg basis. A possible explana-
tion for these observations could also be a difference in diet and more Asian
children taking their medication under fasting conditions. Despite potential
ethnic influences on lopinavir pharmacokinetics, exposure in all subgroups
was adequate. In conclusion, the FDA weight band dosing recommenda-
tions provide adequate exposure in HIV-infected children when using the
paediatric lopinavir/r tablets
Chapters 7 and 8
The final two chapters focus on the development of a new paediatric formu-
lation of the antiviral drug valaciclovir. Valaciclovir is an oral prodrug of
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aciclovir and is used for the treatment and prophylaxis of herpes simplex
virus and varicella zoster virus infections. It is approved by the EMA
to be used in children from the age of 12 years and above, but it is
also used (off-label) in younger children. No appropriate formulation is
available for young children. The extemporaneous formulation made from
crushed tablets as described in the FDA label information was considered
suboptimal. To overcome problems associated with that formulation, we
aimed to develop a new paediatric formulation, and to assess the bioequiv-
alence of this new formulation compared with the innovator valaciclovir
tablets and to investigate its palatability. For the palatability assess-
ment, both in vivo (children and parents) and in vitro (electronic tongue)
methods were applied. These studies were performed within the so-called
VALID-project, which has been granted by The Netherlands Organisa-
tion for Health Research and Development (ZonMW), within the ‘Priority
Medicines for Children’ Programme.
A 20 mg/ml valaciclovir solution was developed with glycerol and water
as main excipients. Stability of valaciclovir in this formulation has been
shown for at least nine months. Stability of other formulations with a
higher concentration and different excipients did not meet the stability
requirements. An electronic tongue was applied during the formulation
development and to support the in vivo palatability testing. The taste
masking capability of the new formulation was compared with crushed
tablets in OraSweetr SF as suspension vehicle. Both formulations demon-
strated taste-masking efficiency. In vivo palatability was assessed during a
two-period cross-over study in 21 children aged 4–11 years and 20 parents.
The taste of each formulation was scored on a combined 100 mm visual
analogue (VAS)/facial hedonic scale. The primary outcome was the differ-
ence between the VAS scores of the test and the reference formulation as
rated by the children. For the children, mean (95%CI) VAS scores were 26
mm (18, 34) for the test formulation and 24 mm (16, 32) for the reference
formulation with a mean (95%CI) difference of 2.4 (–8.5, 13) mm, in favour
of the test formulation. The mean (95%CI) VAS scores indicated by the
parents (n = 20) were 45 (36, 54) mm for the test formulation and 46 (37,
55) mm for the reference formulation, and a mean difference (95%CI) of
–0.9 (–12, 9.8) mm. Predefined was that non-inferiority was shown when
the lower limit of the two-sided 95%CI for the difference in VAS scores of
the formulations given by the children was above –10 mm. Non-inferiority
of the test compared with the reference formulation was therefore shown.
The bioequivalence of the new paediatric valaciclovir liquid formulation
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was investigated in healthy adult volunteers. The pharmacokinetics of
aciclovir was determined in 16 fasting volunteers after administration of
a single dose of 500 mg of the new valaciclovir formulation and of the
innovator valaciclovir tablet. The new valaciclovir formulation met the
criteria for bioequivalence regarding the AUC0−12. The upper limit of the
90%CI of the ratio for the maximum plasma concentration was 133%, which
is just above the 125% criterion.
The results of the VALID-project support the use of the newly devel-
oped valaciclovir formulation as an alternative formulation for (paediatric)
patients for whom valaciclovir tablets are not or less appropriate.
Discussion
Treatment options for children are often limited because of the lack of
evidence on safe and effective dosing regimens, and the availability of appro-
priate formulations. There are several ways to collect more information on
the appropriate use of medicines in paediatrics. Two studies in this thesis, a
clinical trial and an observational cohort study, were performed to support
once-daily use of lopinavir. Regulatory and practical issues are described of
performing clinical trials in children compared to use of data from a real-life
setting as an alternative approach to collect information. Although done
with caution, a comparison of the results from both studies supports the
use of real-life research as possible valuable alternative for the performance
of a clinical trial.
It is important to evaluate safety and efficacy or efficiency when drugs
are used off-label and to report the results found, as has been done in
chapters 1 and 2 for the once-daily use of lopinavir/r in children. However,
after approval, further research is sometimes needed to support the use of
a drug, or to optimize dosing recommendations for all potential users.
The lack of appropriate formulations for children and information on
dosing, efficacy and safety has been recognized by regulators already
decades ago and resulted in new regulation to stimulate the development
of paediatric formulations. Despite all efforts, there is still a lack of appro-
priate formulations and information on medicines for children in daily
practice. Consequently, there is an on-going need of pharmacists and clini-
cians to search for safe, effective and acceptable treatments for paediatric
patients. When administering alternative formulations or manipulating
formulations attention is warranted. Taking into account the biopharma-
ceutical properties of a drug, combined with the knowledge of pharma-
ceutical formulations and the function of the excipients used, (possible)
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differences in exposure can be explained or predicted. Pharmacists are
equipped with the knowledge of these areas of interest and should be able
to combine the relevant information and translate it to a comprehensible
advice for patients and caregivers.
A more recent guideline of the EMA describes requirements for the devel-
opment of medicines for paediatric use, also with regard to patient accept-
ability. It is debatable when a drug formulation can be considered accept-
able, and how acceptability should best be tested in children. Combining
expertise from different areas of (paediatric) research while taking into
account differences in ethical and regulatory requirements, methods can be
modified and used in paediatric drug research to optimize testing of drugs.
The number of children needed to be included in clinical trials can thus
be limited and safe and efficacious treatments can be made more timely
available for children.
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Inleiding
Kinderen kunnen niet simpelweg dezelfde geneesmiddelformuleringen en
doseringen gebruiken als volwassenen. Of een formulering geschikt is
hangt af van de patie¨nt die behandeld moet worden met geneesmid-
delen, het geneesmiddel zelf en de dosering die moet worden toegediend,
alsook de omgeving waarin de toediening plaatsvindt. Orale toediening
van geneesmiddelen wordt in het algemeen als de meest geschikte manier
van toedienen beschouwd, ook voor kinderen. Geneesmiddelformuleringen
waarmee flexibel doseren mogelijk is hebben de voorkeur, omdat door
de groei en ontwikkeling van kinderen regelmatig een aanpassing van
de dosering nodig is. Verschillende aspecten bepalen in hoeverre een
geneesmiddelformulering acceptabel is, zoals het al dan niet in moeten
nemen met voedsel, de grootte van de tablet, de hoeveelheid en het aantal
tabletten dat ingenomen moet worden, alsook de smaak. Het kan worden
verwacht dat hoe minder acceptabel een formulering is, hoe belangrijker de
doseerfrequentie is.
Het doel van dit proefschrift was om te onderzoeken hoe de behandeling
van kinderen met geneesmiddelen kan worden geoptimaliseerd, om zo zorg
te dragen voor een veilige en effectieve behandeling van kinderen met acute
of chronische virusinfecties.
Deel 1: Doseerregime – farmacokinetiek
Kinderen die ge¨ınfecteerd zijn met het humaan immunodeficie¨ntie
virus (hiv) worden behandeld met antiretrovirale geneesmiddelen om te
voorkomen dat zij het verworven immunodeficie¨ntiesyndroom (AIDS)
ontwikkelen. Met de huidige kennis en behandelmogelijkheden hebben
hiv-ge¨ınfecteerde kinderen een normale levensverwachting, maar wel met de
noodzaak de anti-hiv-behandeling de rest van hun leven vol te houden. De
levenslange behandeling gecombineerd met het belang van therapietrouw is
een uitdaging voor patie¨nten en zorgverleners. De eerstelijns behandeling
van een hiv-infectie, zoals geadviseerd door PENTA (Paediatric European
Network for Treatment of AIDS), bestaat uit twee of drie zogenaamde
nucleoside reverse transcriptase remmers (NRTI) als basis, gecombineerd
met of een proteaseremmer met ritonavir of een non-nucleoside reverse
transcriptase remmer (NNRTI).
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Het eerste deel van dit proefschrift richt zich op hoe we de dosering van
antiretrovirale middelen kunnen vereenvoudigen en optimaliseren.
Hoofdstuk 1
In dit hoofdstuk worden de resultaten van de studie met de naam
KONCERT besproken. KONCERT is het acroniem voor ‘Kaletra ONCE
daily Randomised Trial of the pharmacokinetics, safety and efficacy of
twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight
as part of combination antiretroviral therapy in HIV-1 infected children
(PENTA 18).’ In deze studie werd gekeken naar de farmacokinetiek,
veiligheid en effectiviteit van eenmaal daags lopinavir met ritonavir
(lopinavir/r), in vergelijking met het gebruik van deze middelen tweemaal
daags bij hiv-ge¨ınfecteerde kinderen. Deze grote en internationale studie
werd uitgevoerd door het PENTA-netwerk. Kinderen konden meedoen
met de studie als ze minimaal 15 kg wogen, tabletten in zijn geheel door
konden slikken, behandeld werden met tweemaal daags lopinavir/r en
als er geen virusdeeltjes meetbaar waren in het bloed voor minimaal 24
weken. De kinderen werden gerandomiseerd om door te gaan met hun
tweemaal daagse behandeling of om lopinavir/r eenmaal daags te gaan
gebruiken. Het belangrijkste waar naar werd gekeken was of het virus
te meten was in het bloed (> 50 virusdeeltjes/ml) gedurende 48 weken. De
marge om noninferioriteit aan te tonen was vooraf vastgesteld op 12%. De
belangrijkste uitkomstmaten voor de farmacokinetische substudie waren de
farmacokinetische parameters van lopinavir na eenmaal daagse toediening
in vergelijking met tweemaal daagse toediening bij dezelfde kinderen.
In totaal deden 173 kinderen mee met de studie, verdeeld over de twee
behandelgroepen, waarvan 86 in de groep voor eenmaal daagse behan-
deling met lopinavir/r. Er waren maar weinig kinderen bij wie virusdeeltjes
meetbaar waren in het bloed gedurende de studie: 12 kinderen (14%) in de
eenmaal daagse groep en 7 (8%) in de tweemaal daagse groep. Het verschil
in percentage van kinderen bij wie virusdeeltjes meetbaar waren was 6%
met een 90% betrouwbaarheidsinterval (90%BI) van –2 tot 14%. Noninfe-
rioriteit van eenmaal daags in vergelijking met tweemaal daags lopinavir/r
kon daarmee formeel niet aangetoond worden. Het verschil in percentages
kon gedeeltelijk worden verklaard doordat bij de start van de studiebe-
handeling bij een aantal kinderen in de eenmaal daagse groep virusdeeltjes
meetbaar waren. Van 26 kinderen die meededen aan de farmacokinetische
substudie werden de farmacokinetische parameters vergeleken na eenmaal
daags en na tweemaal daags lopinavir/r; dit waren met name de opper-
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Hoofdstuk 2
vlakte onder de plasmaconcentratie-tijd-curve (AUC) en de laatst gemeten
plasmaconcentratie in het doseerinterval (dalspiegel, Clast). Na eenmaal
daagse toediening was de blootstelling lager dan na tweemaal daagse toedie-
ning (AUC0−24 161 uur×mg/l vs. 224 uur×mg/l) en Clast (1,03 mg/l
vs. 5,69 mg/l). Met de resultaten van deze studie kan eenmaal daags
lopinavir/r bij kinderen niet standaard geadviseerd worden. Echter, omdat
er geen problemen met veiligheid en resistentie werden gezien suggereert dit
dat eenmaal daags een optie zou kunnen zijn voor geselecteerde kinderen
waarvan verwacht wordt dat ze therapietrouw zijn en bij wie de behandel-
uitkomst goed vervolgd wordt.
Hoofdstuk 2
De effectiviteit van de off-label behandeling met eenmaal daags lopinavir/r
in de praktijk wordt beschreven in hoofdstuk 2. Er zijn in de laatste
decennia verschillende onderzoeken naar de farmacokinetiek en klinische
effectiviteit van eenmaal daags lopinavr/r in hiv-ge¨ınfecteerde kinderen
gepubliceerd. Ondanks dat er in deze studies regelmatig subtherapeutische
dalspiegels werden gemeten, werden op korte termijn (6–12 maanden) goede
behandeluitkomsten gezien. Twee van de farmacokinetische studies werden
uitgevoerd in het Erasmus medisch centrum (Rotterdam) in 2002. Na
afloop van de studie mochten kinderen die met eenmaal daags lopinavir/r
werden behandeld dit regime voortzetten, zolang er geen virusdeeltjes
meetbaar waren in het bloed. Vervolgens werd een aantal geselecteerde
kinderen aangeboden om ook lopinavir/r eenmaal daags te gaan gebruiken.
Om te controleren of de blootstelling aan lopinavir voldoende was, werden
regelmatig de concentratie van lopinavir in het bloed gemeten. De lange-
termijn effectiviteit van de behandeling in de dagelijkse praktijk bij deze
kinderen werd gee¨valueerd. De belangrijkste uitkomstmaten waren het
percentage kinderen waarbij geen virusdeeltjes meetbaar waren in het bloed
elk jaar na start met het eenmaal daags regime en gedurende elk controle
bezoek. Tevens werd de blootstelling aan lopinavir gemeten direct na start
van het eenmaal daagse regime.
Veertig kinderen deden mee aan de studie, waarbij de mediane opvolg-
duur 6,3 jaar was, uiteenlopend van 1,0 tot 10,3 jaar. Bij de jaarlijkse
controle waren geen virusdeeltjes meetbaar bij 82–100% van de kinderen die
nog eenmaal daags lopinavir/r gebruikten. De farmacokinetische parame-
ters van lopinavir waren een geometrisch gemiddelde AUC0−24 van 169,3
uur×mg/l en een Clast van 1,35 mg/l. De conclusie van deze studie was
dat eenmaal daags lopinavr/r als onderdeel van antiretrovirale behandeling
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van hiv-ge¨ınfecteerde kinderen die intensief gevolgd worden, goed verdragen
wordt en goede langetermijn behandelresultaten geeft.
Hoofdstuk 3
Voor hiv-ge¨ınfecteerde kinderen van 3–12 jaar oud is het eenmaal daags
gebruik van darunavir met ritonavir (darunavir/r) eind 2014 geregistreerd
door het Europees geneesmiddelen agentschap (EMA). De doseeradviezen
voor kinderen 6–12 jaar zijn door de farmaceutische industrie gebaseerd op
extrapolatie van farmacokinetische gegevens met behulp van een farmaco-
kinetisch populatiemodel. Ondanks dat het eenmaal daagse doseerregime is
geregistreerd werd het voor kinderen jonger dan 12 jaar eind 2015 nog niet
geadviseerd in de diverse richtlijnen. De reden hiervoor was het ontbreken
van gegevens over effectiviteit, veiligheid en blootstelling. Deze farmaco-
kinetische studie had als doel om de geregistreerde doseeradviezen voor
eenmaal daags darunavir/r te valideren bij hiv-ge¨ınfecteerde kinderen van
6 tot 12 jaar. Twaalf kinderen waarbij geen virusdeeltjes in het bloed
meetbaar waren konden meedoen met de studie. Na inname van hun
medicatie in het ziekenhuis werd verspreid over 24 uur bloed afgenomen
om de concentratie darunavir in het bloed te meten.
De gemiddelde (%CV) AUC0−24 was 64,2 (34%) uur×mg/l, Cmax 5,7
(35%) mg/l en Clast was 1,5 (46%) mg/l. Vooraf was bepaald dat de bloot-
stelling adequaat zou zijn als de ondergrens van het 90%BI van de gemid-
delde AUC0−24 boven 80% van de gemiddelde waarde bij volwassenen zou
liggen (0,8×89,7 = 71,8 uur×mg/l). De ondergrens was 56,0 uur×mg/l,
wat 62% is van de gemiddelde waarde bij volwassenen. De streefwaarde
voor blootstelling (AUC) werd dus niet gehaald. De gemiddelde AUC0−24
was 72% van de gemiddelde waarde bij volwassenen. Negen van de 11
kinderen hadden een AUC0−24 die onder dit gemiddelde lag, en zeven
kinderen hadden een AUC0−24 lager dan 80% van de gemiddelde waarde bij
volwassenen. De gemeten Clast van alle kinderen was boven 0,55 mg/l, wat
de streefwaarde is voor hiv-ge¨ınfecteerde patie¨nten die reeds eerder behan-
deld zijn met proteaseremmers. De blootstelling aan darunavir, gemeten als
AUC, bij kinderen van 6 tot 12 jaar was aanzienlijk lager dan voorspeld was
met behulp van het farmacokinetisch populatiemodel, zoals dat overlegd is
voor de registratie van het eenmaal daagse doseerregime voor kinderen.
Aangezien de dalspiegels wel boven de streefwaarde waren, werd de behan-
deling toch als adequaat beschouwd.
212 Making things easier
Hoofdstuk 4
Hoofdstuk 4
Lamivudine is een nucleoside reverse transcriptase remmer (NRTI) die veel
wordt toegepast bij de antiretrovirale behandeling van kinderen. Over
sommige punten is discussie bij de behandeling met lamivudine, zoals
verschillen in biologische beschikbaarheid tussen formuleringen en een
mogelijk te lage dosering bij jonge kinderen. Doseringen voor kinderen
zouden gebaseerd moeten worden op kennis en begrip van de ontwikkeling
in farmacokinetiek en farmacodynamiek bij kinderen van het geneesmiddel.
Het doel van deze studie was om leeftijdsgebonden veranderingen in de
farmacokinetiek van lamivudine te beschrijven in een populatiemodel en
te testen of dit populatiemodel voor andere groepen kinderen kon worden
gebruikt. Met behulp van het berekende populatiemodel werd gekeken of
met de momenteel toegepaste dosering bij alle groepen kinderen een goede
blootstelling te verwachten is.
Het lichaamsgewicht was een belangrijke factor om veranderingen in de
farmacokinetische parameters klaring en verdelingsvolume te voorspellen.
Voor kinderen met een lichaamsgewicht onder de 14 kg werd de streefwaarde
voor de blootstelling (AUC) niet gehaald. Op basis van het model wordt
voorgesteld om de dosering voor deze groep kinderen te verhogen van 8
naar 10 mg/kg.
Deel 2: Kinderformuleringen
Hoofdstukken 5 en 6
Er zijn vele antiretrovirale geneesmiddelformuleringen beschikbaar voor de
behandeling van hiv-ge¨ınfecteerde kinderen en volwassenen. Dit zijn formu-
leringen met maar e´e´n geneesmiddel of een combinatie van verschillende
geneesmiddelen, waaronder ook merkloze formuleringen. Het is belangrijk
om te weten of verschillende formuleringen, zoals een drank en een tablet, of
een merkloos geneesmiddel en het oorspronkelijke geneesmiddel (specialite´),
dezelfde blootstelling geven. De mate en snelheid van opname vanuit
het maagdarmkanaal wordt be¨ınvloed door onder andere de oplossnelheid,
oplosbaarheid en permeabiliteit van het geneesmiddel. Diverse fysiologische
factoren zijn ook belangrijk voor opname van een geneesmiddel. Voordat
een geneesmiddel kan worden opgenomen in het lichaam moet het opgelost
zijn. Fysisch-chemische eigenschappen bepalen de oplosbaarheid en perme-
abiliteit van het geneesmiddel. Volgens het biofarmaceutisch classificering
systeem wordt een geneesmiddel ingedeeld in e´e´n van vier categoriee¨n
afhankelijk van de oplosbaarheid in water en de permeabiliteit. Theoretisch
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kan worden verwacht dat de invloed van de formulering op de farmaco-
kinetiek het grootste is bij geneesmiddelen met een slechte oplosbaarheid.
Veel antiretrovirale middelen hebben een lage biologische beschikbaarheid
en een slechte oplosbaarheid in water.
Een overzicht van studies waarbij is gekeken naar het verschil in
farmacokinetiek van geneesmiddelen in verschillende formuleringen wordt
beschreven in hoofdstuk 5. Voor een aantal antiretrovirale geneesmid-
delen worden verschillen in farmacokinetiek beschreven, waarbij de grootste
verschillen worden gevonden wanneer vloeibare en vaste (tablet, capsule)
formuleringen worden vergeleken. Het is belangrijk om te realiseren dat
kinderen soms andere formuleringen gebruiken dan volwassenen.
Wanneer er geen geschikte formulering beschikbaar is, worden bestaande
formuleringen soms gemanipuleerd. Tabletten worden bijvoorbeeld gedeeld
of verpulverd om de juiste dosering te krijgen of om de toediening te verge-
makkelijken. Afwijkingen van de juiste dosering kunnen optreden wanneer
tabletten gedeeld of verpulverd worden; ook kan dit invloed hebben op de
effectiviteit en toxiciteit. Slechts enkele studies werden gevonden waarbij
het effect van het manipuleren van vaste formuleringen was onderzocht. Het
is belangrijk om te weten of the blootstelling nog steeds adequaat is. Dit
is van belang voor hiv-ge¨ınfecteerde kinderen, maar ook voor volwassen
die (tijdelijk) niet goed in staat zijn om vaste toedieningsvormen in te
nemen. Gezien het toenemende aantal nieuwe formuleringen en combi-
naties van geneesmiddelen is het belangrijk om bewust te zijn van het feit
dat de formulering en hulpstoffen de farmacokinetiek van antiretrovirale
geneesmiddelen significant kunnen be¨ınvloeden.
De resultaten van de studie waarin de farmacokinetiek van een nieuwe
tablet voor kinderen met lopinavir en ritonavir werd onderzocht, wordt
beschreven in hoofdstuk 6. De lopinavir/r kindertabletten (100 mg
lopinavir en 25 mg ritonavir) zijn goedgekeurd door de Amerikaanse regis-
tratie autoriteit (FDA) en EMA als onderdeel van een behandeling van hiv-
ge¨ınfecteerde kinderen. Op het moment van start van de KONCERT studie
was de dosering zoals goedgekeurd door de FDA gebaseerd op lichaams-
gewicht of lichaamsoppervlakte en door de EMA alleen op lichaamsopper-
vlakte. Dit kan leiden tot verschillen in doseren. Verder was de op lichaams-
gewicht gebaseerde dosering nog niet onderzocht in de doelgroep. De eerste
kinderen die meededen aan de KONCERT studie, werden geselecteerd om
deel te nemen aan een farmacokinetische substudie waarin deze dosering
onderzocht werd.
In totaal deden 53 kinderen mee aan deze studie. Voor de totale
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groep werden de volgende geometrisch gemiddelde waarden gevonden voor
respectievelijk de AUC0−12, Cmax en C12: 106,9 uur×mg/l, 12,0 mg/l en
4,9 mg/l. Er werden geen significante verschillen in farmacokinetische para-
meters gevonden tussen de verschillende gewichtscategoriee¨n. Er was geen
relatie tussen het lichaamsgewicht en variatie in Cmax, C12 of AUC0−12.
Gezien het hoge percentage aan Aziatische kinderen dat meedeed, werd
ook gekeken of er verschillen waren in de farmacokinetische parameters
tussen Aziatische en niet Aziatische kinderen. Een significant verschil werd
gevonden voor de klaring (CL/F), waarbij Aziatische kinderen gemiddeld
een 21% hogere klaring hadden dan niet Aziatische kinderen. Ondanks
de hogere klaring werd geen verschil gevonden in de AUC0−24, wat deels
kan worden verklaard door de relatief hogere dosering die de Aziatiche
kinderen kregen. Een mogelijke verklaring kan verder het verschil in dieet
zijn en het feit dat meer Aziatische kinderen de medicatie op nuchtere
maag innamen. Ondanks mogelijke invloeden van de etniciteit, was de
blootstelling aan lopinavir in alle subgroepen adequaat. Uit deze resul-
taten kan geconcludeerd worden dat met de op lichaamsgewicht gebaseerde
doseringen een adequate blootstelling wordt bereikt bij hiv-ge¨ınfecteerde
kinderen die de lopinavir/r kindertabletten gebruiken.
Hoofdstukken 7 en 8
De laatste twee hoofdstukken beschrijven de ontwikkeling van een nieuwe
kinderformulering van het antivirale middel valaciclovir. Valaciclovir wordt
in het lichaam omgezet in de werkzame stof aciclovir en wordt gebruikt
voor de behandeling en profylaxe van infecties met het herpes simplex
virus en varicella zoster virus. Het is geregistreerd door de EMA voor
gebruik bij kinderen vanaf 12 jaar, maar wordt ook (off-label) toegepast
bij jongere kinderen. De magistrale bereiding vanuit verpulverde tabletten,
zoals beschreven in de FDA bijsluiter, wordt gezien als suboptimale formu-
lering. Om problemen met die formulering te vermijden werd een nieuwe
kinderformulering ontwikkeld. Hiervan werd de bioequivalentie onderzocht
in vergelijking met tabletten en werd gekeken naar de smaak. Voor de
smaaktesten werd gebruik gemaakt van zowel in vivo (kinderen en hun
ouders) als in vitro (elektronische tong) methoden. De onderzoeken werden
uitgevoerd binnen het zogenaamde ‘VALID-project’ waarvoor een subsidie
van de Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie
(ZonMW) werd toegekend binnen het programma ‘Priority Medicines for
Children.’
Een oplossing met 20 mg/ml werd ontwikkeld met glycerol en water als
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belangrijkste hulpstoffen. De stabiliteit van valaciclovir in deze formulering
werd aangetoond voor minimaal 9 maanden. Gedurende de ontwikkelfase
en ter ondersteuning van de in vivo smaaktesten werd gebruik gemaakt van
een elektronische tong. De mate van smaakmaskering van de nieuwe formu-
lering werd vergeleken met die van verpulverde tabletten in OraSweetr SF
als referentie formulering. Beide formuleringen maskeerden gedeeltelijk de
smaak van valaciclovir. De in vivo smaaktesten werden uitgevoerd door
middel van een cross-over studie met twee perioden. Eenentwintig kinderen
in de leeftijd van 4 tot 12 jaar en 20 ouders deden mee aan de smaaktest.
Hoe lekker of hoe vies ze elke formulering vonden werd aangegeven op
een gecombineerde visueel analoge-gezichtjes schaal (VAS) van 100 mm.
De belangrijkste uitkomstmaat was het verschil in VAS scores tussen de
nieuwe en referentie formulering, zoals aangegeven door de kinderen. De
kinderen gaven een gemiddelde (95%BI) VAS score van 26 mm (18, 34) aan
de nieuwe formulering en 24 mm (16, 32) aan de referentie formulering met
een gemiddeld (95%BI) verschil van 2.4 (–8,5, 13) mm, ten gunste van de
nieuwe formulering. De ouders gaven een gemiddelde (95%BI) VAS score
van 45 (36, 54) mm aan de nieuwe formulering en 46 (37, 55) mm voor de
referentie formulering met een gemiddelde (95%CI) verschil van –0,9 (–12,
9,8) mm). Vooraf was vastgesteld dat noninferioriteit kon worden aange-
toond wanneer de ondergrens van het 95%BI van het verschil in VAS scores
aangegeven door de kinderen boven de –10 zou liggen. Met de gevonden
resultaten kon daarom noninferioriteit van de nieuwe formulering in verge-
lijking met de referentie formulering worden aangetoond.
De bioequivalentie van de nieuwe vloeibare kinderformulering van valaci-
clovir werd onderzocht in gezonde volwassen vrijwilligers. De farmaco-
kinetiek van aciclovir werd bepaald bij 16 vrijwilligers die 500 mg van de
nieuwe valaciclovir formulering en van de merktabletten nuchter innamen.
De nieuwe formulering voldeed aan de bioequivalentie criteria voor wat
betreft de AUC0−12. De bovengrens van het 90%BI van de ratio van
de maximale plasma concentraties was 133%, welke net boven het 125%
criterium ligt.
De resultaten van het VALID-project ondersteunen de toepassing van
de nieuw ontwikkelde valaciclovir formulering als alternatieve formulering
voor (pediatrische) patie¨nten voor wie valaciclovir tabletten minder of niet
geschikt zijn.
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Behandelopties voor kinderen worden vaak beperkt door een gebrek aan
informatie over veilige en effectieve doseerregimes en de beperkte beschik-
baarheid van geschikte formuleringen. Op verschillende manieren kunnen
gegevens verzameld worden voor een betere toepassing van geneesmid-
delen bij kinderen. Twee studies in dit proefschrift, een klinisch onderzoek
en een observationeel cohort onderzoek, werden uitgevoerd om eenmaal
daags gebruik van lopinavir/r te onderzoeken. Regulatorische en praktische
aspecten worden besproken die bij de uitvoer van deze twee typen onder-
zoek van belang zijn. Wanneer, met enige voorzichtigheid, de resul-
taten van beide studies worden vergeleken, kan worden gesteld dat studies
waarin gebruik wordt gemaakt van gegevens uit de dagelijkse praktijk een
waardevol alternatief kunnen zijn voor de uitvoer van een klinische studie.
Het is belangrijk om de veiligheid en effectiviteit te bewaken
wanneer geneesmiddelen off-label worden toegepast en om uitkomsten te
rapporteren, zoals is gedaan in hoofdstuk 1 en 2, voor het gebruik van
eenmaal daags lopinavir/r bij kinderen. Echter, ook na registratie is verder
onderzoek soms nodig om beter gebruik van geneesmiddelen te onder-
steunen voor alle (potentie¨le) gebruikers.
Het gebrek aan geschikte formuleringen voor kinderen en informatie
over de juiste dosering, effectiviteit en veiligheid is decennia geleden reeds
erkend door de registratie autoriteiten. Dit heeft geleid tot nieuwe regel-
geving om de ontwikkeling van kinderformuleringen te stimuleren. Ondanks
alle ontwikkelingen is er momenteel nog steeds een gebrek aan geschikte
formuleringen en informatie over geneesmiddelen voor kinderen. Het is
daarom nog regelmatig nodig dat door apothekers en dokters gezocht
moet worden naar een veilige, effectieve en acceptabele behandeling voor
kinderen. Bij het toedienen van alternatieve formuleringen of het mani-
puleren van formuleringen is oplettendheid geboden. Door de kennis van de
biofarmaceutische eigenschappen van een geneesmiddel te combineren met
de kennis van farmaceutische formuleringen en de functie van hulpstoffen,
kunnen (mogelijke) verschillen in absorptie worden verklaard of voorspeld.
Apothekers hebben kennis van deze gebieden en zouden de relevante infor-
matie moeten kunnen combineren en vertalen in een begrijpelijk advies
voor patie¨nten en zorgverleners.
Een recente EMA-richtlijn beschrijft de eisen voor de ontwikkeling van
geneesmiddelen voor kinderen, waarin ook aandacht is voor acceptatie.
Wanneer een formulering acceptabel is, is onderwerp van discussie, als ook
hoe dit het beste getest zou moeten worden bij kinderen. Door exper-
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tise te combineren vanuit verschillende (pediatrische) onderzoeksgebieden
en rekening te houden met de ethische en regulatorische eisen, kunnen
methoden aangepast en gebruikt worden om zo studies voor en bij kinderen
te optimaliseren. Het aantal kinderen dat benodigd is voor medisch weten-
schappelijk onderzoek kan zo beperkt worden en mede daardoor kunnen
veilige en effectieve behandelingen eerder beschikbaar zijn voor kinderen.
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Acronym Explanation
3TC Lamivudine
ABC Abacavir
AIDS Acquired immune deficiency syndrome
ANOVA Analysis of variance
ANRS Agence nationale de recherches sur le sida et les he´patites
virales
ARIEL Darunavir/ritonavir in treatment-experienced pediatric
patients aged 3 to < 6 years
ARROW Anti-retroviral research for Watoto
ART Antiretroviral therapy
ARV Antiretroviral
AUC Area under the plasma concentration time curve
AZT Zidovudine
b.i.d. Twice daily (bis in die)
BCS Biopharmaceutics classification system
BDDCS Biopharmaceutics drug disposition classification system
BSA Body surface area
BW Bodyweight
cART Combination antiretroviral therapy
CCMO Centrale commisie mensgebonden onderzoek
CD(4/8) Cluster of differentation (4/8), subtype of white blood cells
CDC Centers for disease control and prevention
CHAPAS Children with HIV in Africa – Pharmacokinetics and
Adherence of Simple antiretroviral regimens
CI Confidence interval
CL Clearance
Clast Last observed plasma concentration
Cmax Maximum plasma concentration
CMO-an Commisie mensgebonden onderzoek Arnhem-Nijmegen
cov Covariate
CV Variation coefficient
CYP Cytochrome
D Absorption phase
d4T Stavudine
Darunavir/r Darunavir boosted with ritonavir
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DIONE Darunavir/ritonavir once daily in treatment-na¨ıve
adolescents
EFV Efavirenz
EMA European medicines agency
ETA Estimates of variability
EudraCT European clinical trials database
F Fraction of an extravascular dose of drug that is absorbed
FDA US Food and drug administration
FDC Fixed-dose combination
FNA Formulary of the Dutch pharmacists
FP7 Seventh framework program from the European Union
FTC Emtricitabine
GEE Generalized estimating equations
GMP Good manufacturing practice
GMR Geometric mean ratio
HIV Human immmunodeficiency virus
HIV-NAT The HIV Netherlands Australia Thailand research
collaboration
HPLC High performance liquid chromatography
HSV Herpes simplex virus
IDV/r Indinavir boosted with ritonavir
INSERM Institut national de la sante´ et de la recherche me´dicale
IQR Interquartile range
ISRCTN International standard (randomised controlled) trial number
k Exponent
Ka Absorption rate constant
KNMP Royal Dutch pharmacists association
KONCERT A Kaletra ONCE daily Randomised Trial of the
pharmacokinetics, safety and efficacy of twice-daily versus
once-daily lopinavir/ritonavir tablets dosed by weight as
part of combination antiretroviral therapy in HIV-1 infected
children (PENTA 18)
LLOQ Lower limit of quantification
LOCF Last observation carried forward
Lopinavir/r Lopinavir boosted with ritonavir
LPV Lopinavir
LPV/r Lopinavir boosted with ritonavir
MEC Medical ethical committee
NCT number National clinical trial number (clinicaltrials.gov)
220 Making things easier
List of abbreviations and acronyms
NKFK Dutch knowledge centre for paediatric pharmacotherapy
NNRTI Non-nucleoside reverse transcriptase inhibitor
NONMEM Nonlinear mixed effects modelling
NPDE Normalised prediction distribution error
NRTI Nucleoside reverse transcriptase inhibitor
NVK Dutch paediatric association
NVP Nevirapine
NVZA Dutch association of hospital pharmacists
NWO Dutch organisation for scientific research
OFV Objective function value
P Parameter estimate
PCA Principal component analysis
PD Pharmacodynamics
PENTA Paediatric European network for treatment of AIDS
PHPT Program for HIV prevention and treatment
PI Protease inhibitor
PIP Paediatric investigation plan
PK Pharmacokinetic(s)
pKa Acid dissociation constant
PUMA Paediatric use marketing authorisation
Q Intercompartmental clearance
q.d. Once daily (quaque die)
RNA Ribonucleic acid
RONDO Pharmacokinetics of a once-daily regimen of lopinavir/
ritonavir in HIV-infected children
RSE Relative standard error
RTV Ritonavir
SAE Serious adverse event
SAS Statistical analysis system
SD Standard deviation
SF Sugar free
SGC Soft gel capsule
SPSS Statistical package for the social sciences
STEP Safety and toxicity of pharmaceutical excipients for
paediatrics
T0 Time of start of dosing interval
t1/2 Elimination half-life
TAM Thymidine associated mutation
TDF Tenofovir disoproxil fumarate
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TDM Therapeutic drug monitoring
Tmax Time of maximum plasma concentration
US FDA US Food and drug administration
UV Ultraviolet
V Volume of distribution
VALID Development of a new paediatric formulation of valaciclovir
for the prophylaxis and treatment of VZV and HSV
infections in children
VAS Visual analogue scale
VZV Varicella zoster virus
WHO World health organization
ZDV Zidovudine
ZonMW The Netherlands organisation for health research and
development
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Diane Bastiaans behaalde in 1994 haar VWO-diploma aan het Augustini-
anum in Eindhoven. Ze studeerde farmacie aan de Universiteit Utrecht en
studeerde in 1998 af bij de vakgroep Biofarmacie op het onderwerp ‘Specific
active immunotherapy using liposomal peptide antigens.’
Na het behalen van haar apothekersbul in 2001 werkte ze als project-
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